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Abstract 
 
Host restriction factors such as Fv1 in mice and Trim5α in primates block 
retroviral infection through their interaction with capsids. One major form of Fv1, 
encoded by the Fv1b allele, restricts only N-tropic MLV (N-MLV) when 
expressed at the lower endogenous level, but also restricts B-tropic MLV (B-
MLV) and NB-tropic MLV (NB-MLV) at the higher levels seen in cells 
transduced with Fv1b-expressing retroviral vector. However, a previous pull-
down study detected almost equal binding of Fv1b to all three MLV capsids. In 
this study, the relationships between Fv1 binding, restriction and expression 
level were studied in detail.  
 
To study the restriction specificity of Fv1b at different expression levels, 
new Tet-On vectors were developed to allow doxycycline-inducible expression 
of Fv1. These vectors allowed restriction studies from a very low Fv1b level 
where no restriction could be observed, to a high level where inhibitions of B-
MLV and NB-MLV are also observed. Similar phenomenon is also observed in 
other Fv1 mutants. By contrast, Fv1n, even when over-expressed, restricted 
only B-MLV but not NB-MLV or N-MLV. The binding of Fv1b to different capsids 
at different Fv1 concentration were compared using a new pull-down assay 
performed on microtitre plates. Fv1b appears to bind to all MLV capsids at the 
lowest concentration of Fv1 where binding could be detected. The study was 
extended to include other Fv1 mutants, and as expected binding could be 
detected for all restrictive Fv1-MLV pairs. Interestingly, a few outliers including 
Fv1b vs B-MLV demonstrated strong binding but either weak or low restriction, 
suggesting there may be other factors causing the lack of restriction. Together, 
these data suggest that although Fv1b have very similar apparent binding 
affinities to different MLV capsids, different amount of Fv1b are required for the 
restriction of N-, B- and NB-MLV. 
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Chapter 1 
 
Introduction 
 
 
Retroviruses are enveloped viruses which involve two important features in their 
life cycles: the synthesis of complementary DNA (cDNA) from viral RNA 
template (reverse transcription), and the insertion of viral cDNA into the 
genomes of infected cells to form a provirus (integration). As pathogens to 
many animal species, retroviruses have important implications for human and 
animal health. This literature review focuses on the biology of two retroviruses, 
murine leukaemia virus (MLV) and human immunodeficiency virus type 1 (HIV-
1). The intrinsic mechanisms used by the host cells to defend against these 
retroviruses and the counteracting strategies developed by these retroviruses 
will be discussed in detail, with emphases on two capsid-binding restriction 
factors, Friend virus susceptibility-1 (Fv1) and Trim5α (T5). 
 
1.1 Retroviruses 
 
1.1.1 Classification 
 
Early retrovirus classification systems assigned virus particles into type A, B, C 
and D based on the morphology of viral particles observed using thin-section 
electron microscopy techniques (Vogt, 1997). In the later classification system, 
the family of retroviridae is divided into two sub-families (Figure 1.1) – 
orthoretrovirinae and spumaretrovirinae (Stoye et al., 2011). Orthoretrovirinae 
consists of 6 different genera of retroviruses – alpha-retroviruses such as Rous 
sarcoma virus (RSV), beta-retroviruses such as mouse mammary tumour virus 
(MMTV), gamma-retroviruses such as MLV, delta-retroviruses such as human 
T-cell lymphotropic virus type 1 (HTLV-1), epsilon-retroviruses such as walleye 
dermal sarcoma virus (WDSV), and lentiviruses such as HIV-1. Particles of 
orthoretroviruses contain an RNA genome, which is reverse-transcribed into  
 
23 
 
 
 
 
 
 
 
Figure 1.1 Phylogeny of retroviruses 
 
A phylogenetic tree showing the approximate relatedness in sequences from different retroviral 
genera. Reproduced from (Weiss, 2006), with permission under BioMed Central open access 
policy and the Creative Commons Attribution (CC BY) license. 
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cDNA upon entry into the target cell. Spumavirinae comprise a single genus of 
spumaviruses such as Prototypic foamy virus (PFV). In contrast to 
orthoretroviruses, spumaviruses display features resembling hepadnaviruses 
including a DNA genome resulted from the completion of reverse transcription 
in the producer cell (Moebes et al., 1997) and the budding of nascent particles 
through intracellular compartments (Hutter et al., 2013). 
 
 Retroviruses could also be classified as complex or simple retroviruses 
based on their genome organisations and gene regulations (Cullen, 1991). 
Simple retroviruses consist of members from alpha-retroviruses, gamma-
retroviruses, epsilon-retroviruses (Weiss, 2006) and some beta-retroviruses 
including Mason-Pfizer monkey virus (MPMV) (Hayward et al., 2013). These 
viruses contain a relatively simple genomic structure with viral proteins 
expressed from unspliced and singly spliced viral RNAs. In contrast, complex 
retroviruses including members of delta-retroviruses, lentiviruses, spumaviruses 
(Weiss, 2006) and some beta-retroviruses including MMTV (Hayward et al., 
2013; Mertz et al., 2005) encode viral proteins for transcriptional regulation and 
for nuclear export of viral RNA. Many complex retroviruses also regulate the 
expression of some viral proteins through multiply spliced viral RNAs. 
 
1.1.2 History of retrovirus discovery 
 
Discovery of RNA tumour viruses 
The discovery of retroviruses began in the early 20th century, when equine 
infectious anaemia was found to be transmittable between horses via a 
filterable agent (Vallée and Carré, 1904), later identified as the lentivirus equine 
infectious anaemia virus (EIAV). This was followed by numerous observations 
of transmission of tumours between animals by infectious agents in cell-free 
filtrates. These included the transmission of leukaemia in chicken by avian 
leukaemia virus (ALV) in filtered cell extract (Ellermann and Bang, 1908); the 
transmission of spindle-cell sarcoma in chicken by RSV in filtered cell extract 
(Rous, 1911); the transmission of mammary carcinoma in mice by MMTV in 
filtered milk (Bittner, 1936); the transmission of leukaemia by MLV in filtered cell 
extract (Gross, 1951); and the transmission of epidermal hyperplasia in fish by 
WDSV (Walker, 1969). The infectious agents were found to be viruses 
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containing RNA (Crawford and Crawford, 1961), and were known as RNA 
tumour viruses. Reverse transcriptase activity, a hallmark of retroviruses, was 
later detected in RNA tumour viruses (Baltimore, 1970; Temin and Mizutani, 
1970). 
 
First isolations of primate and human retroviruses 
Isolation of retrovirus from primates was first described when “foamy viral 
agents”, later known as simian foamy virus (SFV), was isolated from rhesus 
monkey kidney cells (Enders and Peebles, 1954; Rustigian et al., 1955). PFV 
was subsequently isolated from human nasopharyngeal carcinoma cells 
(Achong et al., 1971). However, genetic analyses showed that PFV is not a 
human retrovirus, but most likely a variant of SFV in chimpanzees resulted from 
a zoonotic transmission (Brown et al., 1978). A human retrovirus was first 
described in 1980, when HTLV-1 was isolated as the causative agent of adult 
T-cell leukaemia/lymphoma (ATLL) (Poiesz et al., 1980). A related virus, HTLV-
2, was isolated shortly after (Kalyanaraman et al., 1982). More recently, HTLV-3 
(Calattini et al., 2005; Wolfe et al., 2005) and HTLV-4 (Wolfe et al., 2005) have 
also been identified. 
 
Discovery of human and simian immunodeficiency viruses 
The global epidemic of acquired immunodeficiency syndrome (AIDS) was first 
recognised in 1981, when clustered cases of opportunistic infections and 
Kaposi’s sarcoma were reported in the USA (Gottlieb et al., 1981). In 1983, a 
retrovirus was isolated from lymphatic tissue of a French AIDS patient (Barre-
Sinoussi et al., 1983), and this virus is now known as HIV-1. A related virus, 
simian immunodeficiency virus (SIVmac), was isolated from a rhesus macaque 
with simian AIDS (Daniel et al., 1985). A second human virus, HIV-2, was 
isolated from a West African AIDS patient (Clavel et al., 1986). Subsequent 
genetic analyses revealed different origins of HIV-1 and HIV-2. While SIVmac 
and HIV-2 were closely related to SIV from sooty mangabey (SIVsm) (Hirsch et 
al., 1989), HIV-1 appears to be derived from chimpanzee SIV (SIVcpz) (Huet et 
al., 1990). While HIV-1 is responsible for most infections in the global AIDS 
pandemic, HIV-2 infection remains rare outside West Africa (Sharp and Hahn, 
2011). 
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Discovery of endogenous retrovirus  
While exogenous retroviruses described above were transmitted “horizontally” 
from host to host, endogenous retroviruses were transmitted “vertically” through 
genetic inheritance of provirus after infection of gamete cells such as oocytes 
(Weiss, 2006). The insertion of endogenous retroviruses to the host genome is 
often detrimental to the host (Stoye, 2012). Although some copies of 
endogenous retroviruses are replication-competent, most of them are defective 
due to deletions or point mutations in their genomes. Endogenous retroviruses 
have been identified in all vertebrate species (Stoye, 2012). The description of 
endogenous retroviruses began in late 1960s with an observation that ALV 
group-specific antigen (Gag) could be inherited in ALV-free chicken as a 
dominant gene following Mendelian genetics (Payne and Chubb, 1968). This 
was followed shortly by the detection of retroviral particles resembling MLV 
(Aaronson et al., 1969; Lowy et al., 1971) and MMTV (Bentvelzen and Daams, 
1969; Bentvelzen et al., 1970) released from inbred laboratory mice. 
Endogenous retroviruses in the human genome have been problematic for the 
identification of infectious human retroviruses due to the high background of 
PCR signals from endogenous sequences. This contributed to the numerous 
reports of human “rumour” viruses with suspected disease etiologies, many 
have never been confirmed (Voisset et al., 2008). Porcine endogenous 
retroviruses (PERVs, a gamma-retrovirus) released from pig cells (Armstrong et 
al., 1971) were found to be able to infect human cell lines (Patience et al., 
1997), causing concerns on whether zoonotic infection of PERVs could be 
resulted from xenotransplantation of pig cells or organs to human. However, 
later studies found no evidence of human infection from pig xenografts in vivo 
(Elliott et al., 2000; Gu et al., 2008; Heneine et al., 1998; Paradis et al., 1999; 
Patience et al., 1998; Scobie et al., 2013). Endogenous spurmavirus sequences 
have been identified in genomes of human, lemur, sloth and fish (Cordonnier et 
al., 1995; Han and Worobey, 2012a, b; Katzourakis et al., 2009; Rethwilm and 
Bodem, 2013). Different lineages of  endogenous lentiviruses have been 
identified in the genomes of rabbits and hares (Katzourakis et al., 2007; 
Keckesova et al., 2009; van der Loo et al., 2009), weasels (Cui and Holmes, 
2012; Han and Worobey, 2012c), lemurs (Gifford et al., 2008; Gilbert et al., 
2009) and colugos (Han and Worobey, 2015; Hron et al., 2014). It has been 
estimated that human endogenous retroviruses (HERVs) comprise almost 8% 
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of the human genome (Denner, 2010). HERVs identified in the human genome 
were related to beta-retroviruses (e.g. HERV-K), gamma-retroviruses (e.g. 
HERV-H, HERV-W, HERV-FRD) or spumaviruses (e.g. HERV-L, HERV-S) 
(Blikstad et al., 2008). While most HERVs open reading frames (ORFs) became 
defective after accumulation of mutations, some had evolved with the host 
genome to become functional genes (Stoye, 2012). For example, the env genes 
of HERV-W and HERV-FRD, known as syncytin-1 (Blond et al., 2000; Mi et al., 
2000) and syncytin-2 (Blaise et al., 2003), mediate cell-to-cell fusion events 
during human placental development (Dupressoir et al., 2012).  
 
1.1.3 Genome organisation and gene expression 
 
Long terminal repeats and untranslated regions 
Each orthoretrovirus particle contains a dimer of genomic RNAs, which are 
capped at the 5’ end (Beemon and Keith, 1977) and polyadenylated at the 3’ 
end (Guntaka, 1993). The genome organisation of proviruses of a simple 
retrovirus (MLV) and a complex retrovirus (HIV-1) is shown in Figure 1.2. 
Identical long terminal repeats (LTR) are found at 5’ and 3’ ends of integrated 
retroviral genomes (Bannert et al., 2010). Each LTR contains the unique 3’ 
element (U3), followed by the repeated element (R), and finally the unique 5’ 
element (U5). In the provirus, sequences within the U3 region of the 5’ LTR 
functions as a promoter for the transcription of viral RNA. The transcription of 
retroviral RNA starts at the beginning of the R region of the 5’ LTR, and the 
polyadenylation signal in the 3’ LTR marks the end of the R region. The 
transcribed viral RNA contains the R-U5 sequence at the 5’ end, and the U3-R 
sequence before the poly-A tail at the 3’ end. The R sequences at the 5’ and 3’ 
ends are essential for the transfer of DNA strands during reverse transcription. 
Binding sites for trans-activating proteins encoded by complex retroviruses can 
also be found within the LTR. The primer binding site (pbs) is found immediate 
downstream of the U5 region, and serves as the binding site for cellular tRNA 
primer required for the initiation of reverse transcription. The 5’ untranslated 
region (UTR) also contains sequence responsible for genome dimerisation 
known as dimer linkage sites (DLSs). Sequences found to confer RNA 
encapsidation into virions (ψ-site) are present within the 5’ UTR, often 
overlapping with the DLS, and may extend into the gag coding region. The 3’ 
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UTR contains a polypurine tract (ppt) upstream of the 3’ LTR for priming of plus 
strand synthesis during reverse transcription. Some complex retroviruses 
including lentiviruses contain a second plus strand priming site known as central 
polypurine tract (cppt) (Charneau and Clavel, 1991). 
 
 
 
 
 
Figure 1.2 Genome organisations of MLV and HIV-1 
 
Schematic diagrams of the untranslated and coding regions of MLV and HIV-1 proviral 
genomes. LTR, long terminal repeat; UTR, untranslated region; MA, matrix; CA, capsid; NC, 
nucleocapsid; PR, protease; RT, reverse transcriptase; IN, integrase; TM, transmembrane 
domain; SU, surface domain; RRE, Rev-responsive element. Gag and Gag-Pol are synthesised 
as precursor polyproteins, and processed into individual proteins and small peptides by the viral 
protease during maturation. In MLV, Gag-Pol is expressed by ribosome read-through of the gag 
stop codon into the in-frame pol ORF. In HIV-1, the translation of Gag-Pol involves a -1 
ribosomal frame shift at the boundary of gag and pol ORFs. Env is processed into TM and SU 
by a cellular protease. HIV-1 also expresses accessory genes for functions including gene 
regulation and antagonism of host restriction factors. 
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Expression of Gag, Pol and Env 
All retroviral genomes contain at least 3 genes: gag, pol and env. The Gag 
precursor protein contains subunits which are important for virus assembly and 
integrity of viral core, including matrix (MA), capsid (CA) and nucleocapsid (NC). 
With the exception of spumaviruses, these subunits are released as individual 
proteins upon cleavage by the viral protease during maturation. In many 
retroviruses, other small proteins are also released from Gag during maturation. 
MLV Gag is processed into MA, p12, CA and NC proteins, while HIV-1 is 
processed into MA, CA, SP1, NC, SP2 and p6 proteins (Bannert et al., 2010). In 
MLV, an alternative form of Gag known as Glyco-Gag is synthesised by 
translational initiation from an upstream CUG codon (Prats et al., 1989). The 
resulting 80kD protein includes a leader peptide in the N-terminus, which directs 
the protein to the Golgi complex for glycosylation. The pol gene is expressed in 
the form of a Gag-Pol precursor protein, which in MLV was produced by the 
translational read-through of the UAG amber stop-codon of the gag ORF using 
the cellular suppressor tRNAGlu (Yoshinaka et al., 1985), facilitated by a 
pseudoknot structure of the viral RNA (Wills et al., 1991). The ribosomal read 
through occurs at 5-10% efficiency (Jamjoom et al., 1976). In HIV-1, the 
synthesis of Gag-Pol involves a -1 ribosomal frameshift at 5-10% efficiency 
(Jacks et al., 1988). The processing of Gag-Pol yields three important enzymes: 
protease (PR), reverse transcriptase (RT) and integrase (IN). The Env 
precursor protein is translated from a spliced mRNA lacking most of Gag-Pol 
sequence. This transcript results from a splicing event between a splice donor 
(SD) in the 5’ UTR and a splice acceptor (SA) close the start codon of env 
gene. The precursor protein undergoes extensive co- and post-translational 
modification in the endoplasmic reticulum (ER) and the Golgi complex, and 
cleaved into an N-terminal surface subunit (SU) and a C-terminal trans-
membrane subunit (TM).  
 
Expression of accessory genes 
In addition to the expression of gag, pol and env genes, complex retroviruses 
such as HIV-1 also encode a large number of accessory proteins namely Vif, 
Vpr, Vpu, Tat, Rev and Nef. These accessory genes are found towards the 3’ 
end of the genome, on either side of the env gene. In HIV-1, some accessory 
genes such as vif, vpr and vpu are from a singly spliced transcript, with vpu and 
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env expressed from the same bicistronic transcript (Schwartz et al., 1990). The 
trans-activator tat, the RNA nuclear export protein rev, and nef are expressed 
from multiply spliced transcripts. The Rev responsive element (RRE), an RNA 
element which interacts with Rev, is present in the env coding region between 
the introns of tat and rev. The RRE is present in unspliced and singly spliced 
HIV-1 transcripts, but not in multiply spliced transcripts encoding Tat and Rev. 
In the late stage of gene expression, Rev mediates the selective nuclear export 
of RRE-containing unspliced and singly spliced transcripts. This leads to a 
switch from the translation of gene regulatory proteins from multiply spliced 
RNA, to the expression of structural proteins and packaging of unspliced 
genomic RNA. 
 
1.1.4 Retroviral particles  
 
Retrovirus particles are roughly spherical with diameters ranging from 100 to 
150nm (Bannert et al., 2010). Structures of typical retrovirus particles are shown 
in diagrammatic form in Figure 1.3. The outermost layers of retrovirus particles 
consist of an envelope with lipid bilayer and Env complexes. These Env 
complexes contain heavily glycosylated SU trimers joined to TM trimers on lipid 
bilayer by disulphide bonds (Opstelten et al., 1998). Orthoretrovirus particles 
can contain either mature or immature cores, while only immature cores can be 
found in spumavirus particles. Electron microscopy studies of immature cores 
showed electron-dense radial striations beneath the lipid membrane (Fuller et 
al., 1997; Yeager et al., 1998). These striations are formed by polymerised Gag 
and Gag-Pol proteins, with the N-terminal MA domain attached to the lipid 
bilayer and the C-terminus NC domain of gag bound to viral RNA. The 
maturation of retroviral particles is triggered by the proteolytic processing of 
Gag precursor protein (de Marco et al., 2010b). Mature retroviral cores are 
more condensed than immature cores, and are formed by processed Gag 
subunits. The morphologies of mature cores vary from roughly spherical core of 
MLV, tubular core of MPMV, to conical core of HIV-1 (Yeager, 2011). In mature 
particles, MA proteins are bound to the lipid bilayer, CA proteins form a 
condensed capsid shell, and NC proteins form a condensed ribonucleoprotein 
(RNP) complex with genomic RNA dimers inside the capsid shell.  
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Figure 1.3 Typical immature and mature retroviral particle structures 
 
(A) A typical immature retroviral particle with an envelope consists of lipid bilayer and envelope 
proteins, and an immature core consists of Gag, Gag-Pol and dimeric RNA genome. (B) A 
typical mature retroviral particle formed after the processing of Gag and Gag-Pol precursor 
proteins. The MA layer remains tethered to the viral membrane, the CA proteins form the capsid 
shell of the mature core, while the NC protein forms a ribonucleoprotein (RNP) complex with 
genomic RNAs. In addition, retrovirus particles incorporate many host proteins, lipids and RNA 
molecules (Bannert et al., 2010). 
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1.1.5 Retroviral proteins 
 
Matrix 
The key function of the MA subunit is to target Gag to lipid membrane during 
virus assembly. Despite the lack of sequence conservation, all retroviral MA 
subunits have similar topologies with a globular core formed by 4 helices (Conte 
and Matthews, 1998). The HIV-1 MA subunit has been crystallised as trimers 
(Hill et al., 1996), while the MLV MA subunit has been crystallised as dimers 
(Riffel et al., 2002). Membrane-bound HIV-1 MA has also been found to 
assemble into hexamers of trimers, suggesting the presence of two interfaces 
for multimerisation (Alfadhli et al., 2009a; Alfadhli et al., 2007). The N-terminus 
of MA subunit in gag is modified cotranslationally by the removal of Met1 and 
the attachment of the myristic acid, a 14-carbon saturated fatty acid, to the 
second amino acid of MA in many retroviruses including MLV and HIV-1 (Bryant 
and Ratner, 1990; Rein et al., 1986). The myristoylation of Gag is essential for 
the interaction between Gag and lipid bilayer. A patch of surface exposed basic 
residues is found close to the N-terminus of all retroviral MA, and has been 
hypothesised to participate in the membrane targeting of Gag through 
interactions with acidic head groups of phospholipids (Murray et al., 2005). In 
addition to lipid binding, there are some evidence of interactions between HIV-1 
MA and RNA (Alfadhli et al., 2009b; Chukkapalli et al., 2013; Chukkapalli et al., 
2010). 
 
Capsid 
A number of roles in multiple stages of retroviral life cycle has been suggested 
for CA proteins, including the formation of a curved polymerised lattice of Gag 
during budding (Carlson et al., 2008), the assembly of the capsid shell of 
condensed cores during maturation (de Marco et al., 2010b), the protection of 
viral nucleic acids from the detection by innate sensors (Rasaiyaah et al., 2013), 
as well as the recruitment of host factors for nuclear entry (Schaller et al., 
2011). CA consists of two largely α-helical structural domains, the N-terminal 
domain (CA-NTD) and the C-terminal domain (CA-CTD). CA either as a subunit 
of Gag or as an individual protein forms hexameric rings, which are the main 
building blocks of the retroviral capsid shell (Burns, 2009; Ganser-Pornillos et 
al., 2007; Mortuza et al., 2008; Mortuza et al., 2004; Pornillos et al., 2009). CA 
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is also the target of many host restriction factors such as Fv1, T5 and Mx2 
(Bock et al., 2000; Goujon et al., 2014; Yap et al., 2004). Details on the 
structure and function of CA will be discussed in the next section.  
 
Nucleocapsid 
Through its nucleic acid binding and chaperone activities, NC is important for 
multiple steps of the retroviral life cycle including assembly, maturation, reverse 
transcription, and possibly integration. Orthoretroviral NC contains one (MLV) or 
two (HIV-1) Cys-X4-Cys-X4-His-X4-Cys zinc fingers (Summers et al., 1992), 
which has been shown to form tight interactions with the exposed residues of ψ-
sites present on full-length genomic RNA (D'Souza and Summers, 2004; 
Dannull et al., 1994; De Guzman et al., 1998; Schuler et al., 1999). In addition 
to the zinc fingers, many basic residues also contribute towards RNA binding 
(Dannull et al., 1994). The abilities of Gag to bind genomic RNA through its NC 
subunit and to multimerise through its CA subunits are crucial for core 
assembly. In addition to the strong affinity for ψ-sites, Gag-NC subunits also 
display non-specific binding and chaperone activities towards nucleic acids 
(reviewed in Rein, 2010). Gag-NC subunits have been proposed to facilitate the 
dimerisation of genomic viral RNA and annealing of tRNA primer to pbs in 
producer cells through its chaperone activity. After Gag processing, the non-
specific nucleic acid binding activity of NC is important for condensation of RNA 
or DNA. During maturation, NC binds to viral genomic RNA to form a 
condensed RNP complex. Binding of NC to DNA has also been shown to 
induce DNA condensation in vitro (Krishnamoorthy et al., 2003). The exact role 
of RNA and DNA condensation by NC is unclear, but may include the protection 
of nucleic acids from nuclease attack and innate sensing. 
 
Envelope 
The retroviral Env complex mediates receptor binding and membrane fusion 
during viral entry. Env undergoes a number of modifications including 
glycosylation (Bernstein et al., 1994; Pinter and Honnen, 1988) and sulfation 
(Bernstein and Compans, 1992), and is processed by cellular proteases during 
its transit through the ER and the Golgi network. The resulting Env complex 
consists of a SU trimer anchored to a TM trimer by disulphide bonds (Opstelten 
et al., 1998). In HIV-1, the SU subunit is known as gp120, while the TM subunit 
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is known as gp41. Presented on the exterior of the Env complex, the SU 
subunit is heavily glycosylated and is mediates binding to cellular receptors. 
The TM subunit contains a fusion peptide which is inserted into target 
membranes upon receptor binding for membrane fusion (Mothes and Uchil, 
2010). In addition to SU and TM subunits, the MLV Env precursor contains a 
16aa C-terminal R-peptide which inhibits membrane fusion activity of Env 
before viral bidding (Bobkova et al., 2002; Loving et al., 2011; Loving et al., 
2008). 
 
Protease 
PR is required for the processing of Gag and Gag-Pol precursors into individual 
proteins during maturation. Retroviral aspartic proteases form homodimers, with 
catalytic aspartic acids inside the substrate binding pocket (Lapatto et al., 1989; 
Li et al., 2005; Miller et al., 1989; Navia et al., 1989; Weber et al., 1989). The 
processing of Gag and Gag-Pol is carried out sequentially, due to differences in 
cleavage rates at different processing sites (Erickson-Viitanen et al., 1989). 
 
Reverse transcriptase 
RT carries out reverse transcription of the viral genomic RNA. The structure and 
organisation of RT gene products differs among retroviruses. The MLV RT is a 
monomeric  protein with an N-terminal polymerase domain and a C-terminal 
RNaseH domain (Das and Georgiadis, 2004). The polymerase domain 
synthesises DNA using either RNA or DNA as template, while the RNaseH 
domain degrades RNA from DNA/RNA hybrids. HIV-1 RT is a heterodimer of 
p66 and p51 subunits (Sarafianos et al., 2001). The two HIV-1 RT subunits 
were generated from Gag-Pol using different C-terminal cleavage sites, with 
p51 lacking the RNaseH domain.  
 
Integrase 
IN catalyses the insertion of viral DNA into host chromosome. IN contains 3 
functional domains; an N-terminal domain (IN-NTD) containing a zinc finger 
motif, a catalytic core domain (IN-CCD) and the C-terminal domain (IN-CTD). 
Complex formation of HIV-1 IN and viral DNA involves tetramerisation of IN (Li 
et al., 2006a). Although the structure of full length HIV-1 IN has not been 
solved, crystal structure of complexes with full length PFV IN and viral DNA has 
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revealed a “dimer of dimer”, with DNA binding surfaces and catalytic sites at the 
dimer-dimer interface (Hare et al., 2010). IN also interacts with chromatin 
tethering factors, such as LEDGF which binds lentiviral IN (Cherepanov et al., 
2005; Hare et al., 2009), and BET proteins which bind MLV IN (De Rijck et al., 
2013; Gupta et al., 2013; Sharma et al., 2013). 
 
MLV p12 
p12 is located between MA and CA subunits in the Gag of MLV. Nuclear 
magnetic resonance (NMR) studies of Gag fragments containing p12 and CA-
NTD showed that p12 domain is unstructured (Kyere et al., 2008). Purified p12 
is monomeric (Wight et al., 2012). Functional motifs have been identified in p12, 
including the PPPY late domain which recruits an endosomal sorting complexes 
required for transport (ESCRT) protein HECT ubiquitin ligase for budding 
(Martin-Serrano et al., 2005; Yuan et al., 1999) and a clathrin binding domain 
(Zhang et al., 2011). Regions close to the N-terminus (p12-NTD) and the C-
terminus (p12-CTD) of p12 are required for the infectivity of MLV (Yuan et al., 
1999). p12-CTD is required for the localisation of p12 to mitotic chromatin 
(Prizan-Ravid et al., 2010), and loss of infectivity by mutations in p12-CTD could 
be rescued by heterologous chromatin-binding sequence (Elis et al., 2012; 
Schneider et al., 2013; Wight et al., 2012). The exact function of p12-NTD is not 
known, but cores with mutations in this region were not recognised by capsid-
binding restriction factors, suggesting a defect in core morphology (Wight et al., 
2012). 
 
HIV-1 SP1 and SP2 
Processing of HIV-1 gag releases two spacer peptides (SP1 and SP2) and a 
small protein p6. The SP1 links CA-CTD to NC in Gag. The SP1 peptide 
contains a hypothetical α-helix (Morellet et al., 2005), which has been proposed 
to form a 6-helix bundle under each CA hexamers in HIV-1 Gag (de Marco et 
al., 2010b; Wright et al., 2007). The temporal control of the processing of the 
14aa SP1 and 16aa SP2 from adjacent domains have important roles in 
maturation, evident from the impaired core morphologies of cleavage site 
mutants (de Marco et al., 2012; de Marco et al., 2010b).  
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HIV-1 p6 
The HIV-1 p6 protein is derived from the C-terminus of Gag. NMR studies 
showed that p6 consists of two helices joined by a flexible linker (Fossen et al., 
2005), and both helices have been found to interact with lipid membrane 
(Solbak et al., 2013). Two late domains are present in p6 for recruitment of 
ESCRT proteins for budding, including the PTAP motif near the N-terminus 
which binds Tsg101; and the YPXL motif in the C-terminal helix which binds Alix 
(Demirov et al., 2002; Solbak et al., 2013; Strack et al., 2003). The helices of p6 
also contain motifs for the recruitment of the accessory protein, Vpr (Salgado et 
al., 2009; Zhu et al., 2004). 
 
HIV-1 p6* 
 
The transframe protein p6*, encoded by the N-terminal sequence of the pol 
gene, is one of the cleavage products of GagPol precursor protein. p6* is 
involved in the regulation of the activity of PR (Paulus et al., 1999; Zybarth and 
Carter, 1995). 
 
HIV-1 Tat and Rev 
Complex retroviruses encode transactivator proteins to stimulate transcription of 
viral RNA, these include Tat of HIV-1 (Muesing et al., 1987), Tax of HTLV-1 
(Felber et al., 1985; Fujisawa et al., 1985; Sodroski et al., 1984) and Tas of SFV 
(Campbell et al., 1996). Tat interacts with a stem-loop structure known as trans-
activation response (TAR) at the 5’ end of the viral RNA for transactivation 
(Chun and Jeang, 1996; Feng and Holland, 1988). Complex retroviruses also 
encode viral proteins for selective nuclear export of full length and singly spliced 
RNA containing the RRE, leading to a switch from the expression of accessory 
genes to the translation of structural proteins (Cullen, 1991). These nuclear 
export proteins include Rev of HIV-1 (Malim et al., 1989), Rex of HTLV-1 (Hanly 
et al., 1989) and Rem of MMTV (Mertz et al., 2005). For simple retroviruses 
such as MLV and MPMV, the nuclear export of viral RNA depends on cis-acting 
RNA elements, and requires only host proteins but not viral proteins (Pasquinelli 
et al., 1997; Sakuma et al., 2014). 
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HIV-1 Vif, Vpu, Vpr and Nef 
Vif was found to counteract restriction by multiple members of the APOBEC3 
family (Desimmie et al., 2014). Vpu, which forms ion channels at lipid 
membranes, antagonises the restriction by tetherin (McNatt et al., 2013; Neil et 
al., 2008). Env, Nef and Vpu have all been found to downregulate the HIV-1 
receptor CD4 on cell surface, which has been hypothesised to avoid 
superinfection of cells which may increase immune sensing (Wildum et al., 
2006).  Nef also downregulates a number of cell surface immune proteins 
(Basmaciogullari and Pizzato, 2014). The HIV-1 vpr, which is incorporated into 
viral particles via p6, has been shown in a large number of studies to cause cell 
cycle arrest and apoptosis (Guenzel et al., 2014).  
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1.2 Capsid structure and core assembly 
 
1.2.1 Sequence and structural elements of CA 
 
Retroviral CA consists of two largely α-helical structural domains, CA-NTD and 
CA-CTD. Structures of CA-NTD of many retroviruses had been solved by 
crystallography or NMR, and were found to be highly similar despite of the lack 
of sequence conservation (Bailey et al., 2012; Cornilescu et al., 2001; Ganser-
Pornillos et al., 2007; Gitti et al., 1996; Jin et al., 1999; Mortuza et al., 2008; 
Mortuza et al., 2009; Mortuza et al., 2004; Pornillos et al., 2009). Among the 
structures of the CA-NTD is the β-hairpin, which is present at the N-terminus of 
CA. In crystal structures of CA-NTD, the β-hairpin is stabilised by a salt bridge 
between Pro1 and Asp54 in MLV (Mortuza et al., 2004), and between Pro1 and 
Asp51 in HIV-1 (Gitti et al., 1996). The rest of CA-NTD contains 6 (MLV) or 7 
(HIV-1) α-helices, and a flexible loop between α4 and α5 which in HIV-1 CA 
interacts with the host protein cyclophilin A (CypA) (Gamble et al., 1996). A 
stretch of sequence highly conserved among all retroviruses, known as the 
major homology region (MHR), is found in the CA-CTD. Many conserved 
residues of MHR were found to be essential for virus assembly and infectivity 
(Chang et al., 2007; Ganser-Pornillos et al., 2004; von Schwedler et al., 2003). 
At the C-terminus of MLV CA, a stretch of 41aa highly charged residues has 
been predicted to form α-helical structure, termed the charged assembly helix 
(Cheslock et al., 2003). The charged assembly helix is essential for infectivity 
and virus assembly, although it can tolerate deletion of up to 22aa (Cheslock et 
al., 2003). The HIV-1 equivalent of the charged assembly helix is thought to be 
the SP1 peptide, which can form an α-helix under certain conditions and is 
important for the assembly of viral core (Datta et al., 2011; de Marco et al., 
2010b). 
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1.2.2 The CA hexamer 
 
Early crystal structures of HIV-1 CA-NTD and CA-CTD suggested that both 
domains may form dimers (Gamble et al., 1996; Gamble et al., 1997; 
Worthylake et al., 1999). However, electron cryo-tomography studies of N-
terminally His-tagged HIV-1 and MLV CA immobilised on lipid monolayer 
containing a nickel-chelating lipid revealed a regular capsid array formed of 
hexameric symmetry units (Barklis et al., 1998; Barklis et al., 1997). In vitro 
capsid assemblies can be formed by CA or CA-NC at a high salt concentration 
(1M NaCl), or by mixing CA-NC with RNA (Campbell and Vogt, 1995; Ehrlich et 
al., 1992). These assemblies form a mixture of conical and tubular structures, 
and mutations have been identified to favour the formation of tubes (Ganser-
Pornillos et al., 2004; Ganser et al., 1999). The regularity of tubular capsid 
assemblies allowed high resolution (9Å) electron cryo-microscopy studies of the 
HIV-1 CA array, and docking of known CA-NTD and CA-CTD crystal or NMR 
structures to generate structural models of the CA hexamer (Ganser-Pornillos et 
al., 2007). This model (Figure 1.4) shows extensive contacts between CA-NTD 
of each CA monomer, and led to identification of pairs of cysteine mutations in 
CA-NTD which could mediate disulphide crosslinking between monomers for 
stabilisation of CA hexamer (Pornillos et al., 2010). It also shows potential CTD-
CTD inter-hexameric interactions, from which mutations can be identified to 
destabilise this interaction to assist structural studies by x-ray crystallography 
(Ganser-Pornillos et al., 2007). These crosslinking mutations, together with 
mutations for destabilisation of interaction between CTD domains, were 
introduced to CA to solve the crystal structure of full length HIV-1 CA hexamer 
(Pornillos et al., 2009). This hexamer structure is formed by two concentric 
rings: the CA-NTD forms the inner ring with β-hairpin at the central pore; the 
CA-CTD contains 4 α-helices, forms the outer ring, and mediates inter-
hexameric interactions. CA-NTD of each monomer interacts with both CA-NTD 
and CA-CTD of the neighbouring monomer to form intra-hexameric interactions.  
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Figure 1.4 Hexameric structures of HIV-1 and MLV CA 
 
(A) Crystal structure of full-length HIV-1 CA A14C/E45C/W184A/M185A crosslinked hexamer, 
PDB: 3H47 (Pornillos et al., 2009). (B) Crystal structure of N-MLV CA-NTD hexamer, PDB: 
1U7K (Mortuza et al., 2004). Each individual CA monomer is labelled in different colour in both 
structures using PyMol. The bottom panels show the structures of CA hexamers as viewed from 
exterior of virus particles. 
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CA-NTDs from different strains of MLV have been crystallised as 
hexamers without the need of disulphide stabilisation (Burns, 2009; Mortuza et 
al., 2008; Mortuza et al., 2004). Like HIV-1, CA-NTD monomers form a 
hexameric ring with the β-hairpin at the centre (Figure 1.4), held by NTD-NTD 
interactions. The structure of full length MLV CA with deletion of the charged 
assembly helix has been solved (Burns, 2009). In this structure, the CA-CTD 
contains 5 α-helices, and forms an outer hexameric ring. Similar to HIV-1 CA, 
hexamers are stabilised by interactions between CA-NTD and both NTD and 
CTD of the neighbour CA monomer. These studies showed that despite the 
many differences between HIV-1 and MLV, their CA form conserved hexameric 
CA structures which serve as building blocks of retroviral cores. 
 
1.2.3 Structure of the mature capsid shell 
 
The cores of HIV-1 mature particles are typically conical in shape, with a thinner 
shell compared to cores of immature particles. Electron cryo-tomography 
studies suggested that like the in vitro CA assemblies, natural cores are also 
formed of hexamers (Briggs et al., 2003). Models on how CA hexamers can be 
arranged into conical core have been proposed and refined (Ganser et al., 
1999; Li et al., 2000; Pornillos et al., 2011; Zhao et al., 2013). The formation of 
cores would require contacts between hexamers. Since HIV-1 CA-CTD is 
present in the outer ring, inter-hexameric interactions are likely to be between 
CA-CTDs (Pornillos et al., 2009). Because CA-CTD has been crystallised as 
dimers, it has been proposed that HIV-1 CA-CTD are linked through interactions 
at a dimer interface (Gamble et al., 1997; Ivanov et al., 2007; Worthylake et al., 
1999). This is consistent with the apparent CTD-CTD contacts observed from 
high resolution electron cryo-tomography studies of in vitro CA tubular 
assemblies (Byeon et al., 2009; Ganser-Pornillos et al., 2007; Li et al., 2000). 
Some of these studies also suggested an additional trimer interface forming 
inter-hexameric contacts, and mutations at this trimer interface leads to loss of 
infectivity (Byeon et al., 2009; Zhao et al., 2013). Therefore, the linkage 
between HIV-1 hexamers requires CTD-CTD linkage at both dimer and trimer 
interfaces. Early modelling of the HIV-1 core suggested that the insertion of 12 
CA pentamers in addition to hexamers would be required to form the conical 
core (Ganser et al., 1999). The formation of HIV-1 CA pentamers can be 
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stabilised by disulphide crosslinking, and the crystal structures of pentamer and 
hexamer show high similarity in the inter-molecular interactions (Pornillos et al., 
2011). The most recent structural model of the HIV-1 core was generated with 
CA hexamers and pentamers joined by interactions at the CTD-CTD dimer and 
trimer interfaces (Zhao et al., 2013). In contrast to HIV-1, mature MLV cores are 
polygonal in a roughly spherical shape, and may not require the need of 
pentamers (Yeager et al., 1998). Crystal structures of MLV CA suggested that 
CA hexamers are joined by CTD-CTD dimerisation (Burns, 2009). The 
formation of CTD-CTD interactions between hexamers is in agreement from 
data from study of N-terminally His-tagged MLV CA (Ganser et al., 2003). 
 
1.2.4 Comparison of mature and immature capsid lattice 
 
Immature particles contain electron-dense radial striations beneath the lipid 
membrane composed mainly of polymerised Gag (Fuller et al., 1997; Yeager et 
al., 1998). In an immature core, both the N- and C-termini of CA in Gag are 
tethered to other Gag subunits, and the organisations of CA-NTD and CA-CTD 
are different from those in the mature lattice. Electron cryo-tomography studies 
of HIV-1 immature particles revealed that the CA-SP1 region are arranged in a 
“Y-shape” (Figure 1.5), with the six CA monomers of each hexamer 
interconnected and forming a rod-like structure at the SP1 region (de Marco et 
al., 2010b; Wright et al., 2007). The immature lattice can be mimicked by in vitro 
assemblies of Gag fragment in which CA is tethered at one or both ends. The 
Y-shape arrangement of such immature lattice was also observed in in vitro 
assemblies of a Gag fragment (MA-SP2 with internal MA deletion) with nucleic 
acids (de Marco et al., 2010a). High resolution electron cryo-tomography study 
of HIV-1 CA-NC tubes suggested that in the immature lattice, CA-CTD forms 
hexamers, with SP1 forming a bundle of 6 helices underneath (Bharat et al., 
2014). The organisation of the CA-CTD layer in immature core is unknown in 
MLV, but the charged assembly helix has been proposed to function in a similar 
way to SP1 (Cheslock et al., 2003). A recent study of in vitro assembly of 
xenotropic MLV-related virus (XMRV) CA-NC with a 10aa N-terminal deletion 
did show a rod-like structure between folded domains of CA-CTD and NC 
(Hadravova et al., 2012).  
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Figure 1.5 The HIV-1 immature gag lattice 
 
A) Reconstruction of the HIV-1 immature gag lattice from averaged electron tomogram of 
immature particles. Red arrow indicates the position of a rod-like protrusion which may be 
formed by SP1. Scale bar is 10nm. B) Surface rendering of the reconstruction shown in (A). The 
lipid membrane and MA layers in yellow, CA-NTD in blue, CA-CTD and SP1 in green, and NC-
RNA in grey. Rod-like protrusions, which may be formed by SP1, are indicated by the red arrow. 
Modified from (de Marco et al., 2010b), with permission under PLOS open-access license and 
the Creative Commons Attribution (CC BY) license. 
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The processing of the N-terminus of Gag is also important for the 
transition from immature to mature lattice. NMR studies have shown that the β-
hairpin is unfolded in Gag of both MLV and HIV-1 (Kyere et al., 2008; Tang et 
al., 2002), but stabilised by a salt bridge in the structure of CA-NTD (Burns, 
2009; Mortuza et al., 2008; Mortuza et al., 2004; Pornillos et al., 2009). 
Disruption of the salt bridge by mutagenesis blocks virus assembly and leads to 
changes in the morphologies of in vitro CA or CA-NC assemblies from tubular to 
spherical structures (Abdurahman et al., 2007; Cortines et al., 2011; Gross et 
al., 1998; Hadravova et al., 2012; von Schwedler et al., 1998). One study 
compared the crystal structures of MLV CA with or without insertion of a 4aa 
sequence in the N-terminus to mimic immature and mature CA, respectively 
(Burns, 2009). In the structure with an N-terminal extension, the β-hairpin is 
unfolded, and interactions are formed between NTD hexamers at 2-fold and 3-
fold interfaces. In the structure with an authentic N-terminus, the β-hairpin is 
stabilised, and the inter-hexamer spacing increases from 79Å in immature-like 
structure to 99Å in mature-like structure. The NTD-NTD inter-hexameric 
interactions are lost due to the increased inter-hexameric spacing. Similar 
increases in inter-hexamer spacing from 80Å in immature lattices to 96Å in 
mature lattices have also been observed in HIV-1 particles (Briggs et al., 2004). 
These studies suggested processing at the boundary of the CA domain can 
lead to the rearrangement of CA-NTD and CA-CTD, including an increase in the 
inter-hexameric spacing.  
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1.3 Retroviral replication 
 
The retroviral life cycle can be divided into two phases: the early phase (Figure 
1.6) begins with viral entry and ends after integration, while the late phase 
(Figure 1.7) begins with the transcription of viral RNA and ends after the 
maturation of virus particle. 
 
1.3.1 Entry 
 
Receptor binding 
Retrovirus particles are first attached to the cell surface via weak interactions 
with cell surface molecules such as heparan sulphate for HIV-1 (Saphire et al., 
2001) and heparin for MLV (Walker et al., 2002), before encountering their 
cellular receptor. In MLV, the use of receptor varies among different strains, 
which contributes to the MLV tropism. Based on their host range, MLV strains 
can be classified into ecotropic, xenotropic, polytropic and amphotropic 
subgroups (Hunter, 1997). Ecotropic MLVs only infects mouse or rat cells, and 
includes exogenous viruses such as N-tropic MLV (N-MLV), B-tropic MLV 
(B_MLV), and NB-tropic Moloney MLV (NB-MLV). Ecotropic MLV use the 
mouse cationic amino acid transporter (mCAT-1) as the receptor (Albritton et 
al., 1989). Polytrophic, xenotropic and amphotropic MLVs can infect a broad 
range of mammalian cells with slight differences in their host ranges. 
Amphotropic MLVs use the sodium-dependent phosphate transporter Pit-2 as 
the receptor (Kavanaugh et al., 1994). Polytrophic and xenotropic MLVs use 
different alleles of the cell surface protein Xpr1 as receptor (Kozak, 2010). Xpr1 
functions as an atypical G-Protein-Coupled Receptor (GPCR) in mammalian 
cells (Vaughan et al., 2012). HIV-1 uses CD4, a glycoprotein found on the 
surface of many immune cells including CD4+ T-cells, as the primary receptor 
(Klatzmann et al., 1984). In addition, entry of HIV-1 requires either CXCR4 
(Feng et al., 1996) or CCR5 (Alkhatib et al., 1996) as co-receptor.  
 
Membrane fusion 
The MLV SU subunit of Env contains a CXXC motif, in which one of the 
cysteine residue forms intermolecular disulphide bond with the TM subunit  
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Figure 1.6. The early stage of the retrovirus life cycle 
A schematic diagram showing steps in the early stage of retroviral life cycle (boxes with purple 
border), host restriction factors which target these steps (coloured boxes), and viral antagonists 
which counteract restrictions by these restriction factors (boxes with black border). Binding of 
mature retroviral particles leads to fusion between viral and host membranes, a process which 
can be inhibited by IFITM. Reverse transcription of viral DNA occurs once the viral core is 
released to the cytoplasm. Many restriction factors including APOBEC3G, SAMHD1, REAF and 
T5 inhibit reverse transcription. The complex in which reverse transcription occurs is defined as 
reverse transcription complexes (RTC). The RTC is transformed into an integration-competent 
pre-integration complex (PIC) during its transit on microtubule network towards the microtubule 
organising centre (MTOC) at the periphery of the nuclear envelope. Uncoating of the capsid 
shell occurs at some point between the viral entry and nuclear entry. HIV-1 PIC is actively 
transported into the nucleus, while MLV PIC only enters the nucleus after the disassembly of 
nuclear envelope during mitosis. Integration of viral DNA into the host genome occurs after 
nuclear entry. Capsid-targeting restriction factors Fv1, T5 and Mx2 all impose a block after 
reverse transcription and before integration.  
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Figure 1.7. The late stage of the retrovirus life cycle 
A schematic diagram showing steps in the late stage of retroviral life cycle (boxes with purple 
border), host restriction factors which target these steps (coloured boxes), and viral antagonists 
which counteract restriction by these restriction factors (boxes with black border). Full length 
retroviral RNA is transcribed using the promoter activity in the U3 region of 5’ LTR. The 
restriction factor Trim28 together with other cellular cofactors inhibit the transcription of retroviral 
RNA. Full length transcripts are either exported to cytoplasm directly, or spliced before export. 
Gag and Gag-Pol are translated from full length transcripts, while Env and HIV-1 accessory 
proteins are translated from spliced transcripts. Two copies of full length genomic RNAs are 
packaged into each virion. The assembly of immature particles involves the polymerisation of 
Gag and Gag-Pol. After membrane fission facilitated by the ESCRT machinery, the release of 
immature particles is blocked by the restriction factor tetherin. Immature particles undergo 
maturation, in which the proteolytic processing of Gag triggers the formation of a mature core 
consisting of polymerised CA, and the formation of a condensed RNP consisting of NC and 
genomic RNA.  
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(Pinter et al., 1997). Binding of SU to receptor leads to conformational changes 
in both SU and TM subunits, triggering the exchanges of disulphide bonds and 
insertion of fusion peptides of TM to the target membrane. This results in the 
formation of intramolecular bonds within the CXXC motif, and the release of SU 
from TM (Wallin et al., 2004). TM trimers then fold back to form a 6-helix 
bundle, forcing the viral and cellular membranes together for fusion (White et 
al., 2008). The binding of gp120 to CD4 triggers a conformational change, 
allowing binding of co-receptor (Chen et al., 2005; Kwong et al., 1998). Binding 
of co-receptor triggers membrane fusion in a similar way to ecotropic MLV 
involving isomerisation of disulphide bonds (Abrahamyan et al., 2003; Markovic 
et al., 2004).  
 
Sites of viral entry 
The entry of ecotropic MLV occurs in endosomes and can be blocked by 
inhibitors of endosome acidification (Kubo et al., 2012; McClure et al., 1990). 
This is supported by the observation of ecotropic MLV endocytosis through a 
clathrin-dependent pathway (Lee et al., 1999). There are contradicting 
evidences on whether HIV-1 entry requires an endocytotic (Miyauchi et al., 
2009) or non-endocytotic pathway (Maddon et al., 1988; McClure et al., 1988). 
It should be noted that viruses used in this study are pseudotyped with the 
vesicular stomatitis virus glycoprotein (VSV-g) envelope, which interacts with 
cellular LDL receptors for entry via a clathrin-dependent endocytic pathway 
(Aiken, 1997; Finkelshtein et al., 2013; Soneoka et al., 1995; Sun et al., 2005). 
 
1.3.2 Reverse transcription and uncoating 
  
After the fusion of viral and cellular membranes, the retroviral core is released 
into the cytoplasm of the target cell. Between viral entry and integration, a 
number of events take place including reverse transcription, uncoating of viral 
cores, and the transport of pre-intergation complex (PIC) to the site of 
integration in the nucleus. While MLV infects dividing cells only, HIV-1 can also 
infect non-dividing cells (Lewis et al., 1992; Weinberg et al., 1991) and therefore 
requires nuclear import of PIC. The exact order of these events is not known, 
and it is likely that many of these events occur simultaneously and may 
influence each other.  
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Reverse transcription 
Reverse transcription (Figure 1.8) involves a complex procedure involving 
multiple strand transfer steps and the synthesis of cDNA using both RNA and 
DNA as templates (Hu and Hughes, 2012). The first step of reverse 
transcription involves the binding of tRNA primers to pbs. Different retroviruses 
use different tRNA primers, with MLV utilises tRNApro (Peters et al., 1977) and 
HIV-1 uses tRNAlys3 (Ratner et al., 1985). tRNA primers are packaged into 
virion, and the RNA chaperone activity of Gag-NC has been proposed to 
facilitate the annealing of tRNA primer before viral entry (Cen et al., 2000; 
Crawford and Goff, 1985). The tRNA primer initiates the synthesis of minus 
strand cDNA by the polymerase domain of RT, while the RNase H domain of 
RT degrades the RNA strand in DNA/RNA hybrid. The resulting minus strand 
strong stop DNA contains sequence complementary to the R and U5 elements, 
and is transferred to and hybridised to the R sequence at the 3’ end of the viral 
RNA. Minus strand synthesis is continued while the RNA template is degraded, 
except for the ppt (and also cppt in the case of HIV-1) which is resistant to 
RNase H. The ppt sequence now serves as the primer for synthesis of plus 
strand strong stop DNA. After the degradation of tRNA sequence, the plus 
strand strong stop DNA is transferred and hybridised to pbs at the 3’ end of 
minus strand cDNA. Elongation of both plus and minus strands results in a 
double strand DNA copy of the viral RNA with complete LTR on both 5’ and 3’ 
ends. In HIV-1, plus strand synthesis is initiated at both the ppt and the cppt 
(Charneau and Clavel, 1991). After the transfer of plus strand cDNA initiated 
from the ppt, the elongation of this plus strand cDNA is terminated at the central 
termination sequence (CTS), which is located at 100nt downstream of the cppt 
(Charneau et al., 1994). The 100nt overlapping between the two fully elongated 
plus strand DNA results in a triple strand structure at the centre of the reverse 
transcribed HIV-1 cDNA known as the “DNA flap”. 
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Figure 1.8 Reverse transcription 
RNA is shown in red, DNA is shown in blue, tRNA is shown in purple. tRNA is annealed to the 
primer binding site (pbs) by the chaperone activity of Gag-NC before viral entry. The tRNA 
primer initiates the synthesis of minus strand cDNA by the polymerase domain of RT, while the 
RNase H domain of RT degrades the RNA strand in the DNA/RNA hybrid. The resulting minus 
strand strong stop DNA contains sequence complementary to R and U5, and is transferred to 
and hybridised to R at the 3’ end of the viral RNA. Minus strand synthesis is continued while the 
RNA template is degraded, except for the ppt which is resistant to RNase H. The ppt sequence 
now serves as the primer for synthesis of plus strand strong stop DNA. After the degradation of 
tRNA sequence, the plus strand strong stop DNA is transferred and hybridised to pbs at the 3’ 
end of minus strand cDNA. Elongation of both plus and minus strands results in a double strand 
DNA copy of the viral RNA with complete LTR on both 5’ and 3’ ends.   
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Uncoating  
In order to integrate the reverse transcribed viral DNA into host genome, the 
viral DNA and the associated proteins including IN need to be released from the 
CA core. This uncoating process has been hypothesised to involve the gradual 
conversion of the reverse transcription complex (RTC), where DNA synthesis 
occurs, to PIC, which is capable of integration (Hu and Hughes, 2012). The 
timing and location of CA uncoating appears to be very different between MLV 
and HIV-1 (Fassati, 2012). MLV RTC/PIC contains viral DNA, RT, NC, IN, CA 
and p12 (Bowerman et al., 1989; Fassati and Goff, 1999; Prizan-Ravid et al., 
2010; Risco et al., 1995).  
 CA remained associated with the RTC/PIC for at least 7h post-infection, 
but CA is disassociated from the PIC before entering the nucleus (Elis et al., 
2012; Fassati and Goff, 1999). HIV-1 RTC/PIC isolated from infected cells 
contained viral DNA, NC, MA, RT, IN and vpr, but not CA (Bukrinsky et al., 
1993; Farnet and Haseltine, 1991; Fassati and Goff, 2001; Gallay et al., 1995; 
Iordanskiy et al., 2006; Karageorgos et al., 1993; Miller et al., 1997). Many 
imaging studies showed CA colocalisation with RTC/PIC, with most studies 
suggested that HIV-1 uncoating occurs shortly after entry within 1h post-
infection (Hulme et al., 2011; Jun et al., 2011; Xu et al., 2013), although there 
has been report of detection of HIV-1 core at the nuclear pore (Arhel et al., 
2007). The RTC/PIC is transported towards the nucleus by cytoplasmic dynein 
on microtubules (McDonald et al., 2002). 
 
Relationship between reverse transcription and uncoating 
A number of recent studies have identified links between reverse transcription 
and uncoating of HIV-1 (Ambrose and Aiken, 2014). The observation that the 
disassociation of CA from RTC/PIC precedes the completion of reverse 
transcription suggested that both events occur simultaneously (Hulme et al., 
2011). Blocking of reverse transcription with RT inhibitors has been reported to 
increase HIV-1 core stability in vitro and decrease the rate of uncoating in vivo 
(Hulme et al., 2011; Yang et al., 2013). Mutations that either increase or 
decrease core stability were found to inhibit reverse transcription (Forshey et 
al., 2002).  
 
1.3.3 Nuclear localisation and integration 
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Nuclear entry 
A key difference between HIV-1 and MLV is the ability of HIV-1 to infect non-
dividing cells (Lewis et al., 1992; Weinberg et al., 1991). MLV particles only 
enter the nucleus during mitosis when the nuclear envelope is dissolved (Roe et 
al., 1993a), and p12 has been shown to target PIC to chromatin during mitosis 
(Elis et al., 2012; Prizan-Ravid et al., 2010; Schneider et al., 2013; Wight et al., 
2012). The entry of HIV-1 into nucleus of non-dividing cells would involve active 
transport mechanism across the nuclear envelope. The main determinants for 
nuclear import lies within the HIV-1 CA domain (Yamashita and Emerman, 
2004). Many host proteins, including components of the nuclear pore complex 
(NPC), have been identified through siRNA screens to promote HIV-1 nuclear 
entry, (Brass et al., 2008; Konig et al., 2008; Yeung et al., 2009; Zhou et al., 
2008). Nuclear import mediated by Nup153, Nup358 or TNPO3 appears to be 
important for optimal integration site selection, depletion of these proteins leads 
to reduced infectivity and switching of integration site from high to low gene 
density regions (Koh et al., 2013; Matreyek and Engelman, 2011; Ocwieja et al., 
2011; Schaller et al., 2011).  
 
Recent studies have been focused on the roles of Nup153, Nup358, 
TNPO3, CPSF6 and CypA on nuclear entry and their interactions with CA 
(Hilditch and Towers, 2014; Matreyek and Engelman, 2013). Nup153 contains a 
NTD, which is a structural component of the nuclear basket in the NPC 
(Enarson et al., 1998), and a flexible CTD which interacts with CA-NTD and IN 
(Matreyek et al., 2013; Woodward et al., 2009). Nup358/RanBP2 forms long 
filaments on the cytoplasmic side of nuclear pore, and is involved in the 
regulation of protein import through NPC (Wu et al., 1995; Yokoyama et al., 
1995). The C-terminal sequence of Nup358 is similar to that of the peptidyl-
propyl isomerase CypA (Bosco et al., 2002; Lin et al., 2013). Both CypA and the 
CypA-like domain of Nup358 directly interact with the cyclophilin binding loop of 
CA, between α-helices 4 and 5 of CA-NTD (Bichel et al., 2013; Gamble et al., 
1996; Luban et al., 1993; Schaller et al., 2011). Cleavage and polyadenylation 
specific factor 6 (CPSF6), an mRNA splicing protein, binds to CA-NTD (Lee et 
al., 2012; Price et al., 2012). CPSF6 also contains a C-terminal nuclear 
localisation signal (NLS) formed of RS repeats, which interacts with transportin 
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3 (TNPO3) (Maertens et al., 2014). TNPO3 is a member of the karyopherin-β 
protein family, mediating the import of splicing factors across NPC (Lai et al., 
2001). Karyopherin-β shuttles between the cytoplasmic and nuclear sides of the 
NPC, transporting cargo using the RanGTPase cycle (Chook and Suel, 2011). 
Karyopherin-β binds to its cargo protein at the cytoplasmic side of NPC, which 
include Nup153 and other components. At the nuclear side, it binds to Ran-GTP 
with high affinity while releasing its cargo. Once back to the cytoplasmic side, 
the RanGTPase activity is activated by a complex of RanGAP, RanBP1 and 
Nup358, and the RanGDP is released from karyopherin-β for the next round of 
cargo binding.  
 
The role of CypA and Nup358 in nuclear import have been studied using 
the small molecule cyclosporine (Cs) that abolish CypA but not Nup358 binding 
to CA (Luban et al., 1993; Schaller et al., 2011), and CA mutations (G89V and 
P90A) that abolish binding of both CypA and Nup358 (Schaller et al., 2011). Cs 
treatment or non-binding mutations both caused a switch of integration sites to 
region with higher density, using a nuclear entry pathway still dependent of 
TNPO3 (Matreyek and Engelman, 2011; Schaller et al., 2011). In contrast, a CA 
mutation (N74D) which abolishes binding between CA and CPSF6 led to 
random integration of provirus, using a nuclear entry pathway independent 
Nup153, Nup358 and TPNO3 (Matreyek and Engelman, 2011; Schaller et al., 
2011). These studies suggested the presence of multiple nuclear entry 
pathways that can be used by HIV-1, but only some pathways could lead to 
optimal integration site selection.  
 
Chromatin targeting 
Although the choice of nuclear entry pathway has a strong influence on HIV-1 
integration site selection, a host protein LEDGF has also been shown to target 
HIV-1 integration to transcriptionally active sites (Ciuffi et al., 2005; Marshall et 
al., 2007; Shun et al., 2007). LEDGF binds IN through its C-terminal domain, 
and causes nuclear localisation and chromatin tethering of IN through its NLS 
and chromatin-binding PWWP domain (Maertens et al., 2003). Bromodomain 
and extra-terminal (BET) family proteins Brd2, Brd3 and Brd4 have been shown 
to bind MLV IN and target MLV integration to transcription start sites (De Rijck 
et al., 2013; Gupta et al., 2013; Sharma et al., 2013). These proteins contain 
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two chromatin-interacting bromodomains which bind acetylated histone tails, 
and a conserved ET domain found in BET proteins interacts with the C-terminus 
of IN. The chromatin binding domains in BET proteins and LEDGF are the key 
determinants in integration site targeting. MLV infection in cells expressing a 
fusion protein with LEDGF chromatin binding domain and the ET domain of 
BET leads to HIV-like integration targeting pattern (De Rijck et al., 2013). 
Although MLV p12-CTD also contains sequences required for tethering of p12 
to chromatin (Elis et al., 2012; Prizan-Ravid et al., 2010; Schneider et al., 2013; 
Wight et al., 2012), p12 does not alter integration site selection (Schneider et 
al., 2013). 
 
Integration 
Integration (Figure 1.9) occurs in a tight complex of IN homotetramer and linear 
viral dsDNA (Hare et al., 2010). In addition to linear dsDNA, two types of 
circular viral DNA can also be found in the nucleus: 1-LTR circles are formed by 
intramolecular homologous recombination between the LTRs on the same 
linear dsDNA, while 2-LTR circles are formed by non-homologous end joining 
between the blunt ends of a linear dsDNA. Only linear viral dsDNA can be used 
for integration (Brown et al., 1989). 2-LTR circles are frequently used as a 
marker for nuclear entry. The first step of integration, known as 3’ processing, 
involves the removal of 2 nucleotides from 3’ end of each viral DNA strand by IN 
(Craigie and Bushman, 2012). 3’ processing converts the RTC into the 
integration-competent PIC, and probably occurs in the cytoplasm (Fassati and 
Goff, 1999). With the help of nuclear transport proteins and chromatin targeting 
factors, intasomes are transported to the integration sites. In the second step, 
known as strand transfer, the 3’ hydroxyl groups exposed from 3’ processing 
are used by IN to attack a pair of phosphodiester bonds in the target DNA, 
during which the 3’ end of viral DNA is joined to the 5’ end of host DNA. The 
sites of attack on the two strands of DNA are separated by 4 (MLV) or 5 (HIV-1) 
nucleotides. This resulted in a 4 or 5 nucleotide single strand region and a 
dinucleotide 5’ overhang at both attack sites, which are repaired by cellular 
enzymes. Proviral DNAs integrated into host genome are flanked by 4 or 5 
nucleotides of duplicated sequence.  
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Figure 1.9 Integration 
 
During 3’ processing, 2 nucleotides from 3’ end of each viral DNA strand are removed by IN. 
During strand transfer, the 3’ hydroxyl groups exposed from 3’ processing are used by IN to 
attack a pair of phosphodiester bonds in the target DNA, during which the 3’ end of viral DNA is 
joined to the 5’ end of host DNA. The sites of attack are separated by 4 (MLV) or 5 (HIV-1) 
nucleotides. This resulted in a 4 or 5 nucleotide single strand region and a dinucleotide 5’ 
overhang at both attack sites, which are repaired by cellular enzymes. Proviral DNAs integrated 
into host genome are flanked by 4 or 5 nucleotides of duplicated sequence. Reproduced from 
(Suzuki et al., 2012), permitted under open access license. 
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1.3.4 Transcription, splicing and nuclear export 
 
Transcription 
The U3 sequence of proviral LTR acts as a promoter for the transcription of viral 
RNA. Transcription of retroviral RNA starts at the U3-R boundary of the 5’ LTR, 
and terminates within the U3 region of the 3’ LTR. Each retroviral genomic RNA 
contains a 5o 7-Methylguanosine CAP and a 3’ poly(A) tail. Simple retroviral U3 
promoters are efficient and constitutively active. Complex retroviruses, 
particular those which enter latency, tightly regulate the U3 promoter activity. In 
HIV-1, the transactivator protein Tat is involved in the activation of transcription 
(Karn and Stoltzfus, 2012). Tat binds to the TAR stem-loop at the 5’ end of viral 
RNA (Dingwall et al., 1990; Dingwall et al., 1989), and the P-TEFb protein 
complex consisting of CDK-9 and CycT1 (Wei et al., 1998). Tat binding 
activates P-TEFb, which in turns phosphorylate RNA polymerase II and a 
number of elongation factors to stimulate transcription elongation (Karn and 
Stoltzfus, 2012). Binding sites for the transcription factor NF-κB are found in the 
enhancer region of the U3 promoter of HIV-1, and are required for the activation 
of transcription (Alcami et al., 1995; Nabel and Baltimore, 1987).   
 
Splicing 
Splicing of mRNA involves the removal of introns between a 5’ splice site and a 
3’ splice site, and requires a large RNP complex known as spliceosome. The 
MLV RNA contains only one 5’ splice site and one 3’ splice site, resulting in just 
unspliced and singly spliced RNA. In contrast, splicing of HIV-1 viral RNA is 
highly complex, involving four 5’ splice sites, eight 3’ splice sites and more than 
potential 40 splice variants. However, the relative abundance of different splice 
variants is very different (Purcell and Martin, 1993), with a number of sequence 
and structural RNA elements controlling the strengths of individual splice sites 
(Karn and Stoltzfus, 2012). 
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Nuclear export 
 
Complex retroviruses such as HIV encode proteins for control of RNA export 
and  HIV-1 Rev protein mediates the export of RRE-containing unspliced and 
spliced RNA (Malim et al., 1989). At the early phase of RNA expression, viral 
RNAs are subjected to rapid and multiple splicing in the nucleus, so that the 
majority of the exported viral RNAs would be multiply spliced RNA lacking the 
RRE sequence. These multiply spliced RNA leads to expression of Tat, Rev 
and Nef. At the late phase, the accumulation of Rev in the nucleus leads to the 
binding of Rev to RRE. As a result, RRE-containing viral RNAs are exported 
before splicing is complete. These RRE-containing RNAs include the unspliced 
genomic RNA which is packaged into nascent particles and is required for the 
translation of Gag and GagPol; as well as incompletely spliced RNAs required 
for the translation of Env, Vif, Vpr and Vpu. The Rev-RNA complexes are 
exported across the NPC through the binding of its nuclear export signal (NES) 
to the karyopherin Crm1, and re-enter the nucleus through interaction of its NLS 
with importin-β (Henderson and Percipalle, 1997; Neville et al., 1997). Like 
TNPO3, the transport of cargo by Crm1 and importin-β are driven by the Ran 
GTPase cycle. Although MLV does not express any viral protein for nuclear 
export, it contains a cis-acting cytoplasmic accumulation element (CAE) 
towards the end of the pol gene to mediate nuclear export of both spliced and 
unspliced RNA by the NXF1/TAP karypherin (Pessel-Vivares et al., 2014; 
Sakuma et al., 2014).   
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Translation 
 
The translation of many cellular mRNA requires the recruitment of ribosome at 
the 5’ CAP structure. The ribosome then scans along the mRNA until it 
encounters an initiation codon flanked by a good Kozak sequence (Kozak, 
1986). Despite the close proximity of start codons to the 5’ CAP, the translation 
of MLV Gag, Glyco-Gag and Env all require CAP-independent mechanisms. 
Two separate internal ribosome entry sites (IRES) have been identified in MLV, 
with the first IRES present immediately upstream of the initiation codon of the 
gag gene for the translation of Gag, Glyco-Gag and GagPol proteins, and the 
second IRES present between the splice junction and the initiation codon of the 
env gene for the translation of Env protein (Berlioz and Darlix, 1995; Deffaud 
and Darlix, 2000). Two IRES have been proposed to be involved in the 
translation of HIV-1 Gag, one in the 5’ untranslated region (Brasey et al., 2003; 
Gendron et al., 2011), and one in the gag coding region (Buck et al., 2001). 
While both CAP-dependent and CAP-independent initiation mechanisms can 
drive the translation of HIV-1 Gag and GagPol, the translation of other HIV-1 
proteins requires a CAP-dependent initiation mechanism (Amorim et al., 2014; 
Monette et al., 2013). Many aspects of the translation of HIV-1 and MLV 
proteins were also discussed earlier in section 1.1.3.  
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1.3.5 Assembly and budding 
 
RNA packaging and dimerisation 
Orthoretroviral particles contain dimers of genomic RNA and mostly Gag 
proteins. The packaging of viral genomic RNA into particles requires interaction 
Gag-Gag and Gag-RNA interactions. This is supported by the in vitro assembly 
of CA-NC gag fragments with RNA (Ganser et al., 1999; Zuber et al., 2000). 
Importantly, full length genomic RNA needs to be specifically packaged from a 
mixture of cellular RNA and spliced viral RNA in the cytoplasm. This packaging 
specificity is mediated by the selective binding of Gag-NC domain to the 
packaging signal (ψ-site) in genomic RNA, and in often coupled to the 
dimerisation of genomic RNA (Nikolaitchik et al., 2013; Rasmussen and 
Pedersen, 2004). In MLV, the ψ-site is required for both dimerisation and 
packaging, and is absent in spliced viral RNA (D'Souza and Summers, 2005). 
The MLV ψ-site contains two stem-loops responsible for the initiation of 
dimerisation (DIS-1 and DIS-2) (Ly and Parslow, 2002), and two additional 
stem-loop important for packaging (SL-C and SL-D) (D'Souza et al., 2004). 
Gag-NC causes conformation change in ψ-site, probably through its RNA 
chaperone activity, stabilising an alternative form of the RNA (D'Souza et al., 
2001; D'Souza and Summers, 2004). In this conformation a 4nt palindromic 
sequence in the loop region of DIS-1 and DIS-2 are exposed, leading to inter-
molecular “kissing interactions” between equivalent loop regions of monomers, 
eventually forming extensive dimer linkage during maturation (D'Souza et al., 
2001; Girard et al., 1995; Tounekti et al., 1992). The RNA dimer conformation is 
stabilised by the binding of NC to high affinity sites with the unpaired guanidine 
of UCUG elements, which are exposed in the dimeric conformation (D'Souza et 
al., 2001; Dey et al., 2005). SL-C and SL-D, although not necessary for 
dimerisation, also forms kissing interactions between the conserved palindromic 
GACG tetraloop of RNA monomers (Kim and Tinoco, 2000).  
 
In HIV-1, RNA packaging and dimerisation occurs in the cytoplasm 
(Moore et al., 2009). The HIV-1 ψ-site at the 5’ leader sequence includes four 
stem-loops: SL1, SL2, SL3 and SL4 (Sakuragi et al., 2007) SL1 and SL3 are 
most important for packaging and dimerisation. SL1 contains a 6nt palindromic 
dimerisation initiation signal (DIS), and form kissing interaction between 
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monomeric RNA and can drive dimerisation in vitro (Clever et al., 1996; 
Laughrea and Jette, 1994). The kissing loops are converted into extensive 
dimer linkage structure during maturation with NC as a chaperone (Kafaie et al., 
2008; Ohishi et al., 2011). SL2 contains the 5’ major splice donor site, and is 
dispensable for packaging (Purcell and Martin, 1993). SL3 is the major 
packaging signal, and contains a GGAG tetraloop which forms tight interaction 
with gag-NC (De Guzman et al., 1998). As SL2 precedes SL3, spliced RNAs 
are not packaged.  
 
Membrane targeting 
While core assembly of some retroviruses such as MPMV and MMTV can occur 
in cytoplasm, others including MLV and HIV-1 require attachment to lipid 
membranes. The membrane targeting of Gag-MA allows the transport of HIV-1 
and MLV Gag to lipid membranes enriched in cholesterol and several lipids 
including sphingomyelin, phosphatidyl serine (PS), phosphatidyl ethanolamine 
(PE) and phosphatidyl inositol (4,5) bisphosphate (PIP2) (Chan et al., 2008). N-
terminal myristoylation is essential for stable attachment of Gag to membrane 
and for assembly of MLV and HIV-1 (Bryant and Ratner, 1990; Rein et al., 
1986; Spearman et al., 1994). A switch mechanism has been recently proposed 
between RNA and lipid binding activities of HIV-1 MA (Alfadhli and Barklis, 
2014). Surface basic residues on HIV-1 MA form overlapping binding sites for 
both RNA and lipid with acidic head groups (Alfadhli et al., 2011; Jones et al., 
2011). Gag binds to RNA through both NC and MA subunits (Jones et al., 
2011). Once this complex reaches the plasma membrane, acidic phospholipids 
such as PIP2 compete with RNA for MA binding (Alfadhli et al., 2011; Jones et 
al., 2011). The electrostatic interaction between MA and lipid induces the 
extrusion of N-terminal myristoyl group in MA, allowing stable lipid anchoring of 
gag (Saad et al., 2006). This allows the tethering of gag to lipid membrane via 
MA, and to genomic RNA via NC.  
 
Gag polymerisation 
Once the Gag-RNA complex is tethered to the site of assembly on the plasma 
membrane, polymerisation of Gag begins. The immature gag lattice consists of 
1100-1800 Gag molecules for MLV  (Yeager et al., 1998), and 2500 Gag 
molecules for HIV-1 (Briggs et al., 2004; Carlson et al., 2008). Gag molecules in 
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the lattice are organised into regular symmetric units, and held by strong Gag-
Gag interactions. Electron cryo-tomography analyses of native budding sites 
(Carlson et al., 2010) and native immature particles (Wright et al., 2007; Yeager 
et al., 1998) have shown that Gag proteins of MLV and HIV-1 are arranged into 
regular arrays, with hexagonal symmetry. MA also appears to form inter-
hexameric contacts with its trimer interface (Alfadhli et al., 2007; Huseby et al., 
2005). In addition, there are indirect contacts between NC subunits through the 
binding of viral RNA.  
 
Budding 
Budding of retroviruses involves membrane deformation, followed by membrane 
fission (Votteler and Sundquist, 2013). The membrane deformation transforms 
the planar plasma membrane into a spherical shape in the immature particle. 
The polymerisation of HIV-1 gag into an immature lattice leads to the formation 
of an almost complete spherical particle, which still connects to the cell through 
a neck region (Carlson et al., 2008). The next step, membrane fission, resolves 
this neck region leading to release of the immature particle. Membrane fission 
requires the ESCRT machinery, which contains multiple protein complexes. The 
ESCRT pathway mediates membrane fission during cytokinesis and during the 
formation of intraluminal vesicles in multivesicular bodies (McCullough et al., 
2013). Many retroviruses contain late assembly (L-)domains for the recruitment 
of proteins from the ESCRT pathway. There are 3 types of L-domains: 
P(T/S)AP, LYPXnL and PPXY. The P(T/S)AP motif binds to the UEV domain of 
Tsg101, which is a subunit of the heterotetrameric ESCRT-I complex. This motif 
is found in the MA region of MLV Gag (Segura-Morales et al., 2005) and in the 
p6 region of HIV-1 Gag (Garrus et al., 2001). The LYPXnL motif binds the V 
domain of the ESCRT-associated protein Alix. This motif is found at the junction 
between MA and p12 in MLV (Segura-Morales et al., 2005), in the p6 region of 
HIV-1 (Strack et al., 2003). The HIV-1 NC domain also interacts with the Bro1 
domain of Alix, but this interaction is dependent on RNA-binding (Sette et al., 
2012; Strack et al., 2003). Both ESCRT-I and Alix can activate the ESCRT-III 
proteins such as the CHMP2 and CHMP4 complex (Sundquist and Krausslich, 
2012). Activated ESCRT-III complex generates long filament which coil into a 
dome shape at the neck of the budding virus. The recruitment of the Vps4 
ATPase terminates membrane fission through hydrolysis of ATP, releasing the 
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virus and ESCRT-III proteins. Lastly, the PPXY motif binds to WW motif of 
Nedd4 family ubiquitin ligases. This motif can be found in the p12 region of 
Gag, and mutation of the PPPY motif leads to the formation of tubular particles 
(Yuan et al., 2000). Although little is known about the incorporation of retroviral 
Env, clustering of HIV-1 Env around budding sites containing HIV-1 gag have 
been reported (Muranyi et al., 2013). This recruitment of Env requires the 
cytoplasmic tail of TM, and is sensitive to mutations in MA. 
 
1.3.6 Maturation 
 
Nascent orthoretroviral particles contain an immature core consist of Gag, Gag-
Pol and viral RNA. Retroviral maturation is controlled by the proteolytic 
processing of Gag and Gag-Pol precursor proteins, leading to the formation of a 
condensed capsid core. The transition from immature to mature core involves 
rearrangements of CA, triggered by the stabilisation of β-hairpin at the N-
terminus, and removal of NC (and SP1) on the C-terminus. This leads to an 
increase in inter-hexameric distance and formation of inter-hexameric 
interactions between CA-CTD. In addition to changes in capsid core, maturation 
also leads to the formation of stable dimer linkages, the annealing of tRNA 
primer, and the activation of Env for fusion through the cleavage of R-peptide 
from Env by PR (Loving et al., 2012; Rein, 2010; Sundquist and Krausslich, 
2012; Wyma et al., 2004).  
 
  
63 
In HIV-1, the timing of maturation is tightly controlled by the sequential 
cleavage of different processing sites by PR, with up to 400-fold difference in 
cleavage rates (Figure 1.10) (Pettit et al., 1994). Studies of core morphology of 
HIV-1 processing site mutants by transmission electron microscopy (TEM) have 
led to the evaluation of the effects of each cleavage event (de Marco et al., 
2012; de Marco et al., 2010b; Sundquist and Krausslich, 2012). The first 
cleavage event occurs at the SP1/NC junction forming the MA-SP1 and the 
SP1-p6 products, this triggers the condensation of NC-RNA complex and 
activates Env for fusion (de Marco et al., 2010b; Wyma et al., 2004). At this 
stage, the CA layer remains tethered to the membrane through the MA domain 
(de Marco et al., 2010b). Next, the cleavage at the MA/CA junction releases the 
CA-SP1 product from the lipid membrane. This leads to the stabilisation of β-
hairpins in CA-NTD. Although CA-SP1 is released from membrane tethering, at 
this stage mature core structures are not yet formed, with fragments of capsid 
shell observed in some particles (de Marco et al., 2010b). Finally, the cleavage 
of the SP1 bundle from CA leads to the destabilisation of CA-CTD hexamers, 
allowing the rearrangement of CA-CTD to form interactions at trimer and dimer 
interfaces (Meng et al., 2012). Further processing of the NC-SP2-p6 precursor 
also releases NC, which acts as a chaperone to facilitate the formation of stable 
dimer linkages (Kafaie et al., 2008; Ohishi et al., 2011). Some studies 
suggested that MLV processing sites are cleaved at similar efficiencies (Feher 
et al., 2006; Oshima et al., 2004), but the slower cleavage at the MA/p12 
junction has been reported (Wight et al., 2012). The control of maturation is not 
well understood, although it is known that the formation of mature core requires 
cleavage at the p12/CA junction but not at the MA/p12 junction (Oshima et al., 
2004). 
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Figure 1.10 Sequential processing of HIV-1 gag 
 
In HIV-1, the timing of maturation is tightly controlled by the sequential cleavage of different 
processing sites by PR, with up to 400-fold difference in cleavage rates. The first cleavage 
event occurs at the SP1/NC junction forming MA-SP1 and SP1-p6 products. Cleavage at the 
MA/CA junction releases CA-SP1 from the lipid membrane, but at this stage mature core 
structures are not yet formed. Final cleavage at the CA/SP1 junction leads to the formation of 
mature capsid core. In parallel to the processing of CA, p6 and SP2 are sequentially released 
from the NC-SP2-p6 fragment, allowing the formation of RNP between NC and RNA. 
Reproduced from (de Marco et al., 2010b), with permission under PLOS open-access license 
and the Creative Commons Attribution (CC BY) license.  
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1.4 Retroviral restriction factors 
 
The coevolution between host and retrovirus has led to the emergence of host 
cellular defence mechanisms, as well as viral counteracting mechanisms. In 
recent years, many host proteins have been found to restrict retroviral infection 
by targeting various steps of the retroviral life cycle (Figure 1.6, Figure 1.7). 
These host proteins, termed restriction factors, are often under positive 
selection for their antiviral role (Fay and Wu, 2000). To evade from restriction, 
retroviruses can either mutate viral proteins targeted by restriction factors, or 
encode viral proteins, termed viral antagonists, to mediate the degradation of 
restriction factors. The presence of entry receptors, restriction factors and viral 
antagonists all contributes to the specificity of retroviruses in host cells, or 
retroviral tropism.  
 
1.4.1 Restriction factors targeting viral entry 
 
Some restriction factors inhibit viral infection by blocking envelope mediated 
entry mechanisms. The interferon inducible transmembrane (IFITM) proteins, 
including IFITM1, IFITM2 and IFITM3, restrict a broad range of viruses including 
HIV-1 but not MLV (Brass et al., 2009; Lu et al., 2011; Perreira et al., 2013). 
These IFITM proteins have evolved under positive selection (Everitt et al., 2012; 
Zhang et al., 2012b). IFITM is anchored to the cytosolic side of the plasma 
membrane through two intramembrane domains (Perreira et al., 2013), and 
blocks membrane fusion driven by viral envelope proteins (Li et al., 2013), It has 
been hypothesised that IFITM remodels and strengthens the plasma membrane 
to resist action of viral fusion peptides (John et al., 2013). 
 
1.4.2 Restriction factors targeting reverse transcription 
 
Several restriction factors are known to target reverse transcription by 
retroviruses through different mechanisms. The interferon-inducible 
apolipoprotein C mRNA-editing enzyme catalytic polypeptide 3G (APOBEC3G) 
is a cytidine deaminase which introduce C to U conversion in DNA through the 
nucleophilic attack of the amine group at position 4 of the pyrimidine ring, and 
has been found to inhibit infection by HIV-1 harbouring deletion of Vif (Chen et 
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al., 2006; Sheehy et al., 2002). APOBEC3G has evolved under strong positive 
selection (Sawyer et al., 2004). During reverse transcription, APOBEC3G 
causes CC to CU deamination in the viral minus-strand DNA, leading to GG to 
AG hypermutations in the viral genome (Lecossier et al., 2003). This introduces 
lethal mutations including introduction of in-frame stop codons through TGG to 
TAG mutations (Mangeat et al., 2003). APOBEC3G can also inhibit many steps 
of reverse transcription without introducing hypermutations (Bishop et al., 2008; 
Iwatani et al., 2007). The HIV-1 accessory protein Vif binds APOBEC3G and 
recruits an E3-ubiquitin ligase complex involving cullin 5, elongin B, elongin C, 
RBX1 and CBF-β (Jager et al., 2012; Kobayashi et al., 2005; Yu et al., 2003), 
leading to polyubiquitination and subsequent degradation of APOBEC3G by 
proteasome (Yu et al., 2003).  
 
Another restriction factor, SAM domain and HD domain containing 
protein 1 (SAMHD1), inhibits reverse transcription during HIV-1 infection in 
differentiated myeloid cells (Laguette et al., 2011a). SAMHD1 has evolved 
under positive selection (Zhang et al., 2012a). SAMHD1 hydrolyses dNTP into 
dN and triphosplates, and is thought to restrict reverse transcription by depletion 
of the cellular dNTP pool (Goldstone et al., 2011). The active form of SAMHD1 
is a tetramer consists of 4 catalytic sites and 8 allosteric sites (Ji et al., 2013). 
The restriction of SAMHD1 is abolished by the expression of Vpx from HIV-2 or 
SIVmac (Hrecka et al., 2011; Laguette et al., 2011b). Similar to the antagonism of 
APOBEC3G by Vif, Vpx binds SAMHD1 and recruits an E3-ubiquitin ligase 
complex involving cullin 4A, DDB1 and DCAF1 for polyubiquitination and 
proteasomal degradation of SAMHD1 (Schwefel et al., 2014).  
 
Although the exact restriction mechanism is not known, the RNA-
associated early-stage anti-viral factor (REAF) blocks infection by HIV-1, HIV-2 
and SIV during reverse transcription (Marno et al., 2014). REAF is a 
phosphatase which binds the CTD of RNA polymerase II, and is involved in the 
control of transcription cycle (Ni et al., 2011; Ni et al., 2014). Determinants of 
restriction were found on CA and Env (Schmitz et al., 2004); restriction is 
controlled by the pathway of endocytosis used for virus internalisation (Harrison 
and McKnight, 2011; Marchant et al., 2005). Since REAF binds DNA and is 
degraded by proteasome during reverse transcription, it has been hypothesised 
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to restrict retrovirus by targeting reverse transcription products for degradation 
(Marno et al., 2014). 
 
1.4.3 Capsid-targeting restriction factors 
 
Several restriction factors including Fv1, T5, Trim5Cyp (TCyp), Trim1 and Mx2 
restrict retroviral infection by specifically targeting the capsid core. While Fv1 
restricts retrovirus infection after reverse transcription but before integration 
(Huang et al., 1973; Jolicoeur and Baltimore, 1976); T5, TCyp and Trim1 can 
also block reverse transcription (Keckesova et al., 2004; Nisole et al., 2004; 
Sayah et al., 2004; Stremlau et al., 2004; Yap et al., 2004). Fv1, T5 and TCyp 
will be discussed in detail later. More recently, the interferon-inducible 
myxovirus resistance 2 (Mx2) has been found to restrict HIV-1 (Goujon et al., 
2013; Kane et al., 2013; Liu et al., 2013). Some sites on Mx2 have evolved 
under positive selection (Busnadiego et al., 2014; Sironi et al., 2014). Similar to 
Fv1 and T5, Mx2 contains an N-terminal domain which defines specificity, and a 
C-terminal domain which can mediates dimerisation (Fricke et al., 2014). Mx2 
binds to CA polymers and causes stabilisation of core, and has been proposed 
to restrict HIV-1 by block uncoating (Fricke et al., 2014). 
 
1.4.4 Restriction factors targeting transcription 
 
Some other restriction factors target the late stage of retroviral life cycle, such 
as transcription of viral RNA. Trim28 causes transcriptional silencing of MLV in 
mouse embryonic cells (Wolf et al., 2008). MLV provirus is sensed by different 
zinc finger proteins including ZPF809 which binds specifically to the pbs of 
ecotropic MLV proviruses, and YY1 which binds to the MLV LTR (Schlesinger et 
al., 2013; Wolf and Goff, 2009). Trim28 then recruits a large number of 
chromatin modifiers to form a large silencing complex (Wolf et al., 2008). 
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1.4.5 Restriction factors targeting particle release 
 
Other restriction factors target the release of retrovirus particle from the cell 
surface after viral fission. The interferon-inducible tetherin protein restricts HIV-1 
with Vpu deletions (Neil et al., 2008). The tetherin has a transmembrane 
domain near the N-terminus and a C-terminal glycophospatidylinositol (GPI) 
anchor, and a long coiled-coil helix for dimerisation (Hinz et al., 2010; Kupzig et 
al., 2003; Schubert et al., 2010; Yang et al., 2010). When the two lipid anchors 
are on different membranes, tetherin links virus particles to each other and to 
the plasma membrane (Neil et al., 2008). Different lentiviruses have evolved to 
use different viral antagonists, including HIV-1 Vpu, HIV-2 Env and SIV Nef, all 
appear to sequester tetherin away from the cell surface (Hauser et al., 2010; 
Serra-Moreno et al., 2013). 
 
1.4.6 Innate sensing 
 
In addition to their primary role, some restriction factors including T5 and 
tetherin also act as sensors which activate innate signalling pathways upon 
detection of virus. Upon sensing retroviral CA, the E3 ubiquitin ligase activity T5 
generates K63-linked polyubiquitin chains, which activate TAK1 and the NF-κB 
pathway (Pertel et al., 2011). A long isoform of tetherin has also been bound to 
activate the NF-κB pathway (Cocka and Bates, 2012; Hotter et al., 2013). The 
presence of replicating virus is also sensed by DNA sensors present in the 
cytoplasm. Two cytoplasmic DNA sensors, IFI16 and cGAS, have been found to 
activate STING, which in turn activate IRF3 and NF-κB (Gao et al., 2013; 
Jakobsen et al., 2013; Lahaye et al., 2013; Sun et al., 2013; Thompson et al., 
2014; Towers and Noursadeghi, 2014). The transcription factors IRF3 and NF-
κB activate the production of type 1 interferon and other genes, leading to the 
activation of many interferon-inducible restriction factors including APOBEG3G, 
T5, SAMHD1, tetherin and Mx2 (Towers and Noursadeghi, 2014).  
 
Recently, it has been proposed that CA recruits host proteins to protect 
its DNA against innate sensing (Towers and Noursadeghi, 2014). Abortion of 
CPSF6 or CypA binding to CA through mutations or Cs leads to reduced core 
stability, and stimulation of type 1 interferon production in monocyte-derived 
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macrophages (Briones et al., 2010; Fricke et al., 2013a; Fricke et al., 2013b; 
Rasaiyaah et al., 2013; Tipper and Sodroski, 2014). It has been hypothesised 
that the binding of CypA and CPSF6 suppress the detection of reverse 
transcription products by cytosolic DNA sensors by interfering with the 
uncoating process (Towers and Noursadeghi, 2014). A host DNase, TREX1, 
has also been shown to protect against innate sensing of HIV-1 by digestion of 
excess viral DNA (Yan et al., 2010). The host restriction factors and innate 
sensors form a complex defense system to detect and block retroviral infection. 
Retroviruses counteract these restriction mechanisms in several ways such as 
encoding proteins to degrade or sequester restriction factors, recruiting host 
proteins prevent innate detection, or by mutating the viral target of restriction 
factors. 
 
 
 
 
1.5 Fv1 and Trim5α (T5) 
 
1.5.1 The discovery of Fv1 
 
The discovery of Fv1 began in the 1960s when certain strains of inbred mice 
displayed variable susceptibility to spleen focus formation by Friend Virus (FV) 
(Odaka, 1969; Odaka and Yamamoto, 1965). FV was later found to be a 
complex of two retroviruses: the replication defective spleen focus forming virus 
(SFFV), and the replication competent helper virus Friend MLV (Fr-MLV). The 
variable susceptibility was found to be due to two independently segregating 
genes, Fv1 and Fv2, of which Fv1 was found to target Fr-MLV (Lilly, 1970). 
Simultaneously, MLV strains had been classified into three subgroups based on 
their ability to replicate in embryonic cells derived from NIH Swiss or Balb/c 
mice (Hartley et al., 1970). MLV strains which replicate well in NIH Swiss but 
not Balb/c cells were designated N-tropic MLV (N-MLV), while those which 
replicate well in Balb/c but not NIH Swiss cells were designated B-tropic MLV 
(B-MLV). MLV strains which replicated well on both strains were classified as 
NB-tropic MLV (NB-MLV), and in this thesis NB-MLV refers to Moloney MLV. 
Studies on MLV infection in cells from crossbred mice led to the suggestion of a 
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single locus dominant factor conferring resistance to MLV infection (Pincus et 
al., 1971). Since then a number of alleles of Fv1 have been identified in mice, 
including Fv1n from NIH Swiss mice which restricts B-MLV but not N-MLV, Fv1b 
from Balb/c mice which restricts N-MLV but not B-MLV, and Fv1nr which 
restricts B-MLV and some N-MLV (Lilly and Steeves, 1973; Steeves and Lilly, 
1977). Fv1o (null) alleles which do not restrict any MLV were identified in some 
wild mice (Hartley and Rowe, 1975; Kozak, 1985). These include the Fv1o allele 
in Mus dunni which was later found to contain a premature stop codon (Lander 
and Chattopadhyay, 1984; Qi et al., 1998a). Genetic linkage studies mapped 
Fv1 to chromosome 4 (Rowe and Sato, 1973). The screening of a yeast artificial 
chromosome library of the mouse genome for MLV restriction activity revealed 
the exact location of Fv1, and enabled the subsequently cloning of the Fv1n and 
Fv1b alleles in 1996  (Best et al., 1996). Sequencing of Fv1n and Fv1b alleles 
revealed that the Fv1 gene contains an MHR motif, and is a distant relative of 
the Gag protein of an endogenous retrovirus MERV-L (Benit et al., 1997; Best 
et al., 1996). Since then, many wild mice Fv1 alleles have been cloned and 
studied (Yan et al., 2009; Yap et al., 2014). 
 
1.5.2 Functional domains and restriction determinants of Fv1 
 
The Fv1 protein consists of two structural domains (Figure 1.11): an N-terminal 
domain (Fv1-NTD) and a C-terminal domain (Fv1-CTD), joined by a flexible 
linker (Bishop et al., 2001; Bishop et al., 2006). A fragment of Fv1-NTD 
comprising of residues 20-200 could be bacterially expressed and purified, and 
was found to form dimers (Bishop et al., 2006). A coiled-coil (aa88-115) in the 
Fv1-NTD mediates the tight binding between Fv1-NTD to form antiparallel 
homodimer (Goldstone et al., 2014). Mapping of regions in Fv1 required for 
restriction revealed that Fv1 can tolerate large deletions (aa123-250) in the 
region between the coiled-coil and the Fv1-CTD without abolishing restriction 
activity, while point mutations at the MHR (aa267-286) or large truncations at 
the N- and C-termini abolish restriction (Bishop et al., 2001).  
 
The determinants for Fv1n, Fv1b and Fv1nr restriction specificity are all 
present in the Fv1-CTD, suggesting that the Fv1-CTD may be a specificity 
domain (Bock et al., 2000; Stevens et al., 2004). Fv1n and Fv1b differ at 
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positions 358, 399 and the C-terminus, all of which are present in the Fv1-CTD. 
The Fv1n allele, which only restricts B-MLV, contains the residues K358, V399 
and a short 3aa C-terminal tail (Best et al., 1996). The Fv1b allele, which 
appears to restrict only N-MLV in mice, contains the sequence E358, R399 and 
a long 22aa C-terminal tail (Best et al., 1996). Restriction studies suggested that 
sequence at positions 358, 399 and C-terminus can all influence Fv1 restriction 
specificity, with the strongest effect exerted by the charged residue at position 
358 (Bock et al., 2000). However, mutations at these variable residues do not 
always lead to predictable phenotypes, instead the restriction specificities of 
Fv1 mutants are determined by complex and combinatorial effects the of 
sequences at all 3 positions (Bishop et al., 2001).  
 
A study of wild mice Fv1 showed that like Fv1n and Fv1b, these alleles display 
different restriction specificities towards different MLV strains (Yap et al., 2014). 
In addition to MLV restriction, some Fv1 alleles can restrict non-gamma-
retroviruses including spumavirus and lentivirus (Yap et al., 2014). These alleles 
include Fv1CAR (from M. caroli) which restricts feline foamy virus (FFV) only; 
Fv1SPR1 (from M. spretus) which restricts N-MLV, B-MLV and EIAV; and 
Fv1MAC (from M. macedonicus) which restricts N-MLV and EIAV. Four variable 
regions have been identified in Fv1-CTD, with MHR, aa358, aa399 and the C-
terminus each in a distinct variable region. Like Fv1n and Fv1b, the restriction 
determinants of wild mice Fv1 alleles are complex, and the swapping of 
restriction phenotypes between alleles often require changes in sequence at 
multiple residues. Residues important for specificity were found across the 4 
variable regions, which have evolved under positive selection (Yan et al., 2009; 
Yap et al., 2014). The study of wild mice Fv1 alleles confirmed the role of Fv1-
CTD as a specificity domain, and suggested that the interaction with CA may 
involve a large surface on Fv1-CTD. It has also revealed the complexity of the 
viral recognition by Fv1, where one Fv1 allele can recognise multiple 
retroviruses from different retroviral genera, at the same time one MLV strain 
can be recognised by many but not all Fv1 alleles. 
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Figure 1.11 Sequence and structural features of Fv1   
 
A) Structural domains on Fv1. CC, coiled-coil; MHR, major homology region. Variable sites are 
indicated with blue triangles. B) Sequence variation of major Fv1 alleles.  
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1.5.3 Viral target of Fv1 
 
Shortly after the initial identification of the Fv1 gene, there was evidence 
suggesting that Fv1 restrict MLV by targeting CA. Virus susceptible to both Fv1n 
and Fv1b could be prepared by co-infection of cells with N-MLV and B-MLV 
(Kashmiri et al., 1977; Rein et al., 1976). This suggested that the determinant 
for Fv1 restriction is a component that is mixed in virions, such as proteins. NB-
tropic virus could be obtained by forced passage of B-MLV in cells expressing 
Fv1n, and the change in tropism was found to be associated with a genetic 
change mapping to the gag region (Faller and Hopkins, 1977). By testing the 
tropism of chimeric MLV containing sections of gag sequence from both N-MLV 
and B-MLV, it was found that mutations at residues 109 and 110 are sufficient 
to swap between N and B tropism (DesGroseillers and Jolicoeur, 1983). The 
charged residue at position 110 was subsequently identified as the most 
important determinant for N and B tropisms, while R110 of N-MLV is positively 
changed, E110 of B-MLV is negatively charged (Kozak and Chakraborti, 1996). 
Since K358 of Fv1n is positively charged and E358 of Fv1b is negatively 
charged, it has been hypothesised that aa358 of Fv1 forms a salt bridge with 
aa110 of CA. Detailed studies of NR and NB tropisms revealed that in addition 
to positions 109-110, many other residues on CA including aa 82, 92, 95, 105, 
114 and 117 can influence Fv1-mediated MLV tropism (Jung and Kozak, 2000; 
Lassaux et al., 2005; Stevens et al., 2004). Residues within the β-hairpin 
including positions 7 and 8 also have strong influence on N and B tropisms 
(Ohkura and Stoye, 2013). These residues cover a large exposed area of the 
MLV CA-NTD hexamer (Figure 1.12), suggesting that Fv1 may interact with CA 
through a large binding surface.  
 
1.5.4 Mechanism of Fv1 restriction 
 
Although it has been well established that Fv1 targets MLV CA, the mechanism 
by which Fv1 restrict MLV is not clear. Early infection studies showed that Fv1 
restriction is independent of the choice of pseudotype envelope and rate of 
virus adsorption, but requires the presence of MLV cores (Huang et al., 1973; 
Krontiris et al., 1973). These observations suggested that Fv1 inhibits MLV 
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infection after viral entry. It was also found that while Fv1 restriction did not 
affect synthesis of viral linear DNA, the amount of integrated DNA detected was 
reduced (Jolicoeur and Baltimore, 1976; Sveda and Soeiro, 1976). This 
suggested that Fv1 restriction affects a step after reverse transcription but 
before integration. A study of Fv1 localisation showed that Fv1 is present in the 
cytoplasm and is associated with the trans-golgi network, while a non-restricting 
mutant is mislocalised to the ER (Yap and Stoye, 2003). The block of MLV by 
Fv1 occurs in the cytoplasm. In a process known as abrogation, Fv1 can be 
saturated by pre-exposure to a restrictive virus, leading to loss of restriction 
towards a second virus which is normally restricted (Duran-Troise et al., 1977). 
The saturability of restriction is an important property shared by Fv1 and other 
capsid-targeting restriction factors. 
 
1.5.5 The discovery of Ref1 and Lv1 activities 
 
Early studies have shown that despite the lack of an Fv1-like gene, restriction of 
N-MLV but not B-MLV is observed in cell lines from human and African green 
monkey (AGM) (Towers et al., 2000). This activity was termed Ref1, and is 
associated with many Fv1-like properties including the sensitivity to aa110 of 
CA, and the abrogation of restriction by pre-treatment with a restrictive virus 
(Towers et al., 2002). Meanwhile, HIV-1 was found to be restricted in human but 
not rhesus peripheral blood mononuclear cells (PBMC), and like Fv1 the viral 
determinants of restriction has been mapped to the gag-pol region 
(Himathongkham and Luciw, 1996; Shibata et al., 1991). HIV-1 was also found 
to be restricted in many cell lines derived from old world monkeys, while SIVmac 
is restricted in many cell lines derived from new world monkeys (Hofmann et al., 
1999). One exception among the new world monkeys was owl monkeys, cell 
lines derived from owl monkeys (OMK cells) restrict HIV-1 instead of SIVmac 
(Hofmann et al., 1999). This restriction activity against lentiviruses was named 
Lv1, and like Fv1 this activity is dominant, saturable, and determined by CA 
sequence (Cowan et al., 2002; Munk et al., 2002). In contrast to Fv1, both Ref1 
and Lv1 were found to act before reverse transcription (Besnier et al., 2002; 
Cowan et al., 2002; Munk et al., 2002).  
  
75 
 
 
Figure 1.12. Viral determinants for Fv1 and T5 restriction 
 
Top: Determinants of Fv1 restriction (Stevens et al., 2004) are shown on the hexamer structure 
of N-MLV CA-NTD, PDB: 1U7K (Mortuza et al., 2004). Bottom left: residues involved in HuT5 
escape mutations (Ohkura and Stoye, 2013) are labelled in green. Bottom right: residues 
involved in RhT5 escape mutations (Ohkura et al., 2011) are labelled in red. The residue 110, 
which affects MLV N and B tropisms in both Fv1 and T5, is labelled in yellow in all structures. 
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HIV-1 and SIVmac were both found to be restricted in AGM cells, and 
these activities saturable by pre-treatment with either HIV-1 or SIVmac (Besnier 
et al., 2002). This suggested that the HIV-1 and SIVmac restriction activities were 
due to the presence of the same factor, although the restriction specificity varies 
between alleles (Besnier et al., 2002). Similarly, Ref1 and Lv1 activities were 
found to be due to the same restriction factor after the discoveries of the 
restriction of N-MLV and EIAV in human cells, and the restriction of HIV-1, 
SIVmac, N-MLV and EIAV in AGM cells (Hatziioannou et al., 2003). The 
hypothesis was strengthened by the fact that in these cells, both Lv1 and Ref1 
activities can be abrogated by restrictive lentiviruses and gamma-retroviruses 
(Hatziioannou et al., 2003).  
 
1.5.6 The identification of T5 and TCyp 
 
By screening a rhesus monkey cDNA library for genes which confer HIV-1 
restriction activity in human cells, T5 was identified to be responsible for Lv1 
activity (Stremlau et al., 2004). This was soon confirmed by a number of groups, 
and T5 was found to be restriction factor for both Ref1 and Lv1 activities 
(Hatziioannou et al., 2004; Keckesova et al., 2004; Perron et al., 2004; Yap et 
al., 2004). These studies showed that expression of T5 in non-restricting cells 
can confer resistance, while depletion of endogenous T5 by siRNA can abolish 
restriction. T5 is a tripartite motif family protein and contains the RING, B-box 2, 
coiled-coil (RBCC) domain in the N-terminal region, and a B30.2 domain in the 
C-terminal region (Figure 1.13).  
 
As mentioned earlier, although cells from new world monkey mostly 
restrict SIVmac but not HIV-1, OMK cells restrict HIV-1 but not SIVmac (Hofmann 
et al., 1999). Interestingly, the HIV-1 restriction in OMK cells can be abolished 
by treatment of Cs, which blocks the interaction between the host protein CypA 
and the CypA binding loop of HIV-1 CA (Towers et al., 2003). Subsequent 
cloning of the OMK T5 locus revealed the OMK TCyp allele, which is expressed 
as a fusion protein with RBCC domain of T5 and CypA instead of B30.2 domain 
(Figure 1.13) (Nisole et al., 2004; Sayah et al., 2004). The OMK TCyp allele is 
formed by the retrotransposition of CypA pseudogene into the T5 locus of OMK 
genome (Nisole et al., 2004; Sayah et al., 2004). Since the discovery of OMK 
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TCyp, many other TCyp alleles resulted from separate retrotransposition events 
have been identified. These include a TCyp allele found in old world monkeys 
(Brennan et al., 2007; Newman et al., 2008; Virgen et al., 2008; Wilson et al., 
2008), an ancient but decayed primate TCyp allele (Malfavon-Borja et al., 
2013), a TCyp allele found in zebrafish and pufferfish (Boudinot et al., 2011), 
and more recently a TCyp allele found in tree shrews (Mu et al., 2014). The 
CypA gene is frequently duplicated by retrotransposition, which resulted in over 
60 copies of defective CypA pseudogenes in the human genome (Zhang et al., 
2003). These TCyp alleles are unique among other CypA duplications due of 
the expression of a chimeric T5-CypA fusion protein. The fact that this unusual 
fusion event occurred on 4 independent occasions in different species 
suggested a strong evolutionary advantage for the expression of TCyp, most 
likely by allowing the recognition and restriction of HIV-1 by T5 using the CypA 
domain. There are 17 cyclophilin proteins in human (Davis et al., 2010). There 
has not been any report of retrotransposition events which resulted cyclophilin 
fusion genes apart from T5-CypA fusions. The convergent evolution of TCyp 
fusion proteins, as well as the sensitivity of restriction to the abolishment of 
CypA-CA interaction, suggested that the B30.2 domain in T5 could also be 
involved in the interactions between T5 and CA in other alleles.  
 
1.5.7 The T5 RBCC domain 
 
T5 contains the RBCC domain in the N-terminal region, and the B30.2 domain 
in the C-terminal region (Figure 1.13). Two flexible linker regions are also found 
in T5, with Linker-1 (L1) present between the RING and B-Box2, and Linker-2 
(L2) between the coiled coil and B30.2. The RBCC domain is conserved among 
members of the tripartite motif (Trim) protein family, and is required for many 
properties of T5, including dimerisation, high order self-association, formation of 
cytoplasmic bodies, turnover, and E3-ubiquitination activity. Like Fv1, T5 forms 
antiparallel dimers (Goldstone et al., 2014). Crystal structure of a fragment of T5 
B-Box2 and coiled-coil showed that the dimerisation is mediated by extensive 
interactions between the long continuous α-helices of coiled coil domains 
(Goldstone et al., 2014). The coiled-coil of Trim25 was also crystalised and  
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Figure 1.13 A comparison of domain organisations of Fv1, T5 and TCyp 
 
The coiled-coil (CC) domains are highlighted in blue, while the capsid-targeting domains are 
highlighted in pink.  
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showed similar structure (Sanchez et al., 2014). In the T5 dimer, B-box2 
domains are located on each end of the rod shape coiled-coil (Goldstone et al., 
2014). T5 dimers also form higher order assemblies, and studies of chemically 
crosslinked T5 mutants suggested that this requires the RING domain, the B-
Box2 domain, the L2 region but not the B30.2 domain (Diaz-Griffero et al., 
2009; Li and Sodroski, 2008; Liberatore and Bieniasz, 2011). The formation of 
higher order assembly correlates with stronger binding to HIV-1 CA-NC 
assemblies in vitro (Diaz-Griffero et al., 2009; Li and Sodroski, 2008; Liberatore 
and Bieniasz, 2011). A recombinant T5 protein with a Trim21 RING domain (T5-
21R) was found to self-assembly into regular hexagonal lattice, this led to the 
proposal that the higher order self-association of T5 may allow the formation of 
a T5 super-lattice, which lays on top of the CA hexagonal lattice during 
restriction (Ganser-Pornillos et al., 2011).  
 
Some T5 alleles can also form cytoplasmic bodies (Stremlau et al., 
2004). The determinants for cytoplasmic body formation has been mapped to 
the L2 region (Sastri et al., 2010). The functional importance of T5 cytoplasmic 
bodies remains controversial. Blocking the formation of these cytoplasmic 
bodies with inhibitors did not appear to affect viral restriction (Song et al., 
2005a). In contrast, L2 mutants which do not form cytoplasmic body but still 
multimerise, fail to restrict HIV-1 (Sastri et al., 2010). Co-localisation of T5 
cytoplasmic bodies with viral core and proteasome subunit has also been 
observed during viral infection (Lukic et al., 2011). The RING and B-box2 
domains mediate the rapid turnover of T5 through proteasomal degradation, 
and increased turnover of T5 has been observed in infected cells (Diaz-Griffero 
et al., 2006). E3-ubiquitin ligase activity of RING domain also leads to self-
ubiquitination, this leads to mono-ubiquitination of T5 for translocation which 
signal the translocation of T5 from cytoplasmic body to cytoplasm (Yamauchi et 
al., 2008). E3-ubiquitin ligase also acts with other proteins to synthesise 
unattached K63-linked polyubiquitin chains, which then activate TAK1 kinase 
and transcription factors NF-κB and AP-1, leading to activation of the type 1 
interferon pathway (Pertel et al., 2011).  
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1.5.8 The T5 B30.2 domain and restriction specificity 
 
The restriction specificities of many primate T5 alleles have been studied 
(Ohkura et al., 2006; Song et al., 2005c; Stremlau et al., 2005; Yap et al., 
2008). Like Fv1, some primate T5 alleles restrict retroviruses across gamma-
retroviruses, lentivirus, and spumavirus genera, yet display high specificities 
within the same genus. For example, the Orang-utan T5 can restrict HIV-1, 
SIVmac, N-MLV and FFV, but neither N-MLV nor PFV (Ohkura et al., 2006; Yap 
et al., 2008). Two alleles, human T5 (HuT5) and rhesus T5 (RhT5), are 
important to this thesis. HuT5 restricts N-MLV and EIAV but does not inhibit B-
MLV and NB-MLV, with weak inhibition of HIV-1, SIVmac and the lentivirus feline 
immunodeficiency virus (FIV) reported in some studies; RhT5 restricts HIV-1, N-
MLV, EIAV and FIV but does not inhibit B-MLV and NB-MLV, with weak 
inhibition of SIVmac reported in some studies (Hatziioannou et al., 2004; 
Keckesova et al., 2004; Ohkura et al., 2006; Perron et al., 2004; Saenz et al., 
2005; Song et al., 2005c; Stremlau et al., 2004; Yap et al., 2004). 
 
The specificity determinants of T5 restriction are mostly found on the 
B30.2 domain. The restriction specificity of T5 is defined by many residues in 3 
variable regions of B30.2 domain, with many showing evidence of positive 
selection indicated by a high ratio of non-synonymous to synonymous 
mutations (Kono et al., 2009; Maillard et al., 2007; Ohkura et al., 2006; Perron 
et al., 2006; Pham et al., 2013; Rahm et al., 2011; Sawyer et al., 2005; Song et 
al., 2005b; Stremlau et al., 2005). An example of these important residues is the 
R332 residue in human T5 (HuT5), mutation at this residue such as R332P 
allows HuT5 to fully restrict HIV-1 (Li et al., 2006c; Yap et al., 2005). Residues 
of these regions are present as flexible loops located one side of the core B30.2 
structure, which is formed of a β-sandwich containing two 7-stranded 
antiparallel β-sheets (Biris et al., 2012; Ohkura et al., 2006; Yang et al., 2012). 
These studies suggested that the recognition of retrovirus by T5 involves a 
large binding surface comprising of loops.  
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1.5.9 Viral target of Trim5α 
 
Like Fv1, the E110R mutation leads to the gain of T5 restriction by B-MLV, and 
aa110 was once considered as the primary determinant for Fv1 and T5 
restriction (Figure 1.12) (Perron et al., 2004). Studies of N-MLV escape 
mutants, which were selected through passaging in cells, led to identification of 
many escape mutations (Ohkura et al., 2011; Ohkura and Stoye, 2013). Some 
escape mutants have reduced infectivity, indicating that the escape from T5 
restriction may come with a fitness cost. These escape mutations, many of 
which involved charged residues, are found on the exposed surface of CA-NTD 
hexamer (Figure 1.12). This suggested that the interaction between T5 and CA 
may involve electrostatic interactions between B30.2 and CA-NTD hexamer. 
Since many of these mutations not only alter the sensitivity to T5 but also alter 
the sensitivity to Fv1, there may be significant overlap between the binding sites 
of Fv1 and T5 on MLV CA. A study of HIV-1 escape mutants selected in RhT5-
expressing cells also yielded mutations across the exposed surface of the CA-
NTD hexamer (Soll et al., 2013). In contrast, the restriction of TCyp is sensitive 
to only a few mutations on the CypA binding loop. 
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1.5.10 Mechanism of Trim5α restriction 
 
In contrast to Fv1, T5 also inhibits reverse transcription (Stremlau et al., 2004). 
Inhibition of proteasome can remove the block in reverse transcription, but not 
the viral restriction (Anderson et al., 2006; Wu et al., 2006). There has been 
suggestion that this early proteasome-dependent block is caused by the 
accelerated uncoating of viral core upon T5 binding (Perron et al., 2007; 
Stremlau et al., 2006). This is supported by the observation of HIV-1 CA-NC 
tube disassembly when mixed with cell lysates containing RhT5 (Zhao et al., 
2011), and the fact that accelerated uncoating of core by T5 is also 
proteasome-dependent (Kutluay et al., 2013). In the presence of proteasome 
inhibitors such as MG132, T5 does not block reverse transcription but still 
blocks viral infection before integration, resembling the restriction by Fv1 and 
Mx2. This proteasome-independent block could be due to the formation of a T5 
super-lattice surrounding the core (Ganser-Pornillos et al., 2011), thereby 
preventing binding of host factors required for trafficking or nuclear entry. 
Interestingly, proteasome inhibitors can partially relieve the restriction of HIV-1 
and SIVmac by HuT5 R332P but not by RhT5, suggesting that there are 
situations where both blocks are required to achieve full restriction (Maegawa et 
al., 2010).  
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1.6 Studies of Fv1 binding and restriction 
 
1.6.1 The apparent Fv1b inhibition of NB-MLV and B-MLV  
 
Early studies of Fv1 restriction specificity were carried out by measuring 
infectivity of different MLV strains in mice or cell lines which endogenously 
express Fv1, such as N-3T3 which expresses Fv1n and B-3T3 which expresses 
Fv1b (Kozak and Chakraborti, 1996; Pryciak and Varmus, 1992). However, the 
infectivity of MLV in these mice or cell lines is also affected by other factors 
unrelated to Fv1, and it is difficult to manipulate the Fv1 gene to study the effect 
of mutations and deletions on MLV replication. Therefore, there was a need for 
a reliable assay which allows study of the specific effect of a recombinant Fv1 
on MLV growth, in order to study the Fv1 determinants of MLV tropism. In 2000, 
a flow cytometry based restriction assay was developed in our lab (Bock et al., 
2000), and has since been used in many studies of Fv1 and T5 (Bishop et al., 
2001; Nisole et al., 2004; Stevens et al., 2004; Yap et al., 2014; Yap et al., 
2008; Yap et al., 2004).  
 
In this assay (Figure 1.14), Fv1 is expressed in a retroviral vector which 
will be referred to as LxIG (or pLxIG for the vector plasmid) in this thesis (Bock 
et al., 2000). Infection of cells with this delivery vector virus leads to integration 
of provirus into the host genome. Transcription from the provirus is driven by the 
efficient MLV U3 promoter, synthesising a bicistronic mRNA with the Fv1 ORF 
close to the 5’ end, followed by an internal ribosome entry site (IRES) 
originating from the genome of the encephalomyocarditis virus (EMCV) (Jang et 
al., 1988), and the enhanced green fluorescent protein (EGFP) reporter ORF 
close to the 3’ end (Zhang et al., 1996). Translation initiated at the 5’ CAP 
structure of the transcript allows expression of Fv1, while translation initiated at 
the IRES leads to expression of EGFP. This assay used a mouse cell line 
termed Mus dunni tail fibroblast (MDTF), that cannot express Fv1 due to a 
premature stop codon in its Fv1o allele (Lander and Chattopadhyay, 1984; Qi et 
al., 1998a). Transduction of MDTF cells with the LxIG-Fv1 vector at multiplicities 
of infection (MOI) of 1 or below allows the expression of both Fv1 and EGFP in 
a subpopulation of cells. The restriction caused by Fv1 can then be tested by 
comparing the infectivity of a MLV tester virus in the GFP+ population to that of 
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the GFP- population. These tester viruses were generated using gag sequence 
from N-MLV, B-MLV or NB-MLV (specifically Moloney MLV), and a genome 
which allows expression of EYFP under the MLV U3 promoter. FACS analysis 
allow the separation of cells into 4 populations based on GFP and YFP 
fluorescent signals, and restriction can be measured as a ratio of the 
percentage of YFP+ cells in the GFP+ population relative to the percentage of 
YFP+ cells in the GFP- population. 
 
The study of Fv1n using this assay showed restriction of B-MLV by 
almost 20-fold, but neither N-MLV nor NB-MLV (Bock et al., 2000). However, 
the results for Fv1b were surprising, in addition to the restriction of N-MLV by 
almost 20-fold, Fv1b also appeared to restrict NB-MLV by more than 5-fold, and 
appeared to weakly inhibit B-MLV by about 30% (Bock et al., 2000). These 
results raised many questions about the Fv1-controlled N and B tropisms. Why 
was the observed restriction specificity of Fv1b different from previous reports 
that Fv1b does not restrict NB-MLV and B-MLV (Hartley et al., 1970)? One 
hypothesis was that due to the strong MLV U3 promoter, Fv1 could be 
overexpressed in MDTF cells compared to cells with endogenous expression of 
Fv1 (Bock et al., 2000). Can the over-expression of Fv1b leads to restriction of 
NB-MLV and B-MLV? If it can, why did Fv1n fail to restrict or inhibit N-MLV or 
NB-MLV in the same assay? The observed restriction activities of Fv1b 
appeared to be strongest against N-MLV, intermediate against NB-MLV, and 
weakest against B-MLV. It then seems reasonable to ask whether the 
differences between restriction activities of Fv1b towards MLV strains reflect 
differences in binding activities of Fv1b towards different MLV capsid core.  
 
1.6.2 The complex determinants of Fv1 restriction specificity 
 
In order to study the determinants of Fv1 restriction specificity, 6 Fv1 mutants, 
termed “mix-and-match” mutants, were generated by swapping the amino acid 
sequence between Fv1n and Fv1b at the variable sites aa358, aa399 and the C-
terminus (Bock et al., 2000). The Fv1n allele contains the sequence K358, V399 
and a short 3aa C-terminal tail; while the Fv1b allele contains the sequence 
E358, R399 and a long 22aa C-terminal tail (Best et al., 1996). In this thesis,  
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Figure 1.14 Study of Fv1 restriction using a 2-colour FACS assay 
 
The 2-colour FACS assay was described in (Bock et al., 2000). (A) The pLxIG-Fv1 vector 
plasmid was used to generate delivery virus for transduction of MDTF cells. (B) The pCFG-YFP 
vector plasmid was used to generate tester virus for infection of transduced cells. (C) MDTF 
cells were first infected with delivery virus, allowing expression of Fv1 and EGFP in a 
subpopulation of cells. Subsequent infection with tester virus leads to expression of YFP in 
infected cells. (D) A hypothetical FACS plot showing a situation where the recombinant Fv1 
leads to restriction of YFP tester virus. 
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the wild-type and mutant Fv1 variants will be identified by a 3-letter code, with 
the first, second and third letter corresponding to the source of sequence at 
aa358, aa299 and C-terminus, respectively. Illustrated in Table 1.1, the 
sequence at aa358 appeared to have the strongest influence on the restriction 
of N-MLV, since N-MLV appeared to be restricted by Fv1 variants with E358 but 
not R358 (Bock et al., 2000). Subsequent studies with alanine mutations 
suggested that A358 also leads to restriction of N-MLV, suggesting the 
positively charged R358 may be preventing N-MLV restriction (Bishop et al., 
2001). For B-MLV, full or partial restriction was observed with all Fv1 variants 
except Fv1bbb and Fv1bnb, suggesting that the combination of E358 and a 
long C-terminal tail have inhibitory effect on Fv1 restriction (Bock et al., 2000). 
This was also confirmed by the fact that Fv1bAb (where A represent A399) did 
not restrict B-MLV (Bishop et al., 2001). However, partial restriction of B-MLV is 
observed with Fv1Abb but not Fv1Anb mutant suggesting that R399 also 
enhances B-MLV restriction, and similarly weak inhibition is observed in Fv1bbb 
but not Fv1bnb variants (Bishop et al., 2001; Bock et al., 2000). All variants 
which restrict NB-MLV has R399, although the mutant Fv1nbb did not restrict 
NB-MLV (Bock et al., 2000). The Fv1bAn mutant was also found to partially 
restrict NB-MLV, suggesting that several combinations of sequence at the 
variable sites can lead to NB-MLV restriction (Bishop et al., 2001). 
 
These early studies revealed the complexity of the determinants of Fv1 
restriction specificity. How do different Fv1 mutations lead to different restriction 
specificity against N-MLV, B-MLV and NB-MLV? It has been hypothesised that 
a mutation may change the binding affinities of Fv1-CTD to different MLV CA, 
leading to alteration of restriction specificity. However, other factors such as Fv1 
expression level and localisation may also play a role. For example, the 
mutation may lead to an increase in Fv1 protein concentration, which may allow 
the gain of binding to CA without a change in the intrinsic binding affinity. The 
different concentration of endogenous Fv1n than Fv1b suggested that mutations 
may have an effect on Fv1 protein level, either at transcription or translation 
levels (Yap and Stoye, 2003). Mutations could also alter the intracellular 
localisation of Fv1, sequestering Fv1 from the incoming core. This is supported 
by the fact that an Fv1 mutation with internal deletions (Int1, aa109-118 
deleted) was inactive (Bishop et al., 2001) and mis-localised from the trans-
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Golgi network to ER (Yap and Stoye, 2003). Which of these effects were 
contributing to the Fv1 restriction specificity?  
 
1.6.3 Fv1 and T5 binding require polymeric CA 
 
In order to test the hypothesis that binding has a major role in determining the 
specificity of MLV restriction by Fv1, the development of an assay to study Fv1 
binding to MLV CA would be needed. However, the demonstration of Fv1 to 
MLV binding was found to be difficult. Early attempts in our lab to demonstrate 
the interaction between Fv1 and CA using yeast two-hybrid or co-
immunoprecipitation techniques were unsuccessful (cited in Dodding et al., 
2005). However, in a process known as abrogation, Fv1 can be saturated by 
pre-exposure to a restrictive virus, leading to loss of restriction towards a 
second virus which is normally restricted (Duran-Troise et al., 1977). This 
strongly suggested an interaction between Fv1 and the viral core, and this must 
require a polymerised form of CA rather than monomeric CA. The human factor 
Ref1 which restricts N-MLV but not B-MLV is also sensitive to mutations at 
aa110 in a similar way to Fv1 (Towers et al., 2000). This also led to the question 
on whether Fv1 and Ref1 recognise MLV CA in a similar way. A study in our lab 
showed that the expression of properly processed, monomeric form of MLV CA 
cannot saturate Fv1 and Ref1 activities (Dodding et al., 2005). Furthermore, we 
showed that processing at both N-terminus and C-terminus of MLV CA, as well 
as the stabilisation of β-hairpin by the P1-D54 salt bridge, are essential for 
abrogation of Fv1 and Ref1 activities (Dodding et al., 2005). These data 
suggested that both Fv1 and T5 recognise the mature capsid shell consisting of 
polymerised MLV CA. Similar data on TCyp restriction were published by 
another lab (Forshey et al., 2005). 
 
Since the cloning of T5, the specific pull-down of N-MLV CA by 
glutathione S-transferase (GST)-tagged HuT5 in cell lysate was reported 
(Sebastian and Luban, 2005). However, many attempts in our lab and other 
labs failed to reproduce such finding (Jonathan Stoye, personal 
communication). Shortly afterwards, Stremlau et al demonstrated the specific 
binding of T5 to HIV-1 CA-NC tubes (Stremlau et al., 2006). These tubular  
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Table 1.1 Complex restriction specificity of Fv1 
 
Restriction phenotypes of “mix-and-match” and C-terminal tail truncation Fv1 mutants (Bishop et 
al., 2001; Bock et al., 2000). The mutants were named with a 3 letter code. The first, second 
and third letter represent the origin of sequence at positions 358, 399 and C-terminus, 
respectively. For example, wild-type Fv1
n
, which has the sequence K358, V399 and short 3aa tail at 
C-terminus, is labelled as nnn; while wild-type Fv1
b, which has the sequence E358, R399 and a long 22aa 
tail at C-terminus, is labelled as bbb. Underscore indicates the truncation of C-terminal tail. 
  
Fv1 N-MLV B-MLV NB-MLV 
bbb + (-) (+) 
bbn + + + 
bnb + - - 
bnn + (+) - 
nnn - + - 
nnb (-) + - 
nbn - + + 
nbb - + - 
nn_ - + - 
bb_ + (+) + 
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complexes were assembled by incubating HIV-1 CA-NC with a DNA 
oligonucleotide. Following incubation with lysate from cells transiently over-
expressing T5, the CA-NC tubes together with bound T5 were separated from 
unbound T5 and cellular proteins by ultracentrifugation through a 70% sucrose 
cushion. This study demonstrated the specific binding of RhT5 but not HuT5 to 
HIV-1 CA-NC tubes (Stremlau et al., 2006). The binding was also found to 
require the coiled-coil and B30.2 domains but not the RING and B-box domains, 
suggesting that the basic requirement for restriction factor binding is the 
presence of a multimerisation domain and a capsid-binding domain. This idea 
was confirmed by the discovery that artificial restriction factor against HIV-1 
could be generated by fusing various dimerisation domains to CypA (Yap et al., 
2007). The R332P mutant of HuT5 which restricts HIV-1 was also found to bind 
HIV-1 CA-NC tubes, which confirms the role B30.2 in defining the binding and 
restriction specificity of T5 (Li et al., 2006c; Yap et al., 2005). 
 
1.6.4 The apparent binding of Fv1b to NB-MLV and B-MLV 
 
The demonstration of T5 binding to HIV-1 CA-NC suggested that a similar 
approach could be used to study binding of Fv1 and T5 to MLV CA. However, 
N-MLV and B-MLV CA-NC failed to polymerise in the presence of 
oligonucleotides, so other methods were explored (Hilditch, 2010). Other 
studies have described the assembly of hexameric array by N-terminally His-
tagged MLV CA on planar monolayer lipid containing a Nickel-chelating lipid, 
which have proved useful for high resolution electron tomography studies as the 
averaging of symmetric units of the assay allows reduction of signal to noise 
ratio (Barklis et al., 1997; Ganser et al., 2003; Mayo et al., 2003). An alternative 
method known as helical crystallisation has also been developed to form protein 
arrays on lipid nanotubes (Wilson-Kubalek et al., 2010). These nanotubes 
involve a curvature forming lipid galactosylceramide (GalCer), and a lipid with 
functionalised head group such as the Nickel-chalating 1,2-dioleoyl-sn-glycero-
3-[(N-(5-amino-1-carboxypentyl) iminodiacetic acid)succinyl] (DGS-NTA) (Dang 
et al., 2005a; Dang et al., 2005b). After incubation with C-terminally His-tagged 
MLV CA, lipid nanotubes can be observed to be coated with a regular protein 
layer by electron microscopy (Hilditch et al., 2011). Tomography studies 
showed that the protein array is organised as a hexagonal lattice (Hilditch et al., 
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2011). Binding of Fv1 could be studied by incubation of CA-coated lipid 
nanotubes with lysate from cells over-expressing Fv1, followed by separation of 
nanotubes and bound Fv1 from unbound proteins by ultracentrifucation through 
a 40% sucrose cushion (Hilditch et al., 2011). This study showed the specific 
binding of Fv1n to B-MLV CA, but not to N-MLV or NB-MLV. This binding 
specificity matched the observed restriction specificity from our early study 
(Bock et al., 2000). Similar to the restriction specificity of Fv1n, the binding 
specificity of Fv1n is also sensitive to mutation at aa110. While E110R mutation 
in B-MLV leads to loss of binding, the R110E mutation in N-MLV leads to gain 
of binding to Fv1n. This binding can be abolished by either of two mutations, 
P1G and D54A, which disrupt the formation or stabilisation of β-hairpins. 
Electron microscopy showed disruption to the otherwise regular lattice on 
nanotubes coated with P1G and D54A CA. This confirmed the idea that Fv1 
interacts with the mature form of CA, in which the β-hairpin is stabilised 
(Mortuza et al., 2004). While many Fv1n mutants that do not restrict B-MLV also 
failed to bind B-MLV CA, binding of Int1 mutant to B-MLV could be detected. 
Therefore, the defect in Int1 was most likely due to mis-localisation rather than 
loss of binding (Yap and Stoye, 2003). 
 
The pattern of Fv1b binding observed using this assay was more 
surprising. Fv1b appeared to bind CA from N-MLV, B-MLV and NB-MLV equally 
(Hilditch et al., 2011). These Fv1b binding can be abolished by P1G and D54A 
mutation in CA, ruling out the non-specific interactions with lipids. Since Fv1b 
restriction showed strong restriction of N-MLV, intermediate restriction of NB-
MLV and weak inhibition of B-MLV (Bock et al., 2000), differences between the 
apparent binding affinities of Fv1b to different MLV CA is expected if there is a 
direct restriction-binding correlation. Why was a differential binding of Fv1b to 
different MLV CA not observed using this binding assay? First, it is possible that 
Fv1b distinguishes between CA of different tropisms by recognising a structure 
that present on the mature capsid shell, but not on the CA lattice on lipid 
nanotubes. The curvature of the nanotubes is different from that of a mature 
MLV core. The C-terminus of CA is tethered to the lipids via the His-tag, which 
may have prevented some of the conformational changes required to complete 
the maturation. Secondly, it is possible that although Fv1b binds to all MLV CA 
with similar apparent affinity, there are differences in the amount of Fv1b binding 
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required to cause restriction. Lastly, it is possible that while Fv1b binds to all 
MLV CA, the small differences in apparent binding affinity can only distinguish 
at a small window of Fv1b concentrations.  
 
1.6.5 Fv1 expression level and restriction 
 
Restriction of NB-MLV and weak inhibition of B-MLV by Fv1b was observed in a 
previous study in our lab (Bock et al., 2000), but not in previous studies carried 
out in cell lines expressing Fv1b endogenously (Hartley et al., 1970). On the 
other hand, the binding of Fv1b to all MLV CA on lipid nanotubes appears to be 
similar (Hilditch et al., 2011). To explore the possibility that the apparent Fv1b 
restriction of NB-MLV and inhibition of B-MLV could be due to over-expression, 
an examination of the relationship between Fv1 concentration and restriction 
began in a previous study (Felton, 2012). First, the transcription and translation 
of endogenous Fv1n and Fv1b were studied. The core Fv1 promoter was 
identified within the 431bp upstream of the Fv1 ORF. This promoter is not 
interferon-inducible, but has bidirectional activities for transcription of both Fv1 
and the neighbouring gene Miip, which encode the Migration and invasion 
inhibitory protein. Despite having almost identical promoter sequences, 
quantitation of Fv1 transcripts revealed a 23-fold higher Fv1 mRNA level in N-
3T3 cells endogenously expressing Fv1n than in B-3T3 cells which 
endogenously expressing Fv1b. The protein level of Fv1n in N-3T3 was also 
reported to be higher than that of Fv1b in B-3T3. The protein level of Fv1 
expressed by LxIG-Fv1 vectors in MDTF cells was also found to be higher than 
the endogenous level. This suggested that the MLV U3 promoter in the LxIG 
vectors is more efficient than the Fv1 promoter, and supports the hypothesis 
that the over-expression of Fv1 may affect the restriction specificity of Fv1b. 
 
Next, attempts were made to develop a system to express recombinant 
Fv1 at a level similar to the endogenous level of Fv1, and yet express sufficient 
amount of reporter proteins for FACS-based restriction assay. Despite many 
failed attempts, study of Fv1b restriction using one particular vector did show 
specific restriction of N-MLV without any measureable inhibition of B-MLV. This 
suggested that at low but unknown concentration of Fv1b, no B-MLV inhibition is 
observed. To directly prove that the restriction of NB-MLV and inhibition of B-
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MLV are linked to over-expression of Fv1b, an attempt was made to develop a 
system for inducible expression of Fv1 for restriction study. This system 
employed the Tet-On inducible expression system, which allows dose-
dependent induction of Fv1 and reporter expression by doxycycline. However, 
this system suffers from a number of problems, including the low expression 
level of reporter protein and the high basal expression of Fv1 even in the 
absence of the inducer. Study of Fv1b using this system did show that increase 
of Fv1b expression from the basal level to the maximally induced level can 
reduce infectivity of NB-MLV from 50% to 20%, and reduce infectivity of B-MLV 
from 100% to 70%. Analysis of Fv1b protein level suggested that the basal 
protein level is already much higher than the endogenous level. Data from this 
study suggested that an increase in Fv1b expression from an already over-
expression level can lead to further increase in restriction. However, this did not 
provide direct evidence of how increasing the Fv1b concentration from the 
endogenous level to the overexpression level correlate with the change in 
restriction specificity. 
 
1.6.6 Aims of project 
 
In this thesis I aimed to address some of the unanswered questions on binding 
and restriction of two capsid-binding restriction factors, Fv1 and T5. These 
questions can be broadly summarised into two important questions. 
 
Question 1: What controls the Fv1 restriction specificity? 
Specifically, I wanted to dissect the relationships between Fv1 expression level 
and restriction specificity, between Fv1 concentration and binding specificity, 
and between binding and restriction specificities. I started by first attempting to 
address the question on whether Fv1b specifically bind N-MLV at low 
concentration. A binding assay which allows the comparison of Fv1 binding at 
multiple Fv1 concentrations was developed. However, the specific binding of 
Fv1b to N-MLV only could not be detected. I then attempted to address the 
question on whether an increase in Fv1b concentration from the endogenous 
level to an over-expression level can lead to emergence of NB-MLV and B-MLV 
restriction. This was studied using an optimised inducible expression system 
which allows inducible Fv1 expression from a very low basal level to an over-
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expression level, while at the same time allows high expression of reporter gene 
for FACS-based assay. The results have demonstrated that the inhibition of NB-
MLV and B-MLV was indeed caused by the over-expression level of Fv1b. By 
correlating restriction with Fv1 protein level, I also demonstrated that even at 
the endogenous level, Fv1b imposes a weak inhibition against NB-MLV. Next I 
wanted to address the question on how sequences at the 3 variable sites 
influence the restriction specificity, using a total of 10 Fv1 variants which have 
different sequence at the 3 sites. I compared the over-expression level of 
different Fv1 alleles, and found that some residues have strong effects on Fv1 
protein levels. I then used the new binding assay to compare the binding of all 
10 variants to all 3 MLV CA, and found a good correlation between binding and 
restriction for N-MLV and NB-MLV. Interestingly, the Fv1bnb mutant does not 
seem to restrict B-MLV despite an apparently strong binding to B-MLV CA. 
 
Question 2: Do Fv1 and T5 recognise the same structure on MLV CA?  
Specifically, I wanted to develop a binding assay which allows recognition of 
both Fv1 and T5 to MLV CA, to allow the study of differences in the recognition 
mechanisms by these capsid-binding restriction factors. I first attempted to 
study binding of T5 to MLV CA using the binding assay developed for Fv1 
binding. However, no binding of T5 to N-MLV could be observed. I explored 
other methods of generating binding CA assemblies that can be used for 
binding study in vitro. Since there has been report of success in generating HIV-
1 hyperstable core and in vitro CA assemblies by introducing intra-hexameric 
disulphide crosslinking (Meng et al., 2012; Pornillos et al., 2010), MLV virus 
particles with double cysteine mutations were screened for evidence of 
crosslinking. Two mutants were form crosslinked CA without defects in gag 
processing, however abrogation studies in cells endogenously expressing Fv1b 
and HuT5 suggested that the cores of these mutants do not form a structure 
that can be recognised by restriction factors.  
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Chapter 2 
 
Materials and Methods 
 
2.1 Recombinant DNA 
 
A list of plasmids purchased or obtained for use in this study is shown in Table 
2.1 and Table 2.2. 
 
2.1.1 Polymerase Chain Reaction (PCR) 
 
A list of PCR products with their corresponding templates and primers is shown 
in Table 2.3. Amplification of DNA fragments from plasmids with introduction of 
new restriction sites was performed by PCR using custom made primers 
(Sigma). Each 50µl PCR reaction contained 50ng of plasmid template, 25pmol 
of forward primer, 25pmol of reverse primer, 200µM of each dNTP, 2.5U of 
PfuUltra high fidelity polymerase (Agilent Technologies) in the supplied buffer. 
PCR reactions were carried out using a PTC-100 thermal cycler (MJ research). 
Thermo cycling parameters typically consisted of 2min of initial denaturation at 
95oC; followed by 25 to 30 cycles of 1min denaturation at 95oC, 1min annealing 
at 5oC below the lowest melting temperature (Tm) of the primers, 2min extension 
at 72oC; and a final 10min extension at 72oC. 
 
2.1.2 DNA separation by agarose gel electrophoresis 
 
To analyse the size of DNA fragments, samples were mixed with a 6X DNA-
loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% 
glycerol) and analysed by electrophoresis on agarose gels at 100V along with 
SmartLadder DNA size marker (Eurogentec). Agarose gels were made with 0.8 
to 1.2% agarose (Melford), 0.5µg/ml ethidium bromide (Biorad) and TBE buffer 
(0.09M Tris-HCl, 0.09M borate, 2mM EDTA, at pH 8.4).  
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Short name Long name Source/Reference 
pQCXIX 
 
ClonTech #631515 
pTREPuro-DEST pLenti-CMVTRE3G-Puro-DEST Eric Campeau (Addgene #27565) 
pCMVrtTA3G pLenti-CMV-rtTA3-Blast Eric Campeau (Addgene #26429) 
pVSV-g 
 
(Yee et al., 1994) 
pHIT60 
 
(Soneoka et al., 1995) 
pCIGB 
 
(Bock et al., 2000) 
pCIGN 
 
(Bock et al., 2000) 
pCIGN-57 pCIGN-S57C Ophélie Cosnefroy 
pCIGN-44 pCIGN-V44C Ophélie Cosnefroy 
pCIGN-47 pCIGN-T47C Ophélie Cosnefroy 
pCIGN-48 pCIGN-H48C Ophélie Cosnefroy 
pCIGN-4457 pCIGN-V44C/S57C Ophélie Cosnefroy 
pCIGN-4757 pCIGN-T47C/S57C Ophélie Cosnefroy 
pCIGN-4857 pCIGN-H48C/S57C Ophélie Cosnefroy 
p8.91 
 
(Naldini et al., 1996) 
p8.91-1445 p8.91-A14C/E45C Ophélie Cosnefroy 
pLNCG 
 
(Yap et al., 2004) 
pCFG-YFP pCFG2-fEYFPf (Bock et al., 2000) 
pCSGW 
 
(Bainbridge et al., 2001) 
pHIT111  (Soneoka et al., 1995) 
pENTR-LUC 
 
Eric Campeau (Addgene #17473) 
pENTR-Fv1n 
 
(Yap et al., 2004) 
pENTR-Fv1b 
 
(Yap et al., 2004) 
pLxIG-Fv1n pL-Fv1n-IRES-EGFP (Bock et al., 2000) 
pLxIG-Fv1b pL-Fv1b-IRES-EGFP (Bock et al., 2000) 
pLxIG-Fv1bbn pL-Fv1bbn-IRES-EGFP (Bock et al., 2000) 
pLxIG-Fv1nnb pL-Fv1nnb-IRES-EGFP (Bock et al., 2000) 
pLxIG-Fv1bnb pL-Fv1bnb-IRES-EGFP (Bock et al., 2000) 
pLxIG-Fv1nbn pL-Fv1nbn-IRES-EGFP (Bock et al., 2000) 
pLxIG-Fv1bnn pL-Fv1bnn-IRES-EGFP (Bock et al., 2000) 
pLxIG-Fv1nbb pL-Fv1nbb-IRES-EGFP (Bock et al., 2000) 
pLxIG-Fv1nn_ pL-Fv1nn_-IRES-EGFP (Bishop et al., 2001) 
pLxIG-Fv1bb_ pL-Fv1bb_-IRES-EGFP (Bishop et al., 2001) 
pLxIY-HuT5 pL-HuT5-IRES-EYFP (Yap et al., 2004) 
pLxIY-RhT5 pL-RhT5-IRES-EYFP (Yap et al., 2004) 
pLxIY-HuT5HA pL-HuT5-HA-IRES-EYFP (Hilditch, 2010) 
pLxIY-RhT5HA pL-RhT5-HA-IRES-EYFP (Hilditch, 2010) 
 
Table 2.1 Plasmids obtained for transfection and cloning 
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Short name Long name Source/Reference 
pET22-NCA pET22-N-MLV-CA (Hilditch et al., 2011) 
pET22-NCA-P1G pET22-N-MLV-CA-P1G (Hilditch et al., 2011) 
pET22-NCA-D54A pET22-N-MLV-CA-D54A (Hilditch et al., 2011) 
pET22-NCA-R110E pET22-N-MLV-CA-R110E (Hilditch et al., 2011) 
pET22-BCA pET22-B-MLV-CA (Hilditch et al., 2011) 
pET22-BCA-P1G pET22-B-MLV-CA-P1G (Hilditch et al., 2011) 
pET22-BCA-D54A pET22-B-MLV-CA-D54A (Hilditch et al., 2011) 
pET22-BCA-E110R pET22-B-MLV-CA-E110R (Hilditch et al., 2011) 
pET22-NBCA pET22-NB-MLV-CA (Hilditch et al., 2011) 
pET22-HIVCAp2 pET22-HIV-1-CA-p2 (Hilditch, 2010) 
pET22-Fv1NTD pET22b-Fv1NTD(20-200) (Bishop et al., 2006) 
 
Table 2.2 Plasmids obtained for bacterial expression of recombinant 
proteins 
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PCR 
Product 
Template Primer Sequence 
PCR-TRE3G 
 
pTREPuro-
DEST 
E178P3-F GTATATATCGATCACGAGACTAGCCTCGAGAG 
E178P6-R GTATATGCGGCCGCCCACCACACTGGACTAGTC 
PCR-EGFP 
 
pLxIG-
Fv1n 
E178P18-F GTATATGCGGCCGCCATGGTGAGCAAGGGCGAGG 
E178P19-R GTATATGAATTCTTACTTGTACAGCTCGTCC 
PCR-EYFP 
 
pLxIY-
HuT5 
E178P18-F GTATATGCGGCCGCCATGGTGAGCAAGGGCGAGG 
E178P19-R GTATATGAATTCTTACTTGTACAGCTCGTCC 
PCR-TOPO-
Fv1bbn 
pLxIG-
Fv1bbn 
TOPO-Fv1-F CACCATGAATTTCCCACGTGCGCTTG 
TOPO-Fv1n-R TCGGAGTTTTGTAGCTGCTG 
PCR-TOPO-
Fv1nnb 
pLxIG-
Fv1nnb 
TOPO-Fv1-F CACCATGAATTTCCCACGTGCGCTTG 
TOPO-Fv1b-R TTAACTGTTGCTTTGATGTTTC 
PCR-TOPO-
Fv1bnb 
pLxIG-
Fv1bnb 
TOPO-Fv1-F CACCATGAATTTCCCACGTGCGCTTG 
TOPO-Fv1b-R TTAACTGTTGCTTTGATGTTTC 
PCR-TOPO-
Fv1nbn 
pLxIG-
Fv1nbn 
TOPO-Fv1-F CACCATGAATTTCCCACGTGCGCTTG 
TOPO-Fv1n-R TCGGAGTTTTGTAGCTGCTG 
PCR-TOPO-
Fv1bnn 
pLxIG-
Fv1bnn 
TOPO-Fv1-F CACCATGAATTTCCCACGTGCGCTTG 
TOPO-Fv1n-R TCGGAGTTTTGTAGCTGCTG 
PCR-TOPO-
Fv1nbb 
pLxIG-
Fv1nbb 
TOPO-Fv1-F CACCATGAATTTCCCACGTGCGCTTG 
TOPO-Fv1b-R TTAACTGTTGCTTTGATGTTTC 
PCR-TOPO-
Fv1nn_ 
pLxIG-
Fv1nn_ 
TOPO-Fv1-F CACCATGAATTTCCCACGTGCGCTTG 
TOPO-Fv1-notail-R TCAAGCTGCTGTTGGCTTTAAAC 
PCR-TOPO-
Fv1bb_ 
pLxIG-
Fv1bb_ 
TOPO-Fv1-F CACCATGAATTTCCCACGTGCGCTTG 
TOPO-Fv1-notail-R TCAAGCTGCTGTTGGCTTTAAAC 
PCR-TOPO-
uORF-Fv1b 
pLxIG-
Fv1b 
TOPO-uORF-Fv1-F CACCATGGGTTGACACCATGAATTTCCCACGTGCGC 
TOPO-Fv1b-R TTAACTGTTGCTTTGATGTTTC 
PCR-TOPO-
AGG-Fv1b 
pLxIG-
Fv1b 
TOPO-AGG-Fv1-F CACCAGGAATTTCCCACGTGCGC 
TOPO-Fv1b-R TTAACTGTTGCTTTGATGTTTC 
 
Table 2.3 Primers used for PCR reactions   
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2.1.3 Gel purification of DNA fragments 
 
Bands containing the target DNA fragment are excised from agarose gels on a 
UV transilluminator using a scalpel. DNA fragments were purified from agarose 
gel using the MinElute Gel Extraction Kit (Qiagen, #28604) according to the 
manufacturer’s instructions. DNA was eluted in 10µl of elution buffer. 
 
2.1.4 DNA quantitation 
 
Concentration of DNA in plasmids or purified PCR products were determined by 
measuring the absorbance at 260nm using a NanoDrop 2000 UV 
spectrophotometer. 
 
2.1.5 Restriction digestion 
 
Digestions of plasmid DNA and PCR products were performed with restriction 
enzymes from Roche using the supplied buffer. For double digestions, a buffer 
compatible to both restriction enzymes was chosen. A 20µl digestion reaction 
typically contained up to 1µg of DNA and 1U of restriction enzyme (or 0.5U in 
double digestions) in the appropriate buffer. Reactions were performed at 37oC 
for at least 2h. To screen DNA clones, digested DNA was immediately analysed 
by agarose gel electrophoresis. To prepare digested vector or insert DNA for 
ligation, DNA was isolated by gel purification. 
 
2.1.6 Blunting of 5’overhang 
 
5’ overhangs created by EcoR1 digestion of pQTGIX were filled in using the 5’ 
to 3’ synthesis activity of T4 DNA polymerase (New England Biolabs), to create 
a blunt end for downstream ligation reaction. A 50µl reaction contained 1µg of 
digested vector DNA, 100µg/ml of BSA and 100µM of each dNTP in NEBuffer 
2. The blunting reaction was carried out at 12oC for 30min, followed by 
inactivation at 75oC for 10min. Blunt vector DNA was purified using the 
QIAquick PCR purification kit (Qiagen, #28104) according to the manufacturer’s 
instructions. 
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2.1.7 Dephosphorylation 
 
Dephosphorylation of digested vector DNA was carried out using the Rapid 
DNA Dephos and Ligation Kit (Roche, #04898117001). A 20µl 
dephosphorylation reaction contained up to 1µg of digested vector DNA, and 
1U rARid Alkaline Phosphatase (Roche) in the supplied buffer. 
Dephosphorylation reaction was performed at 37oC for 1h followed by 2min 
inactivation at 75oC. Dephosphorylated vector DNA was used directly in ligation 
reactions without further purification. 
 
2.1.8 DNA Ligation 
 
Ligation between vector and insert DNA was carried out using the Rapid DNA 
Dephos and Ligation Kit (Roche). Dephosphorylated vector and digested insert 
were mixed at a 1:3 molar ratio to a final volume of 4µl. 1µl of 5X DNA dilution 
buffer was added, followed by addition of 5µl of 2X T4 DNA ligation buffer and 
0.5µl of T4 DNA ligase (5U/µl). Ligation reactions were performed at 20oC for 
1h.  
 
2.1.9 Transformation 
 
Table 2.4 shows a list of chemically-treated competent cells used for 
transformation. Different strains of competent cells were used for different 
purposes. In a typical transformation, 50µl of competent cells was thawed on 
ice and mixed with up to 2µl of ligation reaction or 1ng of purified plasmid DNA. 
After 20min incubation on ice, competent cells were heat shocked at 42oC for 
30s and followed immediately by 2min incubation on ice. 250µl of SOC media 
(2% w/v tryptone, 0.5% w/v yeast extract, 8.55mM NaCl, 2.5mM KCl, 10mM 
MgCl2 and 20mM glucose) was added and the cells were incubated at 37
oC 
with shaking. Transformed cells were spread on LB-agar (1.5% agar) plates 
supplemented with antibiotics (Table 2.5) and incubated at 37oC overnight. 
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Competent cells Function Source 
TOP10 General propagation of plasmids Life Technologies #C4040 
ccdB Survival 2 T1 Propagation of Gateway destination vectors Life Technologies #A10460 
dam-/dcm- Propagation of pQCXIX for ClaI digestion NEB #C2925 
XL10 Gold Propagation after QuikChange mutagenesis Agilent #200315 
Rosetta2 DE3 Expression of recombinant CA and Fv1NTD Merck #71400 
 
Table 2.4 Competent cells used for transformation 
 
 
 
Chemical 
Stock  
concentration 
Final 
Concentration 
Source 
Nafcillin 50mg/ml in water 50µg/ml Sigma #N3269 
Ampicillin 50mg/ml in water 50µg/ml Sigma #A9518 
Kanamycin 50mg/ml in water 50µg/ml Sigma #60615 
Chloramphenicol 25mg/ml in ethanol 25µg/ml Sigma #C0378 
Puromycin 10mg/ml in water 10µg/ml Sigma #P9620 
Blasticidin 10mg/ml in water 10µg/ml Sigma #15205 
Penicillin 
Streptomycin 
10000U 
10mg/ml 
100U/ml 
100µg/ml 
Sigma #P0781 
Doxycycline 10mg/ml in water 1-1000ng/ml Sigma #D9891 
MG132 20mg/ml in DMSO 10nM Sigma #C2211 
IPTG 1M in water 500µM Sigma #I6758 
GalCer 5mg/ml in 1:1 chloroform:methanol 
 
Avanti #790404 
DGS-NTA(Ni) 5mg/ml in chloroform 
 
Avanti #860546 
Bio PE 5mg/ml in chloroform 
 
Avanti #870282 
BioCap PE 5mg/ml in chloroform 
 
Avanti #870273 
BioPEG PE 5mg/ml in chloroform 
 
Avanti #880129 
 
Table 2.5 List of antibiotics and chemicals 
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2.1.10 Propagation and purification of plasmid DNA 
 
For small scale production of plasmid DNA, each colony of E coli from agar 
plate was cultured at 37oC with shaking overnight in 3ml LB (1% tryptone, 0.5% 
yeast extract, 1% NaCl, pH 7.0) supplemented with antibiotic. Bacteria from 
1.5ml of culture were pelleted by centrifugation at 13,000 x g for 3min for 
plasmid purification using the QIAprep Spin Miniprep Kit according to 
manufacturer’s instructions. For large scale plasmid production, 50ml of LB with 
antibiotic was inoculated with 100µl of small scale culture, and incubated 
overnight at 37oC with shaking. Bacterial cells were pelleted at 4000 x g for 
15min for plasmid purification using the HiSpeed Plasmid Midi Kit (Qiagen, 
#12643) according to manufacturer’s instructions. 
 
2.1.11 Gateway cloning system 
 
The Gateway cloning system (Life Technologies) has been implemented in our 
lab to allow efficient ligation-free cloning of restriction factors into destination 
vectors (Figure 2.1) (Yap et al., 2004). The system relies on recombination 
reactions between att sequences. Each entry clone consists of a Kanamycin-
resistant backbone and a gene of interest (GOI) flanked by attL1 and attL2 
sequences, while each destination vector consists of an ampicillin-resistant 
backbone and a DEST cassette containing the ccdB suicide gene and the 
chloramphenicol-resistant gene flanked by the attR1 and attR2 sequences. The 
LR reaction allows recombination between attL1 and attL2 sequences in the 
entry clone and attR1 and attR2 sequences in the destination vector, leading to 
the transfer of GOI insert from the entry clone to the destination vector. The 
resulting expression clone can be selected using ampicillin, while the by-product 
donor vector would be eliminated due to the expression of suicide gene. There 
are 3 ways from which entry clones can be obtained. First, entry clones can be 
obtained by BP recombination between an expression clone and a donor 
vector. Alternatively, entry clone can be obtained from BP reactions between a 
PCR product flanked with attB1 and attB2 sequences and a donor vector. 
Lastly, entry clones can be obtained from directional TOPO reaction between a 
blunt end PCR product with 5’ CACC sequence and pENTR-D-TOPO vector 
(Life Technologies).  
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Figure 2.1 Gateway cloning system  
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2.1.12 Cloning of inducible destination vectors 
 
Figure 2.2 shows the steps taken to generate two destination vectors, pTGx-
DEST and pTGIx-DEST. All constructs made are listed in Table 2.6 and the 
PCR products generated are listed in Table 2.3. Briefly, the TRE3G promoter 
was amplified by PCR from pTREPuro-DEST and inserted between ClaI and 
NotI sites of the self-inactivating (SIN) retroviral vector pQCXIX. Since ClaI 
digestion is sensitive to dam methylation, pQCXIX was purified from a dam- E. 
coli strain (Table 2.4). This replaced the CMV promoter in pQCXIX with the 
inducible TRE3G promoter to generate the pQTXIX construct. EGFP sequence 
was amplified from LxIG-Fv1n and inserted between NotI and EcoRI sites of 
pQTXIX. This led to the insertion of EGFP ORF between the TRE3G promoter 
and IRES element in the resulting pQTGIX construct. The blunt DEST cassette 
was obtained by digestion of pTREPuro-DEST with EcoRV. The pTGIx-DEST 
vector was constructed by insertion of the DEST cassette to the EcoRV site. To 
obtain the pTGx-DEST vector, the pQTGIX construct was digested with EcoRI 
and EcoRV followed by blunting of the 5’ overhang to remove the IRES 
element. The DEST cassette was ligated to the blunt vector to obtain the IRES-
free pTGx-DEST vector. Since the DEST cassette contains the ccdB suicide 
gene and the chloramphenicol resistant gene, ccdB Survival competent cells 
were used for transformed (Table 2.4) and selected with ampicillin, nafcillin and 
chloramphenicol (Table 2.5). The orientation of DEST cassettes in both vectors 
were screened by restriction digestion and confirmed by sequencing.  
 
2.1.13 Cloning of entry clones by TOPO reaction 
 
 Fv1 entry clones shown in Table 2.6 were cloned using the pENTR-D-
TOPO vector kit (Life Technologies, #K2400). PCR products of Fv1 ORFs with 
5’ CACC inserted sequence were inserted into the pENTR-D-TOPO vector by 
TOPO reaction. For pENTR-uORF-Fv1b and pENTR-AGG-Fv1b, insertion of 
uORF and mutation of start codon were introduced by the 5’ primers used in the 
TOPO PCR reaction. A typical 3µl reaction contains 5µg of purified PCR 
product, 200mM NaCl, 10mM MgCl2 and 0.5µl of pENTR-D-TOPO vector mix. 
The reaction was incubated at 25oC for 1h before transformation using TOP10 
(Table 2.4). Entry clones were selected with kanamycin (Table 2.5). 
104 
 
 
Figure 2.2 Cloning of pTGIx-DEST and pTGx-DEST vectors 
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Short name Vector Insert Cloning method 
pQTXIX pQCXIX (dam-) PCR-TRE3G ClaI + NotI 
pQTGIX pQTXIX PCR-EGFP NotI + EcoRI 
pTGIx-DEST pQTGIX DEST cassette EcoRV 
pTGx-DEST 
 
pQTGIX 
 
DEST cassette 
 
EcoRI + EcoRV 
End blunting with T4 Pol 
pQTYIX pQTXIX PCR-EYFP NotI + EcoRI 
pTYIx-DEST pQTYIX DEST cassette EcoRV 
pTYx-DEST 
 
pQTYIX 
 
DEST cassette 
 
EcoRI + EcoRV 
End blunting with T4 Pol 
pENTR-Fv1bbn pENTR-D-TOPO PCR-TOPO-Fv1bbn TOPO reaction 
pENTR-Fv1bbn pENTR-D-TOPO PCR-TOPO-Fv1nnb TOPO reaction 
pENTR-Fv1bnb pENTR-D-TOPO PCR-TOPO-Fv1bnb TOPO reaction 
pENTR-Fv1nbn pENTR-D-TOPO PCR-TOPO-Fv1nbn TOPO reaction 
pENTR-Fv1bnn pENTR-D-TOPO PCR-TOPO-Fv1bnn TOPO reaction 
pENTR-Fv1nbb pENTR-D-TOPO PCR-TOPO-Fv1nbb TOPO reaction 
pENTR-Fv1nn_ pENTR-D-TOPO PCR-TOPO-Fv1nn_ TOPO reaction 
pENTR-Fv1bb_ pENTR-D-TOPO PCR-TOPO-Fv1bb_ TOPO reaction 
pENTR-uORF-Fv1b pENTR-D-TOPO PCR-TOPO-uORF-Fv1b TOPO reaction 
pENTR-AGG-Fv1b pENTR-D-TOPO PCR-TOPO-AGG-Fv1b TOPO reaction 
 
 
Table 2.6 Cloning of Gateway destination vectors and entry clones 
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2.1.14 Cloning of expression vectors by Gateway LR reaction 
 
 A list of expression clones constructed by Gateway LR reactions is 
shown in Table 2.7. In a typical 2.5µl LR reaction, 37.5ng of destination vector 
with mixed with 37.5ng of entry clones, diluted to a total of 2µl with TE buffer 
(10mM Tris-HCl, 1mM EDTA, pH 8.0), followed by addition of 0.5µl of LR 
Clonase II enzyme mix (Life Technologies, #11791). After 1h incubation at 
25oC, 0.5µl of the supplied Proteinase K was added and the reaction was 
incubated at 37oC for 10min. The LR reaction was transformed into TOP10 and 
selected with ampicillin and nafcillin.   
 
2.1.15 Generation of cysteine mutants by Site-directed mutagenesis 
 
Primers used for generation of cysteine mutations of pCIGN are listed in Table 
2.8. Forward and reverse primers with the required point mutations flanked by 
complementary sequences were used to amplify mutant plasmid by PCR 
reaction according to the QuikChange site-directed mutagenesis protocol 
(Agilent Technologies). Each 50µl QuikChange PCR reaction contained 50ng of 
plasmid template, 10pmol of forward primer, 10pmol of reverse primer, 200µM 
of each dNTP, 2.5U of PfuUltra high fidelity polymerase (Agilent Technologies) 
in the supplied buffer. PCR reactions were carried out using a PTC-100 thermal 
cycler (MJ research). Thermo cycling parameters typically consisted of 5min of 
initial denaturation at 95oC; followed by 12 cycles of 1min denaturation at 95oC, 
1.5min annealing at 55oC, 15min extension at 68oC; and a final 15min extension 
at 68oC. 30U of DpnI was added to the reaction to digest the methylated 
template DNA but not the unmethylated PCR product, and the reaction was 
further incubated at 37oC for 2h. Amplified mutant plasmids were concentrated 
by ethanol precipitation and transformed into XL10 Gold ultracompetent cells 
(Agilent Technologies). The introduction of mutations was verified by 
sequencing.  
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Short name Long name Destination vector Entry clone 
pTREPuro-Luc pLenti-CMVTRE3G-Puro-Luc pTREPuro-DEST pENTR-Luc 
pTGIx-Fv1n pQ-TRE3G-EGFP-IRES-Fv1n pTGIx-DEST pENTR-Fv1n 
pTGIx-Fv1b pQ-TRE3G-EGFP-IRES-Fv1b pTGIx-DEST pENTR-Fv1B 
pTGIx-Fv1bbn pQ-TRE3G-EGFP-IRES-Fv1bbn pTGIx-DEST pENTR-Fv1bbn 
pTGIx-Fv1nnb pQ-TRE3G-EGFP-IRES-Fv1nnb pTGIx-DEST pENTR-Fv1nnb 
pTGIx-Fv1bnb pQ-TRE3G-EGFP-IRES-Fv1bnb pTGIx-DEST pENTR-Fv1bnb 
pTGIx-Fv1nbn pQ-TRE3G-EGFP-IRES-Fv1nbn pTGIx-DEST pENTR-Fv1nbn 
pTGIx-Fv1bnn pQ-TRE3G-EGFP-IRES-Fv1bnn pTGIx-DEST pENTR-Fv1bnn 
pTGIx-Fv1nbb pQ-TRE3G-EGFP-IRES-Fv1nbb pTGIx-DEST pENTR-Fv1nbb 
pTGIx-Fv1nn_ pQ-TRE3G-EGFP-IRES-Fv1nn_ pTGIx-DEST pENTR-Fv1nn_ 
pTGIx-Fv1bb_ pQ-TRE3G-EGFP-IRES-Fv1bb_ pTGIx-DEST pENTR-Fv1bb_ 
pTGIx-uORF-Fv1b pQ-TRE3G-EGFP-IRES-uORF-Fv1b pTGIx-DEST pENTR-uORF-Fv1b 
pTGIx-AGG-Fv1b pQ-TRE3G-EGFP-IRES-AGG-Fv1b pTGIx-DEST pENTR-AGG-Fv1b 
pTGIx-Luc pQ-TRE3G-EGFP-IRES-Luc pTGIx-DEST pENTR-Luc 
pTGx-Fv1n pQ-TRE3G-EGFP-Fv1n pTGx-DEST pENTR-Fv1n 
pTGx-Fv1b pQ-TRE3G-EGFP-Fv1b pTGx-DEST pENTR-Fv1B 
pTGx-Fv1bbn pQ-TRE3G-EGFP-Fv1bbn pTGx-DEST pENTR-Fv1bbn 
pTGx-Fv1nnb pQ-TRE3G-EGFP-Fv1nnb pTGx-DEST pENTR-Fv1nnb 
pTGx-Fv1bnb pQ-TRE3G-EGFP-Fv1bnb pTGx-DEST pENTR-Fv1bnb 
pTGx-Fv1nbn pQ-TRE3G-EGFP-Fv1nbn pTGx-DEST pENTR-Fv1nbn 
pTGx-Fv1bnn pQ-TRE3G-EGFP-Fv1bnn pTGx-DEST pENTR-Fv1bnn 
pTGx-Fv1nbb pQ-TRE3G-EGFP-Fv1nbb pTGx-DEST pENTR-Fv1nbb 
pTGx-Fv1nn_ pQ-TRE3G-EGFP-Fv1nn_ pTGx-DEST pENTR-Fv1nn_ 
pTGx-Fv1bb_ pQ-TRE3G-EGFP-Fv1bb_ pTGx-DEST pENTR-Fv1bb_ 
pTGx-Luc pQ-TRE3G-EGFP-Luc pTGx-DEST pENTR-Luc 
 
 
Table 2.7 Cloning of Gateway expression vectors by LR reaction  
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Mutations Primer Sequence 
S17C 
F GTACTGGCCGTTTTCCTGCTCTGATCTATATAAC 
R GTTATATAGATCAGAGCAGGAAAACGGCCAGTAC 
D19C 
F GTACTGGCCGTTTTCCTCCTCTTGTCTATATAACTGG 
R CCAGTTATATAGACAAGAGGAGGAAAACGGCCAGTAC 
N22C 
F GGCCGTTTTCCTCCTCTGATCTATATTGCTGGAAAAATAATAATCCTTCC 
R GGAAGGATTATTATTTTTCCAGCAATATAGATCAGAGGAGGAAAACGGCC 
Y21C 
F GGCCGTTTTCCTCCTCTGATCTATGTAACTGGAAAAATAATAATCCTTCC 
R GGAAGGATTATTATTTTTCCAGTTACATAGATCAGAGGAGGAAAACGGCC 
N26C 
F CTGATCTATATAACTGGAAAAATTGTAATCCTTCCTTCTCTGAGGATCC 
R GGATCCTCAGAGAAGGAAGGATTACAATTTTTCCAGTTATATAGATCAG 
N27C 
F GATCTATATAACTGGAAAAATAATTGTCCTTCCTTCTCTGAGGATCCAGG 
R CCTGGATCCTCAGAGAAGGAAGGACAATTATTTTTCCAGTTATATAGATC 
D53C 
F CACCCACCAGCCCACCTGGTGTGATTGCCAGCAATTATTAG 
R CTAATAATTGCTGGCAATCACACCAGGTGGGCTGGTGGGTG  
T46C 
F GATTGAATCTGTCCTCTGCACCCACCAGCCCAC 
R GTGGGCTGGTGGGTGCAGAGGACAGATTCAATC 
S17C 
S19C 
F GTACTGGCCGTTTTCCTGCTCTTGTCTATATAACTGG 
R CCAGTTATATAGACAAGAGCAGGAAAACGGCCAGTAC 
S17C 
N22C 
F GGCCGTTTTCCTGCTCTGATCTATATTGCTGGAAAAATAATAATCCTTCC 
R GGAAGGATTATTATTTTTCCAGCAATATAGATCAGAGCAGGAAAACGGCC 
Y21C 
N26C 
F CTGATCTATGTAACTGGAAAAATTGTAATCCTTCCTTCTCTGAGGATCC 
R GGATCCTCAGAGAAGGAAGGATTACAATTTTTCCAGTTACATAGATCAG 
Y21C 
N27C 
F GATCTATGTAACTGGAAAAATAATTGTCCTTCCTTCTCTGAGGATCCAGG 
R CCTGGATCCTCAGAGAAGGAAGGACAATTATTTTTCCAGTTACATAGATC 
 
 
Table 2.8 Primers used for site-directed mutagenesis of pCIGN  
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2.2 Cell culture 
 
2.2.1 General cell culture 
 
All cell lines used in this study (MDTF, 293T, TE671, N-3T3, B-3T3) were 
maintained at 37oC in 5% CO2, using Dulbecco’s Modified Eagle Medium 
(DMEM) (Life Technologies) supplemented with penicillin/streptomycin (Table 
2.5) and 10% heat-inactivated foetal calf serum (FCS) (Perbio). Cells were 
typically passaged every 3 to 4 days by dislodging confluent monolayer of cells 
from culture flask with trypsin-Versene (0.05% w/v trypsin, 0.53mM EDTA in 
PBS) followed by transferring 10-20% of cells to a new flask. 
 
2.2.2 Virus preparation 
 
Preparation of retroviral or lentiviral vectors were carried by transient 
transfection of 293T with 3 plasmids providing vector, Gag-Pol and Env 
functions (Soneoka et al., 1995). 293T cells at log phase were counted using 
the Countess automatic cell counter (Life Technologies), and 2x106 cells were 
seeded to each 6cm dish (Corning) in 5ml of medium. On the next day, cells 
were transfected 4h after a change of culture medium. 2µg of each plasmid was 
incubated with 600µl of serum-free DMEM and 12µl of Turbofect (Thermo 
Fisher) at room temperature for 20min, and the mixture was added drop wise to 
the cells. 16h later, transfected cells were incubated with medium supplemented 
with 10mM sodium butyrate for 6h to enhance expression of viral proteins by 
CMV promoter, followed by replacement of medium to 2.5ml of supplemented 
DMEM. Supernatant containing vector viruses was harvested 48h after 
transfection, and passed through a 0.45µm filter to remove cell debris. Virus 
stocks were stored as aliquot at -80oC. 
 
2.2.3 Transduction 
 
Retroviral vector viruses used for transduction were prepared using pVSV-g 
(pseudotype envelope), pHIT60 (NB-MLV Gag-Pol) and a retroviral vector 
plasmid. Lentiviral vector viruses used for transduction were prepared using 
pVSV-g, p8.91 (HIV-1 Gag-Pol and accessory proteins) and a lentiviral vector 
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plasmid. MDTF cells were seeded at 5x104/well (for 12 well plate) or 
2.5x104/well (for 24 well plate) 24h before addition of thawed viruses. In cases 
where the volume of viruses to be added exceeded 5% of the total volume of 
medium, an equal volume of medium was removed prior to the addition of 
viruses. 
 
2.2.4 Generation of single cell clones (SCCs) from transduced MDTF cells 
 
MDTF cells that were transduced with vectors without antibiotic resistance 
genes were counted and reseeded on 96 well plates at a concentration of 0.2 
cells per well in DMEM with 20% FCS. After two weeks, SCCs were transferred 
to 24 well plates and allowed to grow until confluent. For selection of MDTF 
cells transduced with vector expressing rtTA3 and the blasticidin-resistance 
gene, blasticidin (Table 2.5) was added to transduced cells at 24h after 
transduction. Cells were seeded on 96-well plates at 7 days post transduction 
using the same procedure as above. 
 
2.2.5 Freezing and resuscitation of cell stocks 
 
To prepare cell stocks for long term storage, cells at 70% confluency were 
dislodged with 2ml of trypsin and 8ml of medium, pelleted by 300 x g 
centrifugation for 5min, and resuspended in 2ml of freezing mix (10% DMSO, 
90% FCS). Cells were frozen as 1ml aliquots in cryovials (Nalgene) using a 
CoolCell FTS30 cell freezing container (Biocision) placed at -80oC. Cells were 
transferred to liquid nitrogen for long term storage after at least 24h. To 
resuscitate cells from frozen stocks, cells were thawed at room temperature and 
pelleted through 10ml of medium to remove DMSO from the freezing mix. Cells 
were then resuspended in fresh medium and transferred to new culture flasks. 
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2.3 Protein expression and purification 
 
2.3.1 Expression and purification of MLV CA and HIV-1 CA-p2 
 
A list of pET22b vectors used for bacterial expression of recombinant proteins is 
shown in Table 2.2. The expression and purification of MLV CA-His and HIV 
CA-p2-His had been described in previous studies (Hilditch, 2010; Hilditch et 
al., 2011). Briefly, Rosetta 2 DE3 competent cells were transformed with 
pET22b vector and plated on ampicillin/nafcillin agar plates. A colony was used 
to inoculate 50ml of LB supplemented with ampicillin at 30oC with shaking 
overnight. Overnight culture was diluted 1 in 100 into 1L of LB, and cells were 
grown at 37oC with shaking. Expression of recombinant protein was induced at 
an optical density (OD) of 0.6 with 0.5mM IPTG for 3h. Cells were centrifuged at 
2k x g for 30min, and the pellet was stored at -20oC until purification. 
 
 Purification of His-tagged proteins was carried out using Nickel columns. 
The thawed cell pellet was resuspended in 50ml of lysis buffer (20mM Tris-HCl 
pH 7.5, 300mM NaCl, 5mM β-mercaptoethanol, 5mM imidazole, complete 
EDTA-free protease inhibitors (Roche), 4µl benzonase (Merck Millipore) and 
1mM MgCl2). Cells were lysed with 50mg of lysozyme (Sigma) for 30min at 4
oC, 
followed by sonication on ice. Insoluble materials were pelleted by 
centrifugation at 23000 x g for 30min at 4oC. Soluble lysate was passed through 
a 5ml HisTrap FF column (GE Healthcare) that had been pre-equilibrated with 
wash buffer (20mM Tris-HCl pH 7.5, 300mM NaCl, 5mM β-mercaptoethanol, 
5mM imidazole) using a P1 pump (GE Healthcare). The column was attached to 
the ÄKTAprime plus system (GE Healthcare), washed with 20ml of wash buffer. 
His-tagged proteins were eluted using a 5 to 300mM imidazole gradient, and 
collected as fractions. Peak fractions were pooled, analysed by SDS-PAGE, 
and concentrated using a Vivaspin column with a 10kDa molecular weight cut 
off (MWCO) (GE Healthcare). The concentration column allows the removal of 
buffer while retaining the recombinant capsid proteins. The samples were 
further purified by size-exclusion chromatography using on a HiLoad 16/600 
Superdex 75 gel filtration column (GE Healthcare) in the gel filtration buffer 
(10mM Tris-HCl pH 8.0, 150mM NaCl, 5mM β-mercaptoethanol). Proteins of 
different sizes travel through the gel filtration column at different speed, so that 
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proteins of different molecular weight collected at different fractions at different 
elution volumes. Peak fractions corresponding to monomeric recombinant 
capsids were pooled and concentrated, and stored as aliquots at -80oC. 
 
2.3.2 Expression and purification of Fv1NTD 
 
The expression of Fv1NTD with N-terminal His-tag had been described before 
(Bishop et al., 2006). The procedure for protein expression was the same as 
described for recombinant CA-His. For the purification procedure, thawed cells 
were lysed with lysis buffer (5mM β-mercaptoethanol, 5mM imidazole, complete 
EDTA-free protease inhibitors (Roche), 4µl benzonase (Merck Millipore) and 
1mM MgCl2 in Y-PER lysis buffer (Thermo Fisher)) for 30min at room 
temperature. Lysate was clarified by centrifugation at 23000 x g for 30min at 
4oC, and purified with HisTrap column as described above. 
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2.4 Protein quantitation and analyses 
  
2.4.1 Quantitation of purified protein by A280 absorbance 
 
The concentration of purified proteins was determined using the Biophotometer 
UV spectrophotometer (Eppendorf). The extinction coefficient value of each 
protein was calculated based on the Tryptophan and Tyrosine content (37410 
cm-1 M-1 for MLV CA, 33570 cm-1 M-1 for HIV-1 CA-p2 and 26700 cm-1 M-1 for 
Fv1NTD), and the concentration of purified protein samples were calculated 
from absorbance at 280nm using the extinction coefficient. 
 
2.4.2 Total protein quantitation by Bradford assay 
 
Total protein concentrations of detergent-free lysate samples were determined 
using a microplate Bradford assay. 5µl of neat or 1/5 diluted lysate samples was 
added to 96-well plates along with BSA standards (Thermo Fisher) of 1000, 
500, 250 and 125µg/ml. 200µl of 1/5 diluted Bradford reagent (Bio-Rad protein 
assay) was mixed with lysate or standard samples in each well. After 10min 
incubation at room temperature, the absorbance at 595nm was measured using 
the Synergy 2 (Biotek) plate reader and the Gen5 software. The protein 
concentration of lysate was interpolated from a standard curve from known BSA 
concentrations. 
 
2.4.3 Total protein quantitation by BCA assay 
 
Total protein concentrations of lysate samples in buffer containing detergent 
(such as RIPA buffer which contains NP40 and SDS) were determined using a 
microplate BCA assay. 5µl of 1/5 diluted lysate was added to 96-well plates 
along with BSA standards of 2000, 1000, 500, 250, 125, 62.5, 31.3 and 0µg/ml. 
200µl of prepared BCA protein assay reagent (Thermo Fisher) was added to 
each well. After 30s of shaking, the plate was incubated at 37oC for 30min. The 
absorbance at 562nm was measured using the Synergy 2 plate reader and the 
Gen5 software. The protein concentration of lysate was interpolated from a 
standard curve from known BSA concentrations. 
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2.4.4 Separation of proteins by SDS-PAGE 
 
For most purposes, samples were separated with hand cast 10% 
polyacrylamide gels containing 33.3% of 30% Acrylamide/Bis 35.1:1 stock (Bio-
rad), 375mM Tris-HCl pH 8.8, 0.1% SDS, 0.11 ammonium persulphate (Bio-
Rad) and 8µl TEMED (Sigma). For analysis of crosslinked MLV capsid 
complexes, 4-20% Mini-Protean TGX Precast Gel (Bio-Rad) was used. 
Samples with Protein samples were mixed with 5X SDS-PAGE loading buffer 
(5X: 250mM Tris-HCl pH 6.8, 10% SDS, 12.5% β-mercaptoethanol, 0.1% w/v 
bromophenol blue, 50% glycerol) in 4:1 ratio, and boiled at 98oC for 5min. 
Electrophoresis was carried at 150V in SDS running buffer (27.6mM Tris-HCl 
pH 8.8, 0.2M glycine, 0.1% SDS). Both the PageRuler Prestained Protein 
Ladder (Thermo Fisher) and the Spectra Multicolor High Range Protein Ladder 
(Thermo Fisher) have been used as molecular weight protein markers. For 
analysis of purified proteins, gels were stained with Imperial Protein Stain 
(Thermo Fisher). 
 
2.4.5 Electro-transfer of proteins to PVDF membrane 
 
For western blot analysis, proteins in polyacrylamide gels were transferred to 
PVDF membranes using the Trans-Blot SD semi-dry transfer cell (Bio-rad). 
SDS gel was placed above a methanol-activated PVDF membrane, and 
sandwiched between stacks of filter papers saturated with transfer buffer 
(48mM Tris, 39mM glycine, 20% methanol). Immobilon-P (Merck Millipore) 
PVDF membrane was used for chemiluminescent western blots, while 
Immobilon-FL (Merck Millipore) was used for LI-COR western blot. Transfer was 
carried out at 20V for 1.5h. The membrane was blocked with 5% non-fat dry 
milk (Marvel) in PBS at 4oC overnight. 
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2.4.6 Western blot with chemiluminescent substrate 
 
Antibodies used for western blot analyses are listed in Table 2.9. Blocked 
membrane was incubated with primary antibody diluted in 5% milk in PBS 
supplemented with 0.1% Tween-20 (PBS-T) for 1h, followed by four 5min 
washes with PBS-T. The membrane was then incubated with HRP-conjugated 
secondary antibody diluted in 5% milk in PBS-T, followed by four 5min washes 
with PBS-T. Protein bands were detected by adding ECL chemiluminescent 
substrate (Merck Millipore) to the membrane, followed by film exposure 
(Kodak).  
 
2.4.7 LI-COR western blot 
 
The LI-COR western blot procedure was similar to that for HRP western blot. 
This system allows the detection of two targets at the same blot, so in some 
cases rabbit anti-Fv1 and mouse anti-His primary antibodies were used 
simultaneously, together with IRDye800-conjugated anti-rabbit and IRDye680-
conjugated anti-mouse secondary antibodies. 0.01% SDS was also added to 
the diluted secondary antibody mix to reduce non-specific binding of secondary 
antibodies. After the last wash with PBS-T, the membrane was washed for 5min 
with PBS before scanning using the Odyssey scanner (LI-COR) at 700nm and 
800nm. Quantitation of signal in each protein band was carried out using the 
ImageStudio software (LI-COR), using median signal from pixels immediately 
above and below the band for background calculation. For absolute quantitation 
of Fv1, a standard curve was generated using the Prism 5 software (GraphPad) 
and fluorescent signals from bands of known quantity of Fv1NTD. The quantity 
of Fv1 in samples was determined by interpolation of measured fluorescent 
signal to the standard curve. 
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Antibody Type Source Dilution 
Anti-Fv1NTD 
(#6689) 
Rabbit polyclonal (Bishop et al., 2006) 1/1000 
Anti-HA Mouse monoclonal 
Sigma  
#H9658 
1/5000 
Anti-His Mouse monoclonal 
QIAgen  
#34660 
1/5000 
Anti-p30 Rat monoclonal 
ATCC  
#CRL-1912 
1/5000 
Anti-p24 Mouse monoclonal Malim Lab 1/1000 
Anti-mouse-HRP 
Rabbit polyclonal 
HRP-conjugated 
Thermo Fisher 1/5000 
Anti-rat-HRP 
Goat polyclonal 
HRP-conjugated 
Thermo Fisher 1/5000 
Anti-rabbit-HRP 
Mouse monoclonal 
HRP-conjugated 
Sigma  
#A2074 
1/5000 
Anti-mouse-680 
Goat polyclonal 
IRDye680RD conjugated 
LI-COR  
#926-68070 
1/5000 
Anti-mouse-800 
Donkey polyclonal 
IRDye 800CW conjugated 
LI-COR  
#926-32212 
1/5000 
Anti-rabbit-800 
Goat polyclonal 
IRDye 800CW conjugated 
LI-COR  
#926-32211 
1/5000 
 
 
Table 2.9 List of antibodies 
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2.4.8 Quantitation of Fv1 in cells 
 
To determine the Fv1 expression level per cell, 7.5x105 cells (3T3 cells, 
transduced cells, or SCCs) were seeded to each 10cm dish (Thermo Fisher) 
and treated with the required amount of doxycycline. 24h later, cells were 
harvested with trypsin, mixed with medium, and pelleted at 300 x g for 5min. 
Cell pellet was resuspended 2ml PBS, and pelleted again at 300 x g for 5min. 
The pellet was snap frozen with liquid nitrogen, and stored at -80oC until 
analysis. 100µl RIPA buffer (Thermo Fisher) supplemented with complete 
EDTA-free protease inhibitors (Roche) was added to each cell pellet. Cells were 
lysed on ice for 30min, and then centrifuged at 13krpm for 10min at 4oC to 
remove cell debris. The total protein concentrations of lysate samples were 
determined with the BCA assay, and the lysates were diluted to 1mg/ml before 
quantitation of Fv1 by LI-COR western blot. In a parallel experiment, it was 
determined that on average 120pg of total protein was extracted per MDTF cell, 
and this value was used to calculate the mean number of Fv1 molecules per 
cell. For mixed transduced cell populations, the percentage of Fv1+/GFP+ cells 
determined by FACS analysis was taken into account for the calculation of 
number of molecules per cell. The average number of Fv1 molecules per cell 
was calculated using the following equation: 
 
𝐹𝑣1 𝑝𝑒𝑟 𝑐𝑒𝑙𝑙 =
[𝐹𝑣1𝐿𝑦𝑠𝑎𝑡𝑒] × 𝑌𝑖𝑒𝑙𝑑 × 𝑁𝐴
[𝑃𝑟𝑜𝑡𝑒𝑖𝑛] × 𝑓𝐺𝐹𝑃+
 
 
 [𝐹𝑣1𝐿𝑦𝑠𝑎𝑡𝑒] The concentration of Fv1 in the 1mg/ml lysate sample, in mole L
-1, 
  determined by the quantitative western blot analysis 
𝑌𝑖𝑒𝑙𝑑  The mass of total protein per cell in lysate of 120 x 10-12 g cell-1 
𝑁𝐴  The Avogadro constant of 6.02214129 x 10
23 mole-1 
[𝑃𝑟𝑜𝑡𝑒𝑖𝑛] The concentration of total protein in standardised lysate, 1 g L-1 
𝑓𝐺𝐹𝑃+  The fraction of GFP
+/Fv1+ cells in all sampled cells 
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2.4.9 Screening of SCCs with overexpression of Fv1 and T5HA 
 
Confluent monolayers of SCC cells on a 10cm dish were scraped off in 10ml 
PBS and pelleted by centrifugation at 300 x g for 5min. Cells were resuspended 
in 500µl hypotonic buffer (10mM Tris-HCl pH 8.0, 10mM KCl) and incubated on 
ice for 10min. Cells were lysed by centrifugation through a QIAShredder column 
(Qiagen, #79654) at 13k x g for 2min at 4oC. Supernatant was centrifuged again 
at 13k x g for 10min to remove cell debris. The total protein concentration of cell 
lysates was measured by Bradford assay and standardised to 0.5mg/ml. 
Standardised lysate samples were analysed by LI-COR western blot to 
compare the relative level of Fv1 or T5HA in different clones.  
 
2.4.10 Analyses of crosslinked capsid complexes in virus particles of HIV-
1 and N-MLV 
 
Viruses with wt or mutant N-MLV capsid sequence were prepared using 
plasmids for pseudotype envelope (pVSV-g), Gag-Pol (wt or mutant pCIGN) 
and vector for GFP expression (pLNCG). Viruses with wt or mutant HIV-1 
capsid sequence were prepared with plasmids for pseudotype envelope (pVSV-
g), Gag-Pol (p8.91 or p8.91CC) and vector for GFP expression (pCSGW). 
Viruses were pelleted either by centrifugation at 14k x g at 4oC (N-MLV) for 2h 
or by ultracentrifugation at 70k x g at 4oC for 1h (HIV-1), and resuspended in 
100µl 1X non-reducing SDS-PAGE loading buffer (50mM Tris-HCl pH 6.8, 2% 
SDS, 0.02% w/v bromophenol blue, 10% glycerol). The sample was divided into 
2 x 50µl aliquots, and 1µl of β-mercaptoethanol was added to 1 aliquot for 
reduced sample. HIV-1 samples were analysed by LI-COR western blot with 
anti-p24, while N-MLV samples were analysed by chemiluminescent western 
blot with anti-p30. 
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2.5 RNA quantitation 
 
2.5.1 Preparation of cell lysate 
 
To determine the relative quantities of Fv1 mRNA in SCCs induced levels, 
7.5x105 cells were seeded to each 10cm dish and treated with the required 
amount of doxycycline. 24h later, cells were harvested with trypsin, mixed with 
medium, and pelleted at 300 x g for 5min. Cell pellet was resuspended 2ml 
PBS, and pelleted again at 300 x g for 5min. The pellet was snap frozen with 
liquid nitrogen, and stored at -80oC until analysis.  
 
2.5.2 RNA extraction 
 
RNA purification was carried out using the RNeasy kit (Qiagen, #74104). Cell 
pellets were resuspended in 350µl RLT buffer, transferred to a QiaShredder 
column, and centrifuged at 14krpm for 2min. 300µl of supernatant was mixed 
with 300µl of 70% ethanol, added to an RNAeasy column, and centrifuged at 
10krpm for 15s. The column was washed with 350µl of RW1, incubated with 
80µl of DNase I mix (DNase:RDD = 1:7; Qiagen, #79254) at room temperature 
for 15min, and then washed again with 350µl RW1. The column was then 
washed with 500µl RPE first for 15s, then again for 2min. The column was 
centrifuged in a new collection tube for 1min to remove residual buffer. RNA 
was eluted by centrifuging 50µl of RNase-free water through the column for 
1min using a new collection tube. The required amount of RNA sample was 
transferred to PCR tubes, and the rest were stored at -80oC. 
 
2.5.3 Reverse transcription 
 
Generation of cDNA was carried out using the High-capacity cDNA reverse 
transcription kit (Life Technologies, #4368814). 10µl of RNA sample was mixed 
with 10µl of 2X RT mix (2µl 10X RT buffer, 0.8µl 25X dNTP, 2µl 10X random RT 
primer, 1µl MultiScribe RT, 4.2µl RNase-free water). Reactions were incubated 
at 25oC for 10min, 37oC for 120min, and 85oC for 5min. cDNA samples were 
stored at -20oC until qPCR. 
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2.5.4 Relative quantitative PCR (qPCR) 
 
Relative quantities of Fv1 cDNA were analysed by TaqMan real-time PCR 
assay (Life Technologies). Primers and probe (Sigma) used for the quantitation 
of Fv1 mRNA are listed in Table 2.10. Each 20µl PCR reaction contained 5µl of 
cDNA sample, 0.9µM forward Fv1 primer, 0.9µM reverse Fv1 primer, 0.25µM of 
Fv1 probe (5’-6FAM/3’-BHQ1), 1µl of Mouse GAPDH Endogenous Control mix 
(VIC/MGB probe, primer limited, Life Technologies, #E4352339E) and 10µl of 
2X TaqMan Fast Universal PCR Master Mix (Life Technologies, #4366072). 
qPCR was carried out using the 7500 Fast Real-Time PCR System (Life 
Technologies) and the supplied software, with default cycling parameters for 
TagMan assays. Relative quantities of Fv1 and GAPDH in each sample were 
interpolated from standard curves of Fv1 and GAPDH derived from serial 
dilutions of cDNA of one particular sample in water. The relative quantities of 
Fv1 cDNA were normalised against the relative quantities of GAPDH cDNA. 
The mean and error values of relative Fv1 mRNA expression were calculated 
from results of 2 qPCR repeats from each of 2 biological samples.  
 
 
 
 
 
Oligonucleotides Sequence 
Forward primer TGTGAGGTTAGCTGATGTGCAA 
Reverse primer TCACCTTATCTGCAGACATTTCC 
Probe 6[FAM]CCCAGGTCATGTGTCAGCCTGCC[BHQ1] 
  
 
Table 2.10 Primers and probe used for TaqMan qPCR analysis of Fv1 
mRNA  
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2.6 Luciferase assay 
 
2.6.1 Screening of rtTA3 SCCs by luciferase assay 
 
rtTA3 SCCs was transduced with TREPuro-Luc vector virus at a MOI less than 
0.1, and selected with puromycin for 10 days. Cells were then reseeded in 24-
well plates, and treated with or without 1µg/ml doxycycline for 24h. Luciferase 
assay was carried out using the Luciferase Assay System (Promega). Cells 
were lysed with 100µl of 1X the supplied Cell Culture Lysis Buffer, and cell 
debris was removed by centrifugation at 450 x g for 10min. For the analysis of 
samples without doxycycline treatment, 20µl of lysate was added to a white 96-
well plate (Corning). Samples treated with 1µg/ml doxycycline were diluted 100-
fold before analysis using 20µl of diluted lysate. Light emitted from the 
bioluminescent reaction catalysed by firefly luciferase was measured (sensitivity 
level of 150, 10s measurement) using the Synergy 2 plate reader and the Gen5 
software. 100µl Luciferase Assay Reagent was dispensed 2s before 
measurement. Cells from duplicate wells in 24-well plate were counted, and 
relative luminescence signal was normalised to the cell count to obtain 
normalised relative luciferase activity. In later experiments with induction at 
multiple doxycycline concentrations, cells transduced with the TREPuro-Luc 
vector and selected with puromycin were directly seeded to white 96-well plate 
and treated with various concentration of doxycycline. Cells were either 
resuspended in trypsin and counted, or lysed with 20µl of lysis buffer for 
luciferase assay under optimised conditions (sensitivity level of 70, 2s delay, 1s 
measurement time, 100µl Luciferase Assay Reagent).  
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2.7 Flow cytometry 
 
2.7.1 Standard flow cytometry (FACS) analyses 
 
Confluent cells in 12-well plates were resuspended in 1ml trypsin and fixed by 
mixing with 3ml of 2% formaldehyde-PBS in 5ml round bottom tubes (Corning, 
#352008). Cells were pelleted by 400 x g centrifugation for 5min, and 
resuspended in 300µl PBS. Samples were filtered through 35µm nylon mesh 
(Corning, #352235) before analysis. Flow cytometry (FACS) analyses were 
carried out using FACSVerse, LSR II or LSRFortessa flow cytometers (BD 
Biosciences), and the FACSDiva and FACSuite software (BD Biosciences). In 
two colour analyses, filters optimised for simultaneous detection of GFP and 
YFP signals were used. Due to the overlapping in the emission spectra of 
EGFP and EYFP, there are significant spillover of GFP signal to the YFP 
detection channel, and vice versa. Therefore, GFP and YFP signals were 
compensated for spillover using a compensation matrix. Further optimisation of 
compensation values and data analyses were carried out using the FlowJo 
software (Tree Star). The 2-colour FACS analysis allows determination of the 
percentages of GFP- YFP-, GFP- YFP+, GFP+ YFP- and GFP+ YFP+ populations 
among the analysed cells. 
 
2.7.2 High throughput FACS analyses 
 
A high throughput procedure was used for analyses of large number of 
samples. Confluent cells in 24-well plates were resuspended in 0.5ml trypsin 
and fixed by mixing with 1.5ml of 2% formaldehyde-PBS in 2ml deep-well plate 
(Eppendorf, #0030501.306). Cells were pelleted by 400 x g centrifugation for 
5min, and resuspended in 150µl PBS. Samples were filtered through a 40µm 
MultiScreen-MESH Filter Plate (Merck Millipore, #MANMN4010) to a round-
bottom 96-well collection plate (Corning), and analysed using FACSVerse with 
microplate sample loader. 
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2.7.3 Screening of SSC with inducible Fv1 expression 
 
To screen SCCs derived from R18 cells transduced with TGx-Fv1 or TGIx-Fv1 
vectors, 2.5x104 SCC cells were seeded in 24-well plate and induced with 
1µg/ml doxycycline for 72h before FACS analysis. SCCs each consisted of a 
single GFP+ population were chosen for later studies. 
 
2.7.4 Restriction assay in cells with non-inducible Fv1 expression  
 
MLV restriction assays in cells with non-inducible Fv1 expression using LxIG-
Fv1 vectors had been described before (Bock et al., 2000). YFP tester viruses 
were prepared using plasmids for expression of the VSV-g envelope (pVSVg), 
MLV gag-pol (pCIGN for N-MLV, pCIGB for B-MLV and pHIT60 for NB-MLV) 
and vector genome for EYFP expression (pCFG-YFP). The MOI of transduction 
is linked to the fraction of cells expressing the fluorescent marker (fp) using the 
following equation: 
𝑀𝑂𝐼 = −2𝑙𝑛 (1 − 𝑓𝑝) 
 
 R18 cells were transduced with LxIG-Fv1 vector at MOI of 0.7 (~30% 
GFP+), and 2.5x104 transduced cells were seeded per well in 24-well plate. 24h 
later, the transduced cells were infected with YFP tester viruses with N, B or 
NB-tropic capsid at MOI of 0.7. At 72hpi, cells were studied by FACS analyses 
to determine the percentages of cells expressing GFP, YFP or both. Restriction 
ratio was calculated as follow: 
𝑅𝑒𝑠𝑡𝑟𝑖𝑐𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑖𝑜 =  
𝐺𝐹𝑃+𝑌𝐹𝑃+
𝐺𝐹𝑃+
÷
𝐺𝐹𝑃−𝑌𝐹𝑃+
𝐺𝐹𝑃−
 
 
  
124 
2.7.5 Restriction assay in cells with non-inducible T5 expression 
 
MLV restriction assays with in MDTF cells with non-inducible T5 expression 
using LxIY-T5 vectors had been described before (Yap et al., 2004). Since the 
transduction vectors expressed EYFP, GFP tester viruses were prepared using 
the vector plasmid pLNCG. Restriction assay was carried out as described for 
Fv1, but restriction ratio was calculated using a modified equation: 
 
𝑅𝑒𝑠𝑡𝑟𝑖𝑐𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑖𝑜 =  
𝑌𝐹𝑃+𝐺𝐹𝑃+
𝑌𝐹𝑃+
÷
𝑌𝐹𝑃−𝐺𝐹𝑃+
𝑌𝐹𝑃−
 
 
2.7.6 Restriction assay in cells with inducible Fv1 expression 
 
MLV restriction in R18 cells transduced with TGIx-Fv1 or TGx-Fv1 vectors at 
MOI of 0.7 were studied using a modified protocol. Transduced cells were 
seeded at 2.5x104/well in 24-well plate in medium containing 0 to 1000ng/ml 
doxycycline. 24h later, cells were infected with YFP tester viruses at MOI of 0.7. 
At 24hpi, a high dose of doxycycline was added to the medium to a final 
concentration of 10µg/ml. At 72hpi, cells were studied by FACS analysis as 
described before. Restriction studies in SCC cells with inducible Fv1 expression 
was carried out as described, except that 1.25x104 SCC cells were seeded 
along with 1.25x104 untransduced R18 cells. 
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2.7.7 Restriction assay in cells with superexpression of Fv1 
 
MDTF cells seeded at 2.5x104/well in a 24-well plate were transduced with 
different volume of LxIG-Fv1 vector viruses, or with the NB-MLV GFP tester 
virus as a control. After 72h, cells from a transduced well were mixed with cells 
from an untransduced well, and reseeded at 2.5x104/well in a 24-well plate. 24h 
later, cells were infected with YFP tested viruses. FACS analyses were carried 
out at 72hpi. The MOI of transduction was calculated as follow: 
 
𝑀𝑂𝐼 = (
−2𝑙𝑛0.7
𝑉30
) × 𝑉 
 
𝑀𝑂𝐼 The MOI of transduction 
𝑉30 The volume of vector virus needed for transduction to obtain a 30% 
GFP+ population (before mixing), interpolated from the plot of percentage 
of GFP+ cells (before mixing) against volume of transducing virus 
𝑉 Volume of vector virus used for transduction 
 
2.7.8 Abrogation assay 
 
Abrogation of endogenous Fv1b in B-3T3 cells and endogenous HuT5 in TE671 
cells had been described before (Dodding et al., 2005). Abrogating particles 
were prepared with plasmids expressing envelope (pVSVg), wt or mutant MLV 
gag-pol (pCIGN for N-MLV, pCIGB for B-MLV), and vector for LacZ expression 
(pHIT111). Cells were seeded at 5x104/well in 12-well plate for TE671 (or 
2.5x104/well in 24-well plate for B-3T3). On the next day, cells were incubated 
with various volumes of freshly prepared abrogating particles for 2h, before 
infection with N-MLV GFP tester virus at a MOI of 0.7 (based on previous 
titration on MDTF cells). The percentage of GFP+ cell population was 
determined by FACS analysis at 72hpi. 
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2.8 Binding assay 
 
2.8.1 Generation of lipid nanotubes 
 
Lipids used for generation of nanotubes are listed in Table 2.5. Typically, 70µl 
of 2.5mg/ml GalCer, 30µl of 2.5mg/ml DGS-NTA(Ni) and 50µl of 25µg/ml 
BioPEG PE were mixed in glass vial using a Hamilton Syringe. Bio PE and 
BioCap PE were also used in initial optimisation experiments. Chloroform and 
methanol were slowly evaporated under a gentle stream of nitrogen gas. Dried 
lipids were resuspended in 500µl of nanotube buffer (10mM Tris-HCl pH 8.0, 
10mM KCl, 100mM NaCl) using a sonication bath and a vortex. 
 
2.8.2 Screening of nanotube immobilisation conditions 
 
Initial optimisation of nanotube immobilisation conditions were carried out using 
High Bind 96-well plate (Corning, #3590) coated with neutravidin (Thermo 
Fisher, #31000, cheaper alternative to Streptavidin) and blocked with 5% BSA 
(Sigma) in house. In these early trials, 100µg/ml of naked or coated nanotubes 
were incubated for 4 to 16h, and coated with CA for 1h. Capsids were eluted in 
1X SDS-Loading buffer, and analysed by SDS-PAGE followed by gel staining. 
 
2.8.3 Preparation of fresh lysate 
 
Confluent cells expressing Fv1 or T5HA on a 10cm dish were scraped off in 
10ml PBS and pelleted by centrifugation at 300 x g for 5min. Cells were 
resuspended in 500µl ice-cold hypotonic buffer (10mM Tris-HCl pH 8.0, 10mM 
KCl) and incubated on ice for 10min. Cells were lysed by centrifugation through 
a QIAShredder column (Qiagen, #79654) at 13k x g for 2min at 4oC. 
Supernatant was centrifuged again at 13k x g for 10min to remove cell debris. 
The salt concentration was adjusted by adding 1/10 volume of 10X salt buffer 
(10X: 10mM Tris-HCl pH 8.0, 10mM KCl, 3M NaCl, and 100mM imidazole). The 
total protein concentration of cell lysate was measured by Bradford assay and 
standardised to 0.5mg/ml. In some experiments, standardised lysate expressing 
Fv1 was diluted with standardised blank lysate from untransduced MDTF cells. 
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2.8.4 Generation of frozen lysate library 
 
MDTF cells were seeded at 5x104/ml in 12-well plate and transduced with LxIG-
Fv1 vectors at different MOIs, and allowed to grow to confluency in a T175 
flask. Cells were resuspended in 5ml trypsin, mixed with 30ml medium and 
pelleted at 300 x g for 5min. Cells were washed with 30ml PBS, pelleted, and 
resuspended in 1.5ml ice-cold hypotonic buffer. Lysate was prepared as 
described above, and dispensed into PCR tubes as 160µl aliquots. Trays of 
PCR tubes were immersed into liquid nitrogen for 10s, and stored at -80oC 
immediately. An aliquot of each sample in the lysate library was thawed for 
analysis of total protein by Bradford assay and for analysis of Fv1 concentration 
by quantitative LI-COR western blot. Diluted Fv1 lysate with specified Fv1 
concentration and 0.5mg/ml total protein concentration was prepared by mixing 
appropriate amount of thawed Fv1 lysate, blank lysate from untransduced 
MDTF cells and binding buffer (10mM Tris-HCl pH 8.0, 10mM KCl, 300mM 
NaCl, and 10mM imidazole). 
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2.8.5 Optimised microplate pull down assay 
 
A Reacti-Bind Streptavidin High Binding Capacity Coated 96-well plate (Thermo 
Fisher, #15501) was washed 3 times with nanotube buffer, followed by addition 
of 100µl/well of 10µg/ml lipid nanotube. The plate was incubated at 25oC for 1h 
with shaking, and washed 3 times with nanotube buffer. 100µl of 15µM MLV 
CA-His or HIV-1 CA-p2-His (confirmed by absorbance at 280nm) was added to 
each well, and the plate was incubated at 25oC for 1h with shaking. After 3 
washes with nanotube buffer, 100µl of 0.5mg/ml lysate was added to each well. 
The plate was incubated at 25oC for 1h with shaking, and then washed 10 times 
with wash buffer (10mM Tris-HCl pH 8.0, 10mM KCl and 300mM NaCl). 1M 
imidazole was added to wash buffer in some control experiments. To elute 
proteins, 100µl of elution buffer (10mM Tris-HCl pH 8.0, 10mM KCl, 300mM 
NaCl, 2% SDS, 0.5M imidazole) pre-heated to 37oC was added to each well, 
and the plate was incubated at 37oC for 20min with shaking. 80µl of eluted 
sample was mixed with 20µl of 5X SDS-free loading buffer (5X: 250mM Tris-
HCl pH 6.8, 10% SDS, 0.1% w/v bromophenol blue, 50% glycerol) in PCR 
tubes, and boiled at 98oC for 5min. Eluted samples were analysed along with 
input samples by chemiluminescent or LI-COR western blot. 
 
 
 
2.9 Software 
 
Analyses of DNA and protein sequences were performed using Lasergene 10 
(DNASTAR) and Serial Cloner (SerialBasics). Flow cytometry data were 
analysed with FlowJo (Tree Star). Quantitative western blot analyses were 
achieved using ImageStudio (LI-COR). Curve fitting and correlation analysis 
were carried out using Prism 5 (GraphPad). Images of capsid structures were 
produced using PyMOL (Schrödinger).  
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Chapter 3 
 
Study of the relationship between Fv1 
expression level and restriction specificity 
 
One of the key questions in this thesis is what controls the Fv1 restriction 
specificity. In addition to sequence determinants in Fv1 alleles, there was some 
evidence that the concentration of Fv1 may also affect the apparent restriction 
specificity (Felton, 2012). This chapter describes a number of experiments to 
study the relationship between Fv1 expression level and restriction specificity.  
 
The two Fv1 alleles which control N and B tropism, Fv1n and Fv1b, differ 
at three variable sites: position 358, position 399 and the C-terminal tail (Best et 
al., 1996). In order to study the determinants controlling the different restriction 
specificities of Fv1n and Fv1b, “mix-and-match” mutants expressing chimeric 
Fv1 proteins harbouring different combinations of sequences at the 3 variable 
sites have been studied along with C-terminal tail deletion mutants (Table 1.1) 
(Bishop et al., 2001; Bock et al., 2000). When over-expressed using the LxIG-
Fv1 vector, these mutants have diverse restriction phenotypes against N-MLV, 
B-MLV and NB-MLV. In section 3.1, I wanted to test the hypothesis that at the 
over-expression level, these residues at the 3 variable sites affect restriction 
specificity mainly through changes in apparent binding affinity to CA. Since Fv1b 
has been hypothesised to gain inhibition of NB-MLV and B-MLV at the over-
expression level, it is possible that some restriction phenotypes of the variable 
site mutants can be explained by the differences in the Fv1 protein levels when 
over-expressed using the LxIG-Fv1 vector. For example, Fv1b and its two tail 
mutants, Fv1bbn and Fv1bb_, all restrict N-MLV and NB-MLV. However, while 
over-expressed Fv1b only weakly inhibits B-MLV, over-expressed Fv1bb_ and 
Fv1bbn showed partial and full restriction, respectively. It is possible that the 
mutation or deletion at the C-terminus increase the Fv1 protein level expressed 
using the LxIG-Fv1 vector, thereby allowing the restriction of B-MLV without 
affecting the apparent binding affinity to B-MLV CA. Therefore I wanted to 
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compare the Fv1 protein levels of the mix-and-match mutants and the C-
terminal deletion mutants. This will allow the identification of sequence which 
leads to higher Fv1 protein level despite being expressed using the same 
vector, and to test if the restriction of B-MLV by Fv1b, Fv1bbn and Fv1bb_ can 
be correlated with the Fv1 concentration in cells.  
 
Fv1b expressed at endogenous levels in BALB/c mice and B-3T3 cells 
restricts N-MLV, but neither B-MLV nor NB-MLV (Hartley et al., 1970). However, 
Fv1b expressed by retroviral vector in MDTF cells appears to restrict N-MLV by 
20-fold, restrict NB-MLV by 5-fold, and inhibit B-MLB by 30% (Bock et al., 
2000). The observations of high Fv1b restriction specificity at the endogenous 
level of B-3T3, and a low Fv1b restriction at the over-expression level in 
transduced MDTF strongly suggested a link between Fv1 concentration and 
restriction specificity. However, since these observations were made in different 
cell lines, it is possible that some other cell type specific factors unrelated to Fv1 
could influence the restriction specificity. To exclude such possibility, it would be 
desirable to develop a system which allow the inducible expression of 
recombinant Fv1 in the Fv1 MDTF cell line, and allow the study of Fv1 
restriction from the endogenous level to an over-expression level using the 
FACS-based restriction assay. In section 3.2, I wanted to test the hypothesis 
that the over-expression of Fv1b leads to an increase in restriction specificity, 
using a novel inducible expression system which allow the expression of Fv1 
from the endogenous level to an over-expression level. 
 
Fv1n expressed at endogenous levels in NIH/Swiss mice and N-3T3 cells 
restricts B-MLV, but neither N-MLV nor NB-MLV (Hartley et al., 1970). In 
contrast to Fv1b, which appears to inhibit all MLV strains at the over-expression 
level, Fv1n does not appear to inhibit N-MLV and NB-MLV even when over-
expressed (Bock et al., 2000). In section 3.3, I asked the question whether Fv1n 
can inhibit N-MLV and NB-MLV at a very high “super-expression” level. 
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3.1 Study of Fv1 expression using a quantitative assay 
 
3.1.1 The vector-mediated Fv1b protein expression was 26-fold higher 
than the endogenous level 
 
In order to test the hypothesis that residues at the 3 variable sites affect 
restriction specificity solely through changes in apparent binding affinity to CA, I 
compared the Fv1 protein levels of Fv1n, Fv1b, 6 mix-and-match mutants and 2 
C-terminal tail deletion mutants (Table 1.1). I started by developing an Fv1 
quantitation assay by optimising the LI-COR quantitative western blot 
procedure. The LI-COR system uses a high resolution scanner to detect 
infrared fluorescent signals from secondary antibody conjugated to an infrared 
dye (IRDye). This system is advantageous over traditional chemiluminescent 
detection using HRP-conjugated antibodies by having a wider sensitivity range 
and much better linearity between signal and protein quantity. The high 
resolution of western blot image also allows easy quantitation of protein bands. 
Absolute quantitation of the target protein can also be carried out by relating the 
fluorescent signals from samples to that from purified protein standards of 
known concentration. 
 
Figure 3.1 shows an example of quantitative western blot analysis for Fv1. In 
this assay, the absolute quantities of Fv1 were measured from cell lines that 
express Fv1 endogenously (N-3T3 and B-3T3) and from MDTF cells transduced 
with LxIG-Fv1 vectors expressing various Fv1 alleles and mutants. Cells were 
lysed in RIPA buffer, and the total protein concentration of cell lysates were 
measured by BCA protein assay and standardised to 1mg/ml. 25µg of cell 
lysate were analysed by western blot along with purified Fv1-NTD standards of 
various known quantities. While there has been no reported success in the 
purification of full length Fv1, the amino-terminal domain comprising residues 
20-200 of Fv1 (Fv1-NTD) is highly stable and could be purified as standard 
(Bishop et al., 2006). Because the much smaller size of Fv1-NTD (22kDa) 
compared to full length Fv1 (about 50kDa), the samples and standards could be 
loaded to the same lane to maximise the number of lysates that can be 
compared on the same blot. Fv1 was detected using an anti-Fv1 rabbit serum 
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(#6689) which was raised against Fv1-NTD as the primary antibody, and an 
IRDye-800 conjugated secondary antibody.  
 
Figure 3.1 Quantitation of Fv1 in cell lysate by LI-COR western blot 
 
Cells of MDTF, N-3T3, B-3T3, and MDTF transduced with LxIG-Fv1 vectors (~30% GFP
+
) 
expressing wild type or mutant Fv1 were lysed in RIPA buffer. The 3-letter code for each mutant 
indicated the source of sequence at position 358, position 399 and C-terminus, respectively. 
Cell lysates were analysed by SDS-PAGE along with purified Fv1-NTD standards of known 
concentration. Fv1 was detected by LI-COR quantitative western blot using anti-Fv1 primary 
antibody and IRDye-800 labelled secondary antibody. Signals detected from the 800nm channel 
were shown in green. Quantification data from this western blot is shown in Figure 3.3. 
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The infrared fluorescent signal at 800nm of each band was measured 
using the LI-COR Odyssey scanner. Using the GraphPad Prism software, the 
quantity of Fv1 from each sample band was interpolated from a standard curve 
fitted to data from Fv1-NTD (Figure 3.2). To relate the quantity of Fv1 in cell 
lysate to the expression level in cells, I determined that on average each lysed 
cell results in 120pg of proteins using my lysis protocol. This was determined by 
lysing 2x106 MDTF cells in 100µl lysis buffer, measuring the total protein 
concentration by BCA assay, and finally dividing the total protein yield by the 
number of cells lysed. This allowed the calculation of the average number of 
Fv1 molecules per cell. For the transduced MDTF samples, the percentage of 
Fv1+/GFP+ cells was determined by FACS analysis. In the restriction assay as 
well as this Fv1 quantitation assay, MDTF cells were transduced at a MOI of 1 
or below, typically at 0.7. Based on the Poisson distribution, it is calculated that 
after transduction at a MOI of 0.7, 50% of cells will be transduced, of which 69% 
would contain 1 copy of provirus. However, since each integration event occurs 
in one copy of the diploid genome, it will only be inherited by one of the 
daughter cells. After cell division, 30% of cells will contain provirus, of which the 
majority of cells (84%) will have a single copy of provirus. The number of Fv1 
molecules in the transduced population was calculated by dividing the average 
number of Fv1 molecules per cell by the percentage of GFP+ cells. 
 
The results from the Fv1 quantitation assay are illustrated in Figure 3.2. 
In agreement with earlier studies, the Fv1 protein level in transduced MDTF was 
found to be significantly higher than the endogenous level for both Fv1n and 
Fv1b. The exogenous Fv1n level is 37-fold higher than the endogenous level, 
while the exogenous Fv1b level is 26-fold higher than the endogenous level. 
The high Fv1 protein levels in transduced cells are consistent with the 
hypothesis that the additional inhibition activities in cells expressing Fv1b 
exogenously are due to overexpression of Fv1. It is surprising that although a 
26-fold increase in Fv1b expression appears to cause significant increase in 
restriction activities, a 37-fold increase of Fv1n still does not allow inhibition of 
N-MLV and NB-MLV. 
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Figure 3.2 A typical standard curve for Fv1 quantitation 
 
Signals of bands from different known quantities of Fv1-NTD in Figure 3.1 were fitted to a 
standard curve using the GraphPad Prism software.   
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3.1.2 Sequences at position 358 and the C-terminus of Fv1 strongly 
influence the vector-mediated Fv1 expression level 
 
Since Fv1n and Fv1b differ from each other at positions 358, 399 and the C-
terminus, Fv1 quantification was carried out on MDTF cells transduced with 
LxIG-Fv1 vectors expressing 6 mix-and-match Fv1 mutants (bbn, nnb, bnn, 
nbb, nbn and bnb) and two C-terminal tail-truncation Fv1 mutants (nn_ and bb_) 
previously made to study determinants of MLV restriction (Bishop et al., 2001; 
Bock et al., 2000). Study of Fv1 protein levels of these mutants in MDTF cells 
would be very useful to understand the contributions of the 3 positions to 
protein expression level, and may also help to explain some of the restriction 
phenotypes of these mutants. 
 
In MDTF cells transduced with LxIG-Fv1 vectors, the Fv1n protein level 
was 4-fold higher than the Fv1b level (Figure 3.3). Previously, equal mRNA level 
was found in MDTF cells transduced with Fv1n and Fv1b vectors. The fact that 
both alleles were expressed using the same promoter, vector and cell line 
suggested that the difference in exogenous protein levels was due to 
differences during or after translation. An analysis on how mutations at each 
position influenced the Fv1 protein level is summarised in Table 3.1. The 
presence of the Fv1n-specific Lys residue instead of the Fv1b-specific Glu 
residue at position 358 consistently led to higher Fv1 protein level in all cases. 
The presence of the Fv1n-specific Val residue instead of the Fv1b-specific Arg 
residue at position 399 did not show consistent change in protein level, with 
increase in two cases and decrease in two cases. The short C-terminal tail of 
Fv1n (TKL) was associated with higher Fv1 protein level. In all cases, mutation 
from the Fv1n tail to the Fv1b tail led to decrease in Fv1 protein level. This result 
could be explained either by an enhancing effect of the short Fv1n tail, or by an 
inhibitory effect of the long Fv1b tail. The observations that the truncation of the 
short tail from Fv1n led to a 70% drop in protein level while the deletion of the 
long tail Fv1b did not significantly increase protein level support the first 
possibility. Taken together, the presence of K358 and TKL tail from Fv1n 
strongly enhances the expression of Fv1 in MDTF cells.  
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Figure 3.3 Quantification of endogenous and exogenous Fv1 protein 
levels 
 
The amount of Fv1 in each band was quantified by interpolating from the standard curve shown 
in Figure 3.1. The number of Fv1 molecules per cell was calculated using the Fv1 and total 
protein concentration of lysate, the percentage of GFP
+
 cells expressing Fv1, and the amount of 
protein per lysed cell (120pg/cell). The graph showed mean and mean deviation from two 
independent experiments. 
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Table 3.1 The influence of mutations on the exogenous protein level of 
Fv1 
 
A summary of the data from Figure 3.2 showing the differences in protein expression level (as 
1000 Fv1 molecules/cell) caused by each mutation.  
nxx > bxx Difference % Difference 
nnn > bnn -979 -34% 
nnb > bnb -767 -49% 
nbb > bbb -1907 -74% 
nbn > bbn -2363 -69% 
     
xnx > xbx Difference % Difference 
nnn > nbn 569 20% 
bnb > bbb -125 -16% 
nnb > nbb 1015 65% 
bnn > bbn -815 -43% 
     
xxn > xxb Difference % Difference 
nnn > nnb -1293 -45% 
bbn > bbb -391 -37% 
bnn > bnb -1081 -57% 
nbn > nbb -847 -25% 
     
xxx > xx_ Difference % Difference 
nnn > nn_ -2014 -70% 
bbb > bb_ 82 12% 
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A comparison of the protein levels of Fv1b, Fv1bbn and Fv1bb_ showed 
that Fv1bbn is expressed at the highest level, followed by Fv1bb_ then Fv1b. 
Interestingly, the restriction activities towards B-MLV follows the same order, 
with the strongest effect from Fv1bbn, followed by Fv1bb_ then Fv1b (Bishop et 
al., 2001; Bock et al., 2000). However, the difference in protein levels among 
these Fv1 alleles is low (less than 2-fold), and is unlikely to have significant 
effect on restriction. A comparison of Fv1 protein levels in N-3T3 and B-3T3 
cells showed that the endogenous protein level of Fv1n was 3-fold higher than 
that of Fv1b. Since a higher Fv1 mRNA level in N-3T3 cell than in B-3T3 has 
been reported (Felton, 2012), it is not certain whether the difference in 
endogenous protein levels is mainly due to differences during or after 
translation, or due to the different transcription levels.  
 
3.1.3 The lower vector-mediated Fv1b protein expression compared to 
Fv1n was not due to higher rate of degradation by proteasome  
 
A fusion protein containing the Fv1-NTD and a CypA domain (Fv1Cyp) was 
previously shown to have a long half-life in cells with no detectable reduction in 
protein level 8h after blocking of protein synthesis with cycloheximide (Schaller 
et al., 2007). It is possible the lower expression of Fv1b in MDTF cells was due 
to a higher rate of degradation by proteasomes leading to a more rapid 
turnover. To test this hypothesis, the effect of proteasome inhibitor MG132 on 
Fv1 protein expression in transduced cells was studied using the Fv1 
quantitation assay (Figure 3.4). MDTF cells transduced with either LxIG-Fv1n or 
LxIG-Fv1b vectors were treated with or without 10µM MG132 for 24h. In addition 
to cell lysis with RIPA buffer, lysate was also prepared using a detergent-free 
hypotonic buffer and mechanical sheering of cells through QiaShredder 
columns. Cell lysates were standardised by total protein concentration using the 
BCA assay. The detergent-free method was used in preparing lysate for binding 
assays described in later chapters, and the amount of Fv1 in lysate prepared 
using either method was highly similar. If the lower protein level of Fv1b was 
due to higher rate of degradation by proteasome, similar expression levels of 
Fv1n and Fv1b would be expected in cells treated with MG132. Instead, the Fv1b 
level was lower than the Fv1n level in in both MG132-treated and non-treated 
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cells. The protein level of both Fv1n and Fv1b were lower in cells treated with  
 
Figure 3.4 Effect of protease inhibitor on Fv1 expression level 
 
MDTF cells transduced with either LxIG-Fv1
n
 or LxIG-Fv1
b
 vectors at about 30% GFP
+
, and 
treated with or without 10µM MG132 for 24h before cell lysis. Cells were lysed either by 
spinning through QiaShredder in hypotonic buffer, or by 30min incubation in RIPA buffer. Lysate 
samples were standardised by protein concentration before SDS-PAGE and western blot 
analysis. The graph showed mean and mean deviation from two quantitative western blot 
analyses of the same lysate sample. 
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MG132. Because MG132 treatment causes cell cycle arrest (Mellgren, 1997) 
and accumulation of proteins in cytoplasm, it may lead to an increase in total 
protein quantity per cell. As a result, cell lysate that was standardised to total 
protein concentration would be from fewer cells in samples treated with MG132, 
causing underestimation of Fv1 expression level. From this assay I could 
conclude that degradation by proteasome did not play a major role in the 
different protein expression levels of Fv1n and Fv1b in MDTF cells. 
 
 
 
3.2 Study of the dose dependency of Fv1 restriction using an 
optimised inducible expression system and a 2-colour FACS 
assay 
 
3.2.1 Previous attempts to study restriction of recombinant Fv1 
expressed from natural Fv1 promoter  
 
The observations of high Fv1b restriction specificity at the endogenous level of 
B-3T3, and a low Fv1b restriction at the over-expression level in transduced 
MDTF strongly suggested a link between Fv1 concentration and restriction 
specificity. However, since these observations were made in different cell lines, 
it is possible that some other cell type specific factors unrelated to Fv1 could 
influence the restriction specificity. Several attempts were made to develop new 
retroviral vectors that would allow the expression of Fv1 under its natural 
promoter in MDTF (Felton, 2012), so that the restriction specificity can be 
compared to the LxIG vector using the same FACS-based restriction assay 
(Bock et al., 2000). These vectors were made by introducing the Fv1 promoter 
into self-inactivating (SIN) vectors which contain large deletion in the U3 
promoter of 3’LTR, resulting in the loss of LTR promoter functions after the 
integration of vector into host genome (Yu et al., 1986). Transcripts from these 
vectors contain the Fv1 ORF at the 5’ end, followed by an IRES and a reporter 
gene such as EYFP. However, due to the weak promoter activity the natural 
Fv1 promoter, there was insufficient expression of the reporter gene for the 
separation of transduced cells from untransduced cells by FACS. A dual 
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promoter SIN vector with the arrangement of PFv1-Fv1-PCMV-EYFP did provide 
sufficient YFP separation for 2-colour restriction assay (Felton, 2012). 
Interestingly, results from the study of Fv1b using this vector showed restriction 
of N-MLV and no inhibition of B-MLV, a phenotype which resembles that of 
endogenous Fv1b. However, it was uncertain how the protein level of Fv1 
expressed using this vector compared with the endogenous level in B-3T3. The 
possibility of that the neighbouring CMV promoter could have negatively 
influenced the activity of the Fv1 promoter activity could not be ruled out (Curtin 
et al., 2008). The results from the dual promoter SIN vector showed that at a 
expression level sufficient to restrict N-MLV, Fv1b does not restrict B-MLV. 
However, there was still no direct evidence proving that the inhibition of B-MLV 
and NB-MLV by Fv1b in cells transduced with the LxIG-Fv1 vector was due to 
overexpression of Fv1b above its endogenous level. It was decided that 
restriction studies in cells with inducible expression of Fv1 would be best suited 
to address this question. 
 
3.2.2 Tet-On inducible expression systems 
 
The Tet-On inducible expression system was developed for controlling the 
transcription of transgenes in mammalian cells (Gossen et al., 1995). The 
system consists of two basic components (Figure 3.5): a constitutively 
expressed reverse tetracycline-controlled transactivator (rtTA) protein and a 
tetracycline-controlled inducible promoter containing copies of the tet operator 
sequence (tetO). The rtTA protein specifically binds to tetO sequences only in 
the presence of doxycycline, activating transcription from the inducible 
promoter. As a result, the transcriptional level from the inducible promoter is 
dependent on the concentration of doxycycline added. 
 
The first rtTA protein was constructed through the fusion of a modified 
version of Tet repressor (rTetR) protein (Gossen et al., 1995) and transcriptional 
activating domain of herpes simplex virus (HSV) VP16 protein (Triezenberg et 
al., 1988). Since then, the system had been improved in order to minimise the 
basal transcription activity in the absence of doxycycline (leakiness) and to 
maximise the activation in transcription activity in the presence of doxycycline.  
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Figure 3.5 Components of the Tet-On inducible expression system 
The tet-on system requires a cell line that constitutively expresses the tetracycline-responsive 
transactivator protein, rtTA. The protein was a fusion product between the rtetR and 
transactivating sequence from HSV VP16. The rtTA protein forms a dimer, and specifically 
binds to tetO sequence only in the presence of doxycycline through the rtetR domain, and the 
VP16 domain activates transcription of the gene of interest by the minimal CMV promoter. 
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The rtTA2 using in the second generation Tet-On Advanced system (Urlinger et 
al., 2000) and contains 3 copies of minimal transactivating sequence from VP16 
to maximise induction (Triezenberg et al., 1988), human codon optimised 
sequence, and a number of mutations to reduce non-specific binding to tetO in 
the absence of doxycycline for lower leakiness.  
 
The first generation of inducible promoter consists of a tetracycline-
responsive element (TRE), which contains 7 repeats of tetO sequence 
upstream of a minimal CMV promoter (PCMVmin) (Gossen et al., 1995). The Ptight 
promoter used in the Tet-On Advanced system contains deletions of 
endogenous mammalian transcription factor binding sites in PCMVmin leading to 
reduced leakiness (Pluta et al., 2005). In the PTRE3G promoter used in the Tet-
On 3G system, 5’ UTR region of PCMVmin was replaced with inert sequence from 
turnip yellow mosaic virus (TYMV), resulting in even lower basal transcription 
activity (Loew et al., 2010). 
 
3.2.3 A previous attempt to study dose dependency of Fv1b restriction 
using an inducible system 
 
The Tet-On Advanced inducible system was previously implemented for 
developing cell lines with inducible Fv1 expression (Felton, 2012). The goal was 
to develop cells with inducible expression of Fv1 from an endogenous level to 
an overexpressed level, so the change in restriction could be correlated with the 
Fv1 protein level. First, a MDTF cell line expressing the rtTA2 protein was 
constructed. MTDF cells transduced with a retroviral vector expressing both 
rtTA2 and the neomycin resistance gene, followed by selection with G418. 
Picked single cell clones (SCCs) were transfected with the Ptight-luciferase PCR 
product, and screened for luciferase activity with or without pre-treatment with 
doxycycline. Cell lines with inducible Fv1 expression was then constructed by 
stable transfection of the rtTA2 cell line with a plasmid with the Ptight promoter 
controlling the transcription of Fv1-IRES-EYFP mRNA, along with a plasmid 
with the hygromycin resistance marker. After selection with hygromycin 
selection, picked SCCs were tested for inducibility of Fv1 expression by 
comparing the shift in YFP signal in FACS analysis after doxycycline treatment.  
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 Figure 3.6 shows the restriction data from this previous study (Felton, 
2012), the infectivity of MLV in Fv1n and Fv1b SCCs induced with different 
amount of doxycycline were compared to that in parental rtTA2 cell line. In SCC 
expressing Fv1b, N-MLV is fully restricted in the absence of doxycycline. A 50% 
inhibition of NB-MLV was observed even in the absence of doxycycline, but the 
infectivity is further reduced to about 20% at higher induction level. Despite high 
variation in the infectivity of B-MLV in these cells, at above 250 ng/ml 
doxycycline a mild decrease in infectivity to about 70% could be observed. In 
SCC expressing Fv1n cells, the infectivity of all MLV appeared to be inhibited by 
30% even in the absence of doxycycline. However, further reduction in 
infectivity was only observed for B-MLV at higher doxycycline concentration. 
Since Fv1n was not found to inhibit N-MLV and NB-MLV even when 
overexpressed by using LxIG-Fv1 vector, the 30% inhibition was likely due to 
clone-specific factors unrelated to the expression of Fv1.  From this study it 
could be concluded that increasing Fv1 expression level led to increasing 
inhibition. 
 
The strong inhibition of NB-MLV in SCC expressing Fv1b in the absence 
of doxycycline suggested that the expression of Fv1b is leaky. The high 
leakiness of Fv1 expression using this system prevented the study of whether 
NB-MLV and B-MLV were inhibited by Fv1b at the endogenous level. Further 
improvement in the minimisation of leakiness would be required to study 
restriction of MLV restriction at an endogenous Fv1b level. The lower infectivity 
of all MLV in Fv1n SCC also highlighted the difficulties in determining inhibition 
of Fv1 by comparing MLV infectivity between clonal and parental cell lines. The 
infectivity in SCC could be different from the parental cell line for many reasons 
unrelated to Fv1. This potential difference in infectivity also prevented the 
conclusion on whether B-MLV was inhibited by Fv1b at the uninduced level. 
Minor differences could develop after many passage even in stable clones 
expressing a transgene when compared to its parental cell line. For example, 
since MLV intasome could only reach the chromosomes during mitosis when 
the nuclear membrane is dissolved (Roe et al., 1993b), any difference in mitotic 
rate between two cell lines could potentially lead to a difference in infectivity. It 
is difficult to conclude with confidence that small difference in infectivity between  
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Figure 3.6 A previous analysis of MLV restriction in Fv1 inducible cell 
lines  
Reprinted from the thesis of Victoria Felton (Felton, 2012). Inducible Fv1n or 
Fv1b cell lines were incubated with 0 to 1µg/ml doxycycline for 72h before 
infection with N-MLV, B-MLV or NB-MLV GFP-expressing tester virus. The 
percentage of GFP+ cells was determined by FACS analysis. The results were 
shown as a percentage of that in permissive MDTF cells infected in parallel. 
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two cell lines was due to the presence of Fv1 or other cell line specific 
properties. The use of a transient assay is advantageous over the comparison 
of infectivity between cell lines because the use of an internal untransduced 
control (Bock et al., 2000). The 2-colour assay allowed comparison of infectivity 
between Fv1+ and Fv1- populations from the same passage in the same well, 
with the integration of Fv1-expressing vector being the only difference between 
the two populations. Therefore, an optimised inducible system with lower 
leakiness and the use of a transient 2-colour restriction assay would be needed 
to answer these questions. 
 
3.2.4. Development of a Dox-inducible system for expression of Fv1 from 
sub-endogenous levels 
 
In order to reduce the background expression level of Fv1 to a minimum, I 
sought to minimise the transcriptional leakiness by using the Tet-on 3G system, 
and to reduce the translational efficiency by expressing Fv1 using an IRES or 
inserting extra sequences. The third generation Tet-On 3G system uses the 
rtTA3 protein which has higher sensitivity to doxycycline compared to rtTA2 
used by Tet-On Advanced (Zhou et al., 2006). The Tet-On 3G system also uses 
the PTRE3G promoter, which has a lower basal transcription level compared to 
the Ptight
 used by Tet-On Advanced (Loew et al., 2010). To develop a system 
compatible with the transient restriction assay, a MDTF cell line constitutively 
expressing rtTA3 was generated, and SIN retroviral vectors with PTRE3G driven 
transcription were constructed (Figure 3.7). A cloning site for the Gateway 
system (Thermo Fisher) was introduced to allow efficient enzyme-free cloning of 
Fv1 alleles (Figure 2.1), mutants and potentially other restriction factors from 
our library of pENTR vectors. The expression cassette was also redesigned for 
minimal Fv1 expression and maximal EGFP expression. The approach was 
taken to avoid both the high leakiness observed in previous inducible vectors, 
and the insufficient expression of fluorescent reporter protein for separation of 
Fv1+ from Fv1- populations by FACS assay seen in vectors with endogenous 
Fv1 promoter. 
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Figure 3.7 New gateway-compatible retroviral vectors for inducible 
expression of Fv1 with minimal leakiness 
 
(A) Non-inducible retroviral vector used by Bock et al for studying Fv1 restriction using a 
transient FACS assay. After integration, transcription of Fv1 mRNA was driven by the strong U3 
promoter of MLV LTR. (B and C) In the new TGIx SIN vector, the U3 promoter was inactive and 
transcription of Fv1 mRNA was driven only by the TRE3G promoter. Maximal EGFP protein 
level was achieved by cap-dependent translation. A Gateway site was inserted to allow 
enzyme-free cloning of Fv1 alleles and mutants from pENTR vectors. Attenuated translation of 
Fv1 was achieved either (B) by an IRES-dependent machanism in TGIx vectors, or (C) by 
expressing Fv1 in a downstream ORF through leaky ribosome scanning. 
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3.2.5 Implementation of the Tet-On 3G system 
 
The first step in the implementation of the Tet-On 3G system for study of Fv1 
was the generation of a clonal MDTF cell line expressing the rtTA3 protein. 
Figure 3.8 shows the procedure used in the generation and screening of the 
rtTA3 cell line. MDTF cells were transduced with a lentiviral vector expressing 
rtTA3 and the blasticidin resistance gene. Transduced cells were selected with 
blasticidin, and SCCs were picked from the selected population. These rtTA3 
SCCs were then screened by luciferase induction assay. In this assay, SCC 
cells were transduced with a SIN lentiviral vector with expression of luciferase 
gene under the PTRE3G promoter, and expression of puromycin resistance gene 
under a separate promoter. After selection with puromycin, cells were treated 
with or without 1µg/ml doxycycline for 72h, before analysis by luciferase assay. 
The relative luciferase activity was normalised to cell count. Transduction of 
lentiviral vector at low MOI was used for delivering the luciferase gene instead 
of transfection because it removed the bias from differences in transfection 
efficiency among different SCCs. Together with normalisation by cell count, this 
allowed more accurate measurement of the basal transcription activity of PTRE3G 
in these cells. Figure 3.9 shows the results from the screening of rtTA3 clones. 
Among the four clones which gave the highest activation per cell (SCC 9, 18, 
26, 44), SCC 18 had the lowest activity in the absence of doxycycline. The dose 
dependency of PTRE3G induction in this cell line (named R18) was analysed in a 
separate experiment (Figure 3.10). Induction with up to 1µg/ml doxycycline led 
over 4000-fold activation in signal, with the highest increase in signal observed 
within the range of 1-10ng/ml doxycycline. 
 
3.2.6 New gateway-compatible SIN vectors for inducible expression of 
Fv1 
 
Two new vectors were introduced for inducible expression of Fv1. The original 
retroviral vector used by Bock et al used a non-SIN retroviral vector (Figure 3.7 
A). After reverse transcription and integration of vector sequence, transcription 
of Fv1 mRNA was controlled by promoter activity in the U3 region  
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Figure 3.8 Generation of MDTF cell lines expressing rtTA3 
 
MDTF cells were transduced with lentivector expressing rtTA3 and the blasticidin resistance 
gene at low MOI. Cells expressing rtTA3 was selected with blasticidin, the plated at limiting 
dilution to obtain SCCs. For screening of SCCs, cells were transduced at low MOI with 
lentivector expressing luciferase gene under the TRE3G promoter and the puromycin resistance 
gene, selected with puromycin, and analysed by luciferase assay normalised to cell count. 
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Figure 3.9 Screening of MDTF SCC expressing rtTA3 
 
48 SCCs were screened by luciferase assay with or without 1µg/ml Dox. 
Luciferase activities were normalised by cell count. In the assay with Dox, lysate 
was diluted 200-fold to ensure the signals within the range of sensitivity. The 
clone, R18 (highlighted in red), was selected for its low uninduced and high 
induced activities. Clone 48 represents a negative control from MDTF cells not 
transduced with the rtTA3 vector virus. 
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Figure 3.10 Dose dependency of PTRE3G promoter to Dox in R18 cells 
 
R18 cells were induced at different concentration of Dox before analysis by luciferase assay. 
The graph showed mean and absolute deviation values from duplicate samples in the same 
experiment. 
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of MLV LTR. The new vectors were constructed using the backbone from a SIN 
vector (Figure 3.10 B and C), deletions in U3 region prevented potential 
promoter interference with the inducible PTRE3G promoter.  
 
Before the first vector was designed, I considered the relative translation 
activity of the two ORFs in a bicistronic mRNA containing an IRES. A previous 
study had identified two major determinants in the level of CAP-independent 
translation activity mediated by the EMCV IRES (Bochkov and Palmenberg, 
2006). First, the EMCV IRES found in our vectors have attenuated translation 
efficiency compared to the wt EMCV IRES. In the wt EMCV IRES, an A-rich 
loop structure termed bifurcation loop contains the A6 (AAAAAA) sequence. 
However, in our vectors an insertion of A into the bifurcation loop leads to the 
A7 (AAAAAAA) sequence. The presence of A7 sequence has been reported to 
cause a 40% drop in translational activity compared the wild type A6 sequence 
(Bochkov and Palmenberg, 2006). Secondly, it was found that the insertion of a 
long sequence between the minimal IRES sequence and the start codon of 
ORF could lead to further attenuation of the IRES activity. It was shown that 
translation from an A7 IRES with a 32nt attenuating sequence was 7.5 fold 
lower than that from the CAP-dependent translation. Therefore, the TGIx-Fv1 
vector was designed to have the EGFP-IRES-Fv1 arrangement to maximise the 
expression of EGFP and minimise the expression of Fv1 (Figure 3.7 B). A 
strong Kozak sequence (GCCGCCATGG) (Kozak, 1986) was used in the EGFP 
start codon for optimal CAP-dependent translation. In order to construct the 
gateway compatible vector, the DEST cassette was inserted downstream of the 
IRES. The DEST cassette contains the suicide gene ccdB and the 
chloramphenicol resistance gene flanked by the attR1 and attR2 recombination 
sites. The LR reaction between the pTGIx-DEST and the pENTR-Fv1 vectors 
resulted in the pTGIx-Fv1 vector, which has an Fv1 ORF flanked by the attB1 
and attB2 sites. The 71nt (mostly from attB1) sequence between the IRES and 
Fv1 ORF also serves as an IRES-attenuating sequence. 
 
Given the very low natural level of Fv1b protein, it was anticipated that 
the 7.5 fold attenuation of translation may not be sufficient for reducing Fv1 
expression to endogenous levels. I therefore studied other IRES-independent 
approaches for further attenuation of translation. There are many natural 
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examples in which the presence of an upstream ORF (uORF) could lead to 
inhibited translation of a downstream ORF in the absence of IRES element 
(Kozak, 2002). Most of these could be explained by a ribosome reinitiation 
mechanism, in which after the termination of translation in the uORF, the 40S 
ribosome subunit remains bound and continues scanning on the mRNA until 
reaching the start codon of the downstream ORF where translation is reinitiated. 
Since ribosome reinitiation is inefficient, the downstream ORF is often 
translated with suboptimal efficiency. Examples of such a mechanism include 
the 4 inhibitory uORFs found in the 5’ UTR of the yeast GCN4 mRNA 
(Hinnebusch et al., 1988) and two uORFs in the long form of human MDM2 
mRNA which caused 10-fold inhibition of MDM2 translation (Jin et al., 2003). In 
the absence of IRES, the efficiency of reinitiation of a downstream ORF in a 
bicistronic mRNA decreases with the length of uORF (Kozak, 2001) and 
increases with the intercistronic distance up to 79nt (Kozak, 1987). In one study 
it was reported that in IRES-free bicistronic mRNAs with two reporter ORFs, the 
expression of the downstream ORF could be between 100 and 1000 fold lower 
than the uORF, depending on the sequence of the uORF (Mizuguchi et al., 
2000). 
  
 Taking advantage of the ribosome reinitiation mechanism, the IRES-free 
bicistronic vector TGx-Fv1 vector was designed (Figure 3.7 C). The EGFP ORF 
was given a strong Kozak sequence (GCCGCCATGG) (Kozak, 1986) and 
serves as the uORF for the attenuation of the downstream Fv1 ORF. The long 
720nt EGFP ORF, together with a relatively short 54nt intercistronic distance 
should provide a strong inhibition in the translation of Fv1. However, further 
shortening of the intercistronic distance would not be possible due to the 
presence of the attB1 site. Similar to the TGIx-DEST vector, the TGx-DEST 
vector contains the DEST cassette for cloning by LR reaction (Figure 2.1) to 
obtain the TGx-Fv1 vector. 
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3.2.7 The new inducible vectors allowed study of restriction from very 
low Fv1 expression levels 
 
Before using the vectors for restriction study, I first tested if the new vectors 
could support the production of sufficient EGFP for separation of Fv1+ 
populations by FACS analysis. Figure 3.11 shows that in R18 cells transduced 
with TGx-Fv1b vector at an MOI of 1, clear separation required 24h incubation 
with doxycycline from a concentration of 100ng/ml. Figure 3.12 shows the 
protocol developed for a 2-colour FACS assay that can be used together with 
the inducible vectors. R18 cells were first transduced with either TGIx-Fv1 or 
TGx-Fv1 vector vectors. After induction at various concentration of doxycycline 
(0 to 1µg/ml), cells were infected with EYFP-expressing tester virus with gag-pol 
from N-MLV, B-MLV or NB-MLV. At 24hpi, a high dose of 10µg/ml doxycycline 
was added, and cells were analysed by FACS after another 48h. This high dose 
of doxycycline leads to full activation of the PTRE3G promoter and maximal 
translation of EGFP in transduced cells. This final addition of doxycycline was 
included to ensure the expression of EGFP to allow separation by FACS 
analysis. It was assumed that at 24hpi, almost all infectious particles would 
have undergone integration, so the accompanied increase in Fv1 expression at 
this time point would not affect the percentage of GFP+/YFP+ cells. 
 
 Figure 3.13 shows the FACS data from a restriction assay with Fv1b from 
the inducible vectors TGx-Fv1b and TGIx-Fv1b, and the non-inducible LxIG-Fv1b 
vector. The 4 populations (GFP-/YFP-, GFP-/YFP+, GFP+/YFP-, GFP+/YFP+) 
could be clearly separated in this assay. Comparing the percentage of YFP+ 
subpopulations between the GFP+/Fv1+ and the GFP-/Fv1- population allows 
the analysis of Fv1 mediated restriction. The second row of Table 3.2 shows the 
results from 3 repeats of such analysis, the restriction by Fv1 is expressed as a 
ratio of the percentage of YFP+ subpopulations in the GFP+/Fv1+ relative to that 
in the GFP-/Fv1- population. A lower restriction ratio indicates stronger inhibition 
by Fv1. In the absence of doxycycline, Fv1b expressed by the TGx-Fv1 vector 
shows not inhibition activity against any MLV. This suggested that the leakiness 
of Fv1 expression from the TGx-Fv1 vector is very low, insufficient for any  
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Figure 3.11 GFP separation of cells transduced with a TGx vector 
 
R18 cells transduced with TGx-Fv1
b
 were induced with different concentration of Dox for 24h 
before analysis by FACS.  
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Figure 3.12 A transient assay to study the dose dependency of Fv1 
restriction 
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Figure 3.13 Restriction of MLV by Fv1b expressed using different vectors 
 
FACS dot plots from a restriction assay of R18 cells transduced with TGIx-Fv1
b
, TGx-Fv1
b
 or 
LxIG-Fv1
b
, with or without the addition of 1µg/ml Dox on day 4. The percentage of YFP
+
 sub-
population in GFP
- 
and GFP
+
 cells were indicated above each plot. 
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Table 3.2 Restriction of MLV by Fv1n, Fv1b and mutants expressed 
using TGx, TGIx and LxIG vectors 
 
A summary of results from transient restriction assays for Fv1
n
, Fv1
b
, mix-and match mutants, 
and C-terminus tail truncation mutants. The 3-letter code for each mutant indicated the source 
of sequence at position 358, position 399 and C-terminus, respectively. Underscore indicated 
deletion. Black shading indicated restriction (ratio < 0.3), while grey shading indicated partial 
restriction (ratio between 0.3 and 0.7). 1µg/ml Dox was used for induction (+DOX). Mean and 
standard deviation values from 3 independent experiments were shown in the table. 
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inhibition of any MLV by Fv1b. After induction with 1µg/ml doxycycline, a 5-fold 
restriction of N-MLV and a 20% inhibition of NB-MLV could be observed in cells 
transduced with TGx-Fv1b. 
 
In the absence of doxycycline, Fv1b expressed by the TGx-Fv1 vector 
causes a 2-fold inhibition of N-MLV but there is no effect on B-MLV or NB-MLV. 
Compared with the previously described inducible system (Figure 3.6), which 
shows full restriction of N-MLV and 2-fold inhibition of NB-MLV by Fv1b in the 
absence of doxycycline, the TGx-Fv1 vector still appears to have a much lower 
leakiness in Fv1 expression. After induction with 1µg/ml doxycycline, an 8-fold 
restriction of N-MLV and 3-fold inhibition of NB-MLV could be observed in cells 
transduced with the TGx-Fv1b. The restriction activities of TGIx-Fv1b vector 
were stronger than those of TGx-Fv1b, but weaker than those of the non-
inducible LxIG-Fv1b vector. Taken together, it appeared that the TGx-Fv1 vector 
has a lower but overlapping Fv1 expression range than the TGIx-Fv1 vector, 
and both TGx-Fv1 and TGIx-Fv1 appeared to have lower expression level than 
the non-inducible LxIG-Fv1 vector. 
 
3.2.8 Restriction phenotype of Fv1n, Fv1b and mutants at low expression 
level 
 
Because of the encouraging results from the study of Fv1b, the assay was 
extended to include Fv1n, the mix-and-match mutants and the C-terminus 
truncation mutant shown in Table 1.1. Since the inducible vector appeared to 
have overlapping Fv1 expression range, both were used in this study. Table 3.2 
showed the summary of data from 3 restriction experiments with all constructs. 
The restriction phenotype of R18 cells transduced with the LxIG-Fv1 vectors 
was in good agreement with previous data (Bishop et al., 2001; Bock et al., 
2000). Interestingly, no inhibition activities were observed with all TGx-Fv1 
constructs in the absent of doxycycline, suggesting that Fv1 mutants were 
expressed below its functional concentration. It was also worth noting that the 
average infectivity ratio in these non-inhibiting phenotypes was 1.14, indicating 
that the transduction with vector may have caused a 13% increase in the 
infectivity of MLV in these cells. Fv1n only inhibited B-MLV in both TGx-Fv1 and 
TGIx-Fv1 vectors; this is expected as the LxIG-Fv1, which has a higher 
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expression of Fv1, does not restrict B-MLV or NB-MLV. Fv1b showed a 
consistent preference of MLV inhibition in the order of N > NB > B. Interestingly, 
none of the conditions tested showed exclusive restriction of N-MLV by Fv1b 
without any inhibition of NB-MLV.  
 
With some mutants, the restriction appeared to be more specific in an 
induction level when compared to the overexpressed level using LxIG-Fv1 
vector. For example, both N-MLV and B-MLV were equally restricted by Fv1bnn 
using the LxIG-Fv1 vector, but only N-MLV restriction could be observed when 
using the TGx-Fv1 vector. Similarly, Fv1bb_ appeared to restrict all MLVs with 
only slight preference to N-MLV and NB-MLV using the LxIG-Fv1 vector. Such 
preference became very obvious when the TGIx-Fv1 vector was used. Some 
other mutants showed consistent but weak preferences to certain MLVs. For 
example, Fv1nbn consistently showed a 10% stronger inhibition of N-MLV than 
NB-MLV using both inducible vectors, while Fv1bbn consistently showed a 10% 
weaker inhibition of B-MLV than N-MLV and NB-MLV. The fact that these small 
differences were observed reproducibly using two different vectors suggested 
that these were genuine properties of these mutants. From the data in this 
study, it could be concluded that the restriction spectrum of Fv1b and many 
other mutants became more specific at lower induction level.  
 
3.2.9 An attempt to improve the induction range of inducible vectors 
 
Although together both inducible vectors had provided a wide induction range 
from no detectable MLV inhibition to phenotypes close to that in the non-
inducible vector, it would be ideal to have a single vector covering the same 
range. An attempt was made to modify the TGIx-Fv1 vector to further reduce 
the basal expression level without changing the maximal expression level. 
Similar to approach used in TGx-Fv1b vector, a short uORF with 3 codons was 
inserted 4nt upstream of the start codon of Fv1. The extremely short 
intercistronic distance would result in very inefficient reinitiation (Kozak, 1987), 
instead leaky scanning would be the main mechanism in the expression of the 
downstream ORF (Ferreira et al., 2013). In such a context, scanning 40S 
ribosomes that did not initiate translation at the start codon of the uORF would 
continue scanning on the mRNA and initiate translation at the downstream ORF 
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(Kozak, 2002). The expression from the downstream ORF dependent on the 
relative strength of Kozak sequences between the two ORFs. The short uORF 
tested here with equally strong ACC sequences before both ORFs had been 
reported to cause a 85% inhibition of translation (Ferreira et al., 2013). Figure 
3.14 shows the comparison in restriction activity of Fv1b of this new TGIx-
uORF-Fv1b vector with the two previously described inducible vector. The 
results showed that although this vector showed a decrease in the inhibition of 
N-MLV in the absence of doxycycline when compared to TGIx-Fv1b, it also led 
to a reduction in NB-MLV inhibition in the presence of doxycycline. These 
results suggested that it was not possible to reduce the basal translation level of 
the TGIx-Fv1b vector without also affecting its maximal expression level. 
 
3.2.10 Inhibition associated with the TGx-Fv1 vector was not due to the 
synthesis of fusion protein 
 
One of the criticisms of the use of the TGx-Fv1 vector was that since the EGFP 
ORF was placed in frame upstream of the Fv1 ORF, there is a possibility that 
the observed restriction could be due to the expression of an EGFP-Fv1 fusion 
protein from the read-through of the EGFP stop codon. In order to address this 
question, the start codon of the Fv1b ORF was mutated to a non-start AGG 
codon resulting in TGx-AGG-Fv1b (Figure 3.15 A). It was anticipated that such 
mutation would abolish the translation of authentic Fv1 but not EGFP-Fv1 fusion 
protein, so the restriction activities should also be abolished unless they were 
caused by the putative fusion protein.  Alternatively, in the TGx-TAATAA-Fv1b 
mutant the EGFP ORF was given an additional stop codon, which should 
definitely eliminate the production of any fusion protein. Figure 3.15 C 
confirmed that the AGG mutation did abolish the translation of authentic Fv1. 
The restriction data showed that while the AGG mutation abolished all 
restriction, the double-stop mutation had no effect. These data strongly 
supported the hypothesis that the restriction phenotypes in cells transduced 
with TGx-Fv1 vectors were not due to the synthesis of fusion protein. 
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Figure 3.14 Restriction of MLV by Fv1b expressed from different 
translation attenuating inducible vectors 
 
(A) The TGIx-uORF-Fv1
b
 vector was generated by inserting a short (2aa) out-of-frame ORF at 
4nt upstream of the start codon of Fv1 ORF. (B) Restriction of MLV by all 3 vectors with or 
without Dox induction (160ng/ml). Mean and mean deviation values from two independent 
experiments were shown in the bar chart. 
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Figure 3.15 Restriction of MLV by Fv1b expressed by mutant TGx-Fv1 
vectors 
 
(A) The TGx-AGG-Fv1
b
 mutant has non-start codon (AGG) instead of the start codon of Fv1 
ORF, while the TGx-TAATAA-Fv1
b
 mutant has a double stop codon at the EGFP ORF. (B) 
Restriction of MLV by different TGx vectors with or without Dox induction (160ng/ml). Mean and 
mean deviation values from two independent experiments were shown in the bar chart. (C) 
Western blot analysis of R18 cells transduced with TGx-Fv1 vectors at a high MOI and induced 
with 1µg/ml Dox. 
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3.2.11 Addition of high dose of doxycycline at 24hpi did not affect 
restriction 
 
It was assumed that the Fv1 sensitive steps of infection by the EYFP-
expressing tester virus should be complete at 24hpi, so increase of Fv1 
expression by doxycycline induction at this time should have no effect on the 
restriction phenotype. To test this hypothesis, N-MLV restriction assay in cells 
transduced with TGx-Fv1b vector was repeated with the final high dose of 
doxycycline added at time points between 0 and 24hpi (Figure 3.16). The 
results showed no further changes in the apparent restriction value when the 
final dose of doxycycline was added after 20hpi, supporting the idea that by 
24hpi no interaction between Fv1 and tested virus will occur. 
 
3.2.12 Correlation between Fv1 protein level and MLV restriction activity in 
transduced R18 cells 
 
The ultimate goal of using the inducible system was to correlate the expression 
level of Fv1 to its restriction activity, and to identify the restriction phenotype of 
Fv1 at the endogenous level. A more detailed analysis of protein expression 
level and restriction activity was carried out with both TGx-Fv1 and TGIx-Fv1 
vectors for both Fv1n and Fv1b. In a pilot experiment, it was shown that there 
was no significant change in the restriction activities of Fv1b between 100 and 
1000ng/ml doxycycline (data not shown); therefore a 2-fold dilution series in the 
range of 1 to 160ng/ml doxycycline was used in this analysis. In addition to Fv1n 
and Fv1b, two other mutants Fv1bbn and Fv1bb_ were also analysed. In the 
restriction data described earlier (Table 3.2), Fv1bbn restricts all MLV when 
expressed using the TGx-Fv1 vector at 1000ng/ml doxycycline, although with 
the restriction activities to N-MLV and NB-MLV appear to be stronger than that 
to B-MLV. Similarly, Fv1bb_ showed stronger restriction towards N-MLV and 
NB-MLV when expressed using the TGIx-Fv1 vector at 1000ng/ml doxycycline. 
I wanted to test whether Fv1b, Fv1bbn and Fv1bb_ are able to demonstrate high 
specificity towards different MLV at lower expression levels. When over-
expressed using the LxIG-Fv1 vector, the protein levels of Fv1b, Fv1bbn and 
Fv1bb_ appear to correlate with their restriction activities against B-MLV (Figure 
3.3, discussed in section 3.1.2). I also wanted to further investigate whether the  
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Figure 3.16 Effect of changing the timing of final Dox induction on the 
observed restriction of N-MLV by TGx-Fv1b 
 
Transient restriction assay was carried out as described before except that 10µg/ml Dox was 
added at various time points after the infection with YFP tester virus, instead of 24hpi normally. 
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C-terminal tail modifications in Fv1bbn and Fv1bb_ enhances the restriction of 
B-MLV by increasing apparent binding affinity, by comparing the amount of 
Fv1b, Fv1bbn and Fv1bb_ required to inhibit B-MLV to the same level. 
 
Figure 3.17 shows the data from the quantitative western blot analysis of 
transduced R18 cells at a range of doxycycline concentration. In all constructs, 
the increase in doxycycline leads to an increase in Fv1 protein level. As 
expected, the TGIx-Fv1 vector leads to a higher expression of Fv1n and Fv1b 
than the TGx-Fv1 vector. The expression levels of Fv1n, Fv1b and Fv1bb_ by 
the TGIx-Fv1 vector at all doxycycline concentrations are sufficient for Fv1 
quantitation. Similar to western blot data from the earlier inducible system 
(Felton, 2012), Fv1n was expressed at higher protein level than Fv1b at all 
doxycycline concentrations using the TGIx-Fv1 vector. From 0 to 40ng/ml 
doxycycline, expression of Fv1bb_ by TGIx-Fv1 vector was lower than that of 
Fv1b. However, similar expression levels of Fv1b and Fv1bb_ were observed 
above 40ng/ml. Unfortunately, the expression of Fv1n, Fv1b and Fv1bbn by the 
TGx-Fv1 vector was too low for quantitation.  
 
The restriction and Fv1 quantitation data from the same doxycycline titration 
experiment is shown in Figure 3.18. In cells expressing Fv1n using the TGIx-
Fv1n vector, no inhibition of N-MLV or B-MLV could be observed. B-MLV is 
inhibited by more than 40% in the absence of doxycycline, and this was 
increased to a 10-fold inhibition from 20ng/ml doxycycline, with no further 
increase in inhibition at higher doxycycline concentrations. In cells expressing 
Fv1n using the TGIx-Fv1b vector, N-MLV is inhibited by more than 60% in the 
absence of doxycycline, and this was increased to a 10-fold inhibition from 
10ng/ml doxycycline, with no further increase in inhibition at higher doxycycline 
concentrations. A 10% inhibition of NB-MLV was observed in the absence of 
doxycycline, and this was increased to about 65% at 40ng/ml doxycycline, with 
no further inhibition at higher doxycycline concentrations. No inhibition of B-MLV 
was observed in the absence of doxycycline, but a weak inhibition of less than 
20% was observed from 10ng/ml doxycycline. All the inhibition activities of Fv1n 
and Fv1b are increased at higher Fv1 protein levels, therefore confirming the 
dependency of Fv1 restriction on Fv1 concentration. A full 10-fold restriction of 
B-MLV of Fv1n was observed from 20ng/ml doxycycline concentration, while full  
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Figure 3.17 Quantitative western blot analysis of Fv1 protein levels at 
different Dox concentrations in transiently transduced cells 
 
R18 cells transduced with TGIx-Fv1 or TGx-Fv1 vectors were reseeded and 
treated with various concentration of Dox for 24h before lysing for quantitative 
western blot analysis. The intensities of bands from TGx-Fv1 samples were 
insufficient for quantification. 
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Figure 3.18 MLV restriction by Fv1n, Fv1b, Fv1bbn and Fv1bb_ at different 
Dox concentrations in transiently transduced cells 
 
R18 cells transduced with TGIx-Fv1 or TGx-Fv1 vectors were reseeded and treated with various 
concentration of Dox for 24h before infecting with YFP tester virus for restriction assay. Mean 
and mean deviation values from two independent restriction experiments were plotted in the 
graphs. Quantity of Fv1 for TGIx-Fv1 samples were represented by black dotted lines. 
Endogenous protein levels of Fv1
n
 and Fv1
b
 were illustrated by the red horizontal dotted lines.  
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restriction of N-MLV by Fv1b was observed from 10ng/ml doxycycline. 
Interestingly, at these conditions the protein level of Fv1n was almost 10-fold 
higher than that of Fv1b; therefore these data suggested that Fv1b was more 
potent in restriction than Fv1n.  
 
In cells expressing Fv1n using the TGx-Fv1n vector, no inhibitions of N-
MLV and NB-MLV are observed in any doxycycline concentration; B-MLV is not 
inhibited in the absence of doxycycline, but inhibition of B-MLV become 
apparent from 10ng/ml doxycycline, and a 5-fold can be observed from 40ng/ml 
doxycycline. In cells expressing Fv1b using the TGx-Fv1b vector, no inhibition of 
any MLV is observed in the absence of doxycycline; the inhibition of N-MLV 
becomes apparent from 5ng/ml doxycycline, and a 5-fold inhibition of N-MLV 
can be observed from 40ng/ml doxycycline; the inhibition of NB-MLV becomes 
apparent from 20ng/ml doxycycline, and a 20% inhibition of NB-MLV can be 
observed from 80ng/ml doxycycline; no inhibition of B-MLV can be observed 
even with 160ng/ml doxycycline.  
 
While Fv1n only restricts B-MLV, Fv1b appears to display different 
restriction specificities at 3 different phases of Fv1b concentrations: phase I 
involves partial restriction of N-MLV only (TGx-Fv1b, 10ng/ml doxycycline); 
phase II involves a 5-fold restriction of N-MLV and mild inhibition of NB-MLV 
(TGx-Fv1b, 40ng/ml doxycycline; TGIx-Fv1b, 5ng/ml doxycycline); and phase III 
involves a 10-fold full restriction of N-MLV, partial restriction of NB-MLV and 
mild inhibition of B-MLV (TGIx-Fv1b, 20ng/ml dox; LxIG-Fv1b). Importantly, at no 
point full restriction of N-MLV alone was observed without inhibition of NB-MLV. 
The expression levels of Fv1 by TGIx-Fv1 were also compared to that of 
endogenous Fv1 determined earlier (Figure 3.2) in order to predict the 
endogenous restriction phenotype. At 5ng/ml doxycycline concentration, the 
Fv1 expression level by TGIx-Fv1 vector was closest to the endogenous level 
for both Fv1n and Fv1b. At this induction level, Fv1n inhibits only B-MLV by 70%; 
while Fv1b restricts N-MLV by 80% and inhibits NB-MLV by 30%. This 
suggested that the endogenous phenotype of Fv1b belongs to the second 
phase, with a mild inhibition of NB-MLV. The switch from phase II to phase III 
requires a 4-fold increase in the protein level of Fv1b (from 20k to 84k Fv1 per 
cell), suggesting that a 4-fold increase in the endogenous protein level of Fv1b 
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was sufficient to achieve partial restriction of NB-MLV and inhibition of B-MLV. 
In cells expressing Fv1b using the non-inducible LxIG-Fv1 vector, which has a 
26-fold higher expression of Fv1b than the endogenous level (Figure 3.3), NB-
MLV is fully restricted by 5-fold and B-MLV is partially restricted by about 40%. 
Therefore, the transition from phase III to this final phenotype would another 6-
fold increase in Fv1b protein level. Together these analyses of Fv1b restriction 
and quantity suggested that Fv1b restricts N-MLV and slightly inhibits NB-MLV 
at the endogenous level, and the overexpression of Fv1b can lead to at least 5-
fold restriction of N-MLV and NB-MLV, and a 40% inhibition of B-MLV. 
 
By comparing the restriction phenotypes of TGx-Fv1b, TGx-Fv1bbn and 
TGIx-Fv1bb_ at various doxycycline concentrations, it appears that in contrast 
to Fv1b, Fv1bbn and Fv1bb_ inhibits N-MLV and NB-MLV equally at all 
concentrations. This suggested that the C-terminal tail mutations have 
increased the ability of Fv1bbn and Fv1bb_ to restriction NB-MLV, most likely 
by increasing the apparent binding affinity to NB-MLV CA. The amount of Fv1b, 
Fv1bbn and Fv1bb_ required to inhibit B-MLV to the same level were 
compared. Fv1bbn clearly has the strongest ability to restrict B-MLV, since it is 
able to restrict B-MLV by 5-fold at a concentration that is too low for quantitation 
analysis. At the highest doxycycline concentration of 160ng/ml, while similar 
levels of Fv1b and Fv1bb_ were expressed using the TGIx-Fv1 vector, Fv1bb_ 
shows a stronger inhibition of B-MLV than Fv1b. Therefore, at the same Fv1 
concentration, the ability for B-MLV restriction is in the order of Fv1bbn > 
Fv1bb_ > Fv1b, and this probably reflects the relative apparent affinities of Fv1 
towards B-MLV CA. The very low concentration of Fv1bbn required for B-MLV 
restriction also suggested that the observed stronger restriction against B-MLV 
by Fv1bbn than Fv1b at over-expression level was due to an increase in binding 
apparent affinity rather than small increase in protein level identified in section 
3.1.2). 
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3.2.13 Relationship between Fv1 protein level and MLV restriction activity 
in SCCs 
 
A shortcoming of the above study was that Fv1 expressed using the TGx-Fv1 
vector was insufficient for quantitation. Since the transduction of R18 cells at a 
MOI of 0.7 would only result in about 30% of Fv1+ cells, the sensitivity of Fv1 
quantitation by western blot was limited. It was hoped that the study of a 100% 
Fv1+ population, such as SCC, would allow higher sensitivity and detection of 
Fv1 expressed from TGx-Fv1 vector. This would allow the confirmation that the 
increase in restriction activities in TGx-Fv1 expressing cells at higher 
doxycycline concentrations is due to a higher Fv1 protein level. By analysing 
the Fv1 RNA and protein levels in the SCCs, it would also allow the 
confirmation that the TGx-Fv1 vector causes a lower Fv1 protein level than 
TGIx-Fv1 due to a stronger inhibition in translation. 
 
One SCC was picked from each transduced R18 population from the 
previous study in section 3.2.12. Transduced R18 cells were seeded at limiting 
cell dilution in 96-well plates, from which individual clones were picked for 
screening. Fv1+ clones were screened by the expression of GFP by FACS 
analysis. Figure 3.19 shows the quantitation of Fv1 from one SCC of each 
construct compared to the endogenous and overexpressed levels. The 
detection and quantitation of Fv1 expressed by TGx-Fv1 vectors were possible 
at 100ng/ml doxycycline. At this doxycycline concentration, Fv1n protein level in 
the TGIx-Fv1n SCC is 17-fold higher than in TGx-Fv1n SCC, while Fv1b protein 
level in the TGIx-Fv1b SCC is 5-fold higher than in TGx-Fv1n SCCs. However, 
comparison between Fv1 protein levels revealed a number of differences 
between quantitation results from experiments using SCC (Figure 3.19) and 
from experiments using transduced cells (Figure 3.17). First, despite the higher 
expression level of TGIx-Fv1n than TGIx-Fv1b across all doxycycline 
concentrations in transduced cells (Figure 3.17), expression of Fv1n was similar 
to that of Fv1b in TGIx-Fv1 SCCs (Figure 3.19). Secondly, the expression level 
of the TGx-Fv1b SCC appeared to be higher than that of the TGx-Fv1n SCC, 
although transduced cells Fv1n is always expressed at higher protein level than 
Fv1b with both inducible and non-inducible vectors. These differences in the  
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Figure 3.19 Quantitative western blot analysis of Fv1 protein levels in 
TGIx-Fv1 and TGx-Fv1 SCCs 
 
(A) SCCs were isolated from R18 cells transduced with TGx-Fv1 or TGIx-Fv1 vectors by plating 
to 96-well plate at limiting cell dilution. GFP
+
 clones were screened by inducing at 1µg/ml 
doxycycline followed by FACS analysis.  One clone of each construct was selected. SCCs were 
induced at 0-100 ng/ml Dox for 24h before quantitative western blot analysis. (B) The 
quantification data from the western blots were illustrated in the bar chart.  
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relative protein levels of Fv1n to Fv1b between transduced cells and SCCs are 
most likely results of clone-to-clone variations in Fv1 expression. In transduced 
R18 cells, each individual cell would express Fv1 at different levels depending 
on the integration site used by the vector virus. Although on average a high 
Fv1n to Fv1b expression ratio can be observed, the expression levels in 
individual clones would vary around the mean expression level following the 
Poisson distribution. Therefore, the comparison of Fv1 levels between any 
SCCs would not be informative unless a large number of clones were used. 
However, these SCC would still allow the correlation between Fv1 protein level 
and restriction activities, as well as Fv1 protein and RNA levels. To confirm that 
the lower expression level of TGx-Fv1 vector relative to TGIx-Fv1 vector is due 
to a stronger inhibition in translation, the relative expression levels of Fv1 
mRNA in SCCs were studied by quantitative PCR (qPCR) (Figure 3.20). At all 
doxycycline induction levels, the relative quantities of Fv1 mRNA expressed 
using both vectors were very similar, while the expression from TGIx-Fv1 
constructs are higher than TGx-Fv1 constructs. This suggested like the TGIx-
Fv1 vector, the IRES-free TGx-Fv1 vector allowed doxycycline-dependent 
protein expression of Fv1 at a more attenuated translational level. 
 
To confirm that the increase in restriction activities in TGx-Fv1 cells at higher 
doxycycline concentrations is due to a higher Fv1 protein level, the restriction of 
MLV in the inducible SCCs was studied using a modified 2-colour FACS assay 
(Figure 3.21). To provide an internal Fv1- control, SCC and R18 cells were 
seeded in the same well at a 1:1 ratio before doxycycline induction. The basal 
infectivity of MLV in SCCs varies significantly from experiment to experiment, 
probably due to slightly different mitotic rate of the SCC at different passages. 
Therefore, results for Fv1n was normalised to the infectivity ratio of N-MLV in 
the absence of doxycycline, while the results for Fv1b was normalised to the 
infectivity ratio of B-MLV in the absence of doxycycline. This would be 
appropriate because restriction data from transient transduction (Table 3.2) 
showed no inhibition of N-MLV by Fv1n and B-MLV by Fv1b in the absence of 
doxycycline using both TGIx-Fv1 and TGx-Fv1 vectors. The normalised 
restriction results are shown in Figure 3.22. In TGx-Fv1n SCC, the increase in 
B-MLV inhibition coincides with the increase in Fv1n protein level, from 10 to 
100ng/ml doxycycline concentrations. Similarly in TGx-Fv1b SCC, the increase 
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in the inhibitions of N-MLV, NB-MLV and B-MLV coincides with the increase in 
Fv1b protein level, from 1 to 100ng/ml doxycycline. Therefore these data 
confirm that in cells transduced with TGx-Fv1 vectors, the increase in Fv1 
protein levels lead to the increase in restriction activities against MLVs.  
 
 
 
 
 
 
Figure 3.20 Quantitative RT-PCR of Fv1 mRNA levels TGIx-Fv1 and TGx-
Fv1 SCCs 
 
SCCs were induced at 0-100 ng/ml Dox for 24h before lysed for quantitative RT-PCR analysis. 
Relative quantity of Fv1 mRNA was normalised to the relative quantity of GAPDH. Mean and 
mean deviation values of 4 repeats (2 biological repeats, each with 2 technical repeats) were 
plotted in the bar chart. 
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Figure 3.21 Study of MLV restriction in SCC with inducible expression of 
Fv1 
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Figure 3.22 MLV restriction by Fv1n and Fv1b at different Dox 
concentrations in TGx-Fv1 and TGIx-Fv1 SCCs 
 
TGIx-Fv1 or TGx-Fv1 SCCs were mixed 1:1 with R18 cells, and treated with various 
concentration of Dox for 24h before infecting with YFP tester virus for restriction assay. Fv1
n
 
restriction values were normalised to the restriction value against B-MLV in the absence of Dox, 
while Fv1
b
 restriction values were normalised to the value against N-MLV in the absence of 
Dox. Mean and mean deviation values from two independent restriction experiments were 
plotted in the graphs. Quantities of Fv1 were represented by the dotted line. 
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3.3 Study of MLV restriction by Fv1 superexpression 
 
The previous data showed that a 26-fold overexpression of Fv1b above its 
endogenous level could cause restriction of NB-MLV and inhibition of B-MLV, 
but 37-fold overexpression of Fv1n above its already higher endogenous level 
did not allow gain of NB-MLV or N-MLV inhibition. Therefore, I wanted to test if 
further increase in Fv1n expression from the overexpression level, or 
“superexpression”, would lead to inhibition of N-MLV and NB-MLV. 
 
3.3.1 A transient assay to study the restriction of MLV by Fv1 “super-
expression” 
 
The procedure for an assay to study restriction during superexpression of Fv1 is 
shown in Figure 3.23. MDTF cells were transduced with different amount of 
LxIG-Fv1 or control vectors up to a MOI of 60 in order to achieve a very high 
expression level of Fv1. A vector expressing EGFP through a CMV promoter 
was used as the negative control. After transduction at a high MOI, almost all 
cells would be GFP+. In order to provide an Fv1- internal control, the transduced 
cells were mixed with untransduced MDTF before reseeding for infection with 
YFP tester virus at an MOI of less than 1. Infected cells were analysed using a 
2-colour FACS assay. Figure 3.24 shows the results for Fv1n and Fv1b. It was 
obvious from the negative control data that high MOI transduction led to an Fv1-
independent inhibition of MLV infectivity. This inhibition became prominent from 
an MOI of 4, and was likely due to a combination of the effects of provirus 
disrupting the genome of transduced cells, as well as the overexpression of 
EGFP. However, the reduction in relative infectivity for Fv1n against N-MLV and 
NB-MLV did not appear to be greater than that of the negative control. Instead, 
the reduction in relative infectivity was greater with the negative control. This 
could be due to a higher expression of EGFP in cells transduced with the 
control vector than in the LxIG-Fv1 vector. EGFP is expressed using a highly 
efficient CMV promoter and CAP-dependent translation in the control vector, 
while EGFP is expressed using the U3 promoter of MLV LTR and IRES-
dependent translation in the LxIG-Fv1 vector. The assay could be improved by 
using an alternative control vector such as an LxIG-Fv1 vector expressing Fv1-
NTD and EGFP. Nevertheless, the data suggest that even at the highest Fv1 
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protein level that can be supported by MDTF cells, Fv1n still does not inhibit N-
MLV and NB-MLV. 
 
 
 
 
 
 
 
 Figure 3.23 A transient assay to study the restriction of MLV during Fv1 
“super-expression” 
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Figure 3.24 Restriction of MLV in MDTF cells transduced with LxIG-Fv1 
vectors at very high MOI 
 
A vector expressing EGFP under a CMV promoter was used as an Fv1
-
 control (GFP, black 
line). Data points from 3 independent experiments were plotted and used for curve fitting. 
  
180 
3.4 Discussion 
 
Through quantitative analyses of the expression level and restriction of Fv1, 
data presented in this chapter highlighted how the overexpression of Fv1 can 
lead to additional inhibition activities. Analysis of the over-expression levels of 
10 different Fv1 variants revealed that sequence at residue 358 and the C-
terminus have strong influence on the relative protein levels of Fv1n and Fv1b. 
Using a novel inducible expression system with minimal leaky expression, I 
studied how expression level of Fv1b can alter its restriction specificity. Fv1b 
appears to restrict N-MLV and weakly inhibit NB-MLV at the endogenous level, 
and an increase in Fv1b concentration allows restriction of both N-MLV and NB-
MLV, as well as inhibition of B-MLV. In contrast, Fv1n only restricts B-MLV and 
shows no inhibition against N-MLV and NB-MLV. This high specificity remains 
the same from the endogenous level to a “super-expression” level. The 
difference in B-MLV inhibition of Fv1b, Fv1bb_ and Fv1bbn observed in previous 
studies (Bishop et al., 2001; Bock et al., 2000) cannot be explained by the 
difference in their over-expression levels alone. Instead, it is likely that these 
Fv1 variants possess different apparent affinities against B-MLV. 
 
Previous studies of Fv1 protein level in cells transduced with LxIG-Fv1 
vector had revealed effects of the sequence of Fv1 on the overexpression level 
(Bishop et al., 2001; Bock et al., 2000). Presumably through effects on protein 
stability, this led to a 4-fold difference in the overexpression levels of Fv1n and 
Fv1b. A similar difference between Fv1n and Fv1b protein levels were also 
observed using the TGIx-Fv1 vector (Figure 3.17). However, it remained 
unclear whether these effects contributed the 3-fold difference between the 
endogenous protein levels in N-3T3 and B-3T3. It would be expected that a 23-
fold higher mRNA level (Felton, 2012) and a 4-fold difference in protein stability 
would lead to a much bigger difference in expression than 3-fold.  
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By relating the restriction activity to the protein level of Fv1 under 
doxycycline induced expression, it was concluded that the endogenous 
restriction phenotype of Fv1b would include a mild inhibition of NB-MLV. 
Interestingly, a previous observation from B-3T3 cells overexpressing Fv1n 
supported this conclusion (Bock et al., 2000). It was found that overexpression 
of an Fv1 allele in cells endogenously expressing a different Fv1 allele leads to 
restriction phenotype of the overexpressed Fv1, and loss of the endogenous 
phenotype. For example, while the transduction of N-3T3 by LxIG-Fv1b reduced 
infectivity of N-MLV and NB-MLV by 15-fold and 3.5-fold, respectively, the 
infectivity of B-MLV was increased by 5.3-fold. The mechanism for the loss of 
endogenous phenotype was not known, but it had been hypothesised that the 
overexpressed Fv1 outcompete the endogenous Fv1 for either localisation site 
or capsid binding. Transduction of B-3T3 by LxIG-Fv1n reduced B-MLV 
infectivity by 8.7-fold and increased the infectivity of N-MLV by 10-fold. 
Surprisingly, a reproducible increase in NB-MLV infectivity from 27% to 34% 
was also observed. This result suggested an endogenous Fv1b phenotype of 
90% restriction of N-MLV and 20% inhibition of NB-MLV. 
 
Weak or moderate retroviral inhibition activities could be found in other 
natural alleles of Fv1. A previous study in our lab analysed the retroviral 
restriction activities of 16 different natural Fv1 alleles from wild mice (Yap et al., 
2014). While some alleles exhibited restriction activities against N-MLV, B-MLV 
and NB-MLV, others also displayed restriction activities against non-
gammaretroviruses. Two alleles, Fv1SPR1 and Fv1MAC, demonstrated 
restriction activity against N-MLV and the lentivirus EIAV. On the other hand, 
Fv1CAR1 showed restriction against the spumavirus FFV. However, since Fv1 
was overexpressed using the LxIY-Fv1 vector (an EYFP-expressing version of 
LxIG-Fv1), there was concern whether these activities would be present at the 
endogenous level. Recent work by Melvyn Yap in our lab studied the restriction 
activities of these Fv1 alleles using the new inducible expression system 
described earlier (Figure 3.25). I constructed an EYFP-expression version of the 
TGIx-DEST vector, named TYIx-DEST, which was used to generate TYIx-Fv1 
vectors for inducible expression of wild mice Fv1 alleles. At a doxycycline 
induction level (10ng/ml) where Fv1b was expressed at endogenous level, the 
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wild mice Fv1 alleles still  
 
 
 
 
 
Figure 3.25 Dose-dependency of retrovial restriction by wild mice Fv1 
This restriction study was carried out by Melvyn Yap. R18 cells transduced with TYIx-Fv1 
vectors were reseeded and treated with various concentration of Dox for 24h before infecting 
with GFP tester virus for restriction assay. Mean and mean deviation values from 4 independent 
restriction experiments were plotted in the graphs. Results for LxIY were published previously 
(Yap et al., 2014). The two dotted lines represent the restriction ratios of 0.7 and 0.3. A 
restriction ratio of less than 0.3 indicates as full restriction, while a restriction ratio of between 
0.3 and 0.7 indicates as partial restriction.  
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inhibited EIAV and FFV by more than 2-fold. The question remains whether 
these moderate inhibition activities could affect outcome of natural retroviral 
infection of wild mice, which could be very different from single-cycle infection 
with pseudotyped viruses on mouse cell line. Given the higher expression of 
Fv1 in N-3T3 than B-3T3, it is also possible that the endogenous level of Fv1 in 
wild mice is very different from that in Fv1b, and may vary among different cell 
types. 
 
The finding that many of the gained restriction activities of Fv1 mutants 
such as Fv1bbn could be observed using a vector with very low expression 
level (TGx-Fv1) suggested that they were not merely caused by overexpression 
of Fv1 (Table 3.2). The gain of restriction activity was most likely due to higher 
apparent binding affinity towards MLV CA, although it is possible that some 
mutations affect binding to other cofactor proteins. Detailed study of binding of 
Fv1, which will be described in chapter 4, would allow the building of a better 
picture of the relationships between CA binding, expression level and restriction 
activities. 
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Chapter 4 
 
Study of the relationship between Fv1 
binding and restriction specificity 
 
As discussed in Chapter 3, while Fv1n only restricts B-MLV, Fv1b displayed 
strong restriction against N-MLV, moderate inhibition against NB-MLV, and 
weak inhibition against B-MLV. If the apparent binding affinity to capsid was the 
major determinant in restriction specificity, a similar binding specificity towards 
MLV capsid would be expected. However, data from a previous binding study in 
our lab showed that while Fv1n appeared to bind B-MLV only, Fv1b appeared to 
bind MLV of all tropisms (Figure 4.1) (Hilditch et al., 2011). Since the 
overexpression of Fv1b could lead to additional inhibition of NB-MLV and B-
MLV, it is possible that a high concentration of Fv1b in cell lysate could have led 
to binding of all MLVs. In parallel to the restriction study in Chapter 3, the first 
goal of the work in this chapter was to test whether Fv1b shows higher binding 
specificity at a lower concentration. I also wanted to understand how the 
restriction specificity was influenced by the sequence at the 3 variable sites of 
Fv1n and Fv1b, namely position 358, position 399 and the C-terminus. In 
particular, I wanted to test whether the diverse restriction specificities of the Fv1 
mix-and-match mutants and C-terminus deletion mutants (Table 1.1) can be 
completely explained by the difference in apparent binding affinity towards 
MLVs of different tropisms (Bishop et al., 2001; Bock et al., 2000). To do this I 
attempted to correlate Fv1 binding and restriction phenotypes of these mutants. 
 
4.1 Development and validation of a microplate assay to 
study Fv1 binding to MLV capsid assembly 
 
The initial aim was to test if the binding of Fv1b could become more specific at a 
lower Fv1 concentration. This would require the comparison of MLV binding 
specificity at multiple Fv1 concentrations in parallel pull down experiments. 
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Unfortunately, the number of samples that can be analysed using the pull down 
assay developed by Hilditch et al was rather limited. This assay requires the 
separation of capsid-coated nanotubes from unbound Fv1 by ultracentrifugation 
through a sucrose cushion (Figure 4.2), hence restricting the number of 
samples that can be analysed to 6 per rotor. Therefore, the study of both Fv1 
alleles at multiple concentrations in the same experiment would require the 
development of a new medium- or high-throughput pull down assay. Such 
assay may also allow the comparison of binding of different Fv1 mutants to 
different MLV capsids, and might eventually be extended to compare the 
binding between Fv1 and T5 to MLV capsid. 
 
4.1.1 Immobilisation of capsid-coated nanotube to microplate 
 
The most obvious way of increasing the sample throughput of the existing pull 
down assay was to eliminate the need of ultracentrifugation. Instead, similar to 
an enzyme-linked immunosorbent assay (ELISA), capsid-coated nanotubes 
could be immobilised on a microplate. In this case, lysate containing Fv1 could 
be incubated with the immobilised nanotubes, and unbound Fv1 could be 
removed by multiple washes with buffer. Bound Fv1 could then either be eluted 
from the well, or assayed directly inside the well. Such approach had been used 
for the development of an assay to study interactions between the membrane-
binding protein kinase Cα (PKCα) protein and lipids present on liposomes 
(Losey et al., 2009). In the PKCα binding assay, a very small amount of a lipid 
with biotin-functionalised anchor was added to the composition of liposomes, 
allowing the immobilisation of liposomes to streptavidin-coated microplates. 
Similarly, biotin-functionalised lipid could be added to the composition of lipid 
nanotube, allowing the immobilisation to streptavidin microplates. Figure 4.3A 
shows the structure of three commercially available lipids with biotin-
functionalised head groups. The length of the linker between the biotin group 
and the nitrogen in the phosphatidylethanolamine (PE) group varies among the 
three lipids. The lipid with a long PEG-2000 linker offered the highest efficiency 
of nanotube immobilisation, and was selected for subsequent experiments 
(Figure 4.3B).  
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Figure 4.1 Binding data from the original MLV capsid pull down assay 
 
Western blot showing Fv1
n
 and Fv1
b
 binding to various MLV CA nanotubes. Mo-MLV, Moloney 
MLV, known as NB-MLV in this thesis. Reproduced with permission from Proceedings of the 
National Academy of Sciences USA (Hilditch et al., 2011). 
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Figure 4.2 The original MLV capsid pull down assay 
 
This pull down assay was developed by Laura Hilditch, a previous student in our lab (Hilditch et 
al., 2011). Lipid nanotubes were generated by mixing the curvature-forming lipid GalCer with 
the His-tag binding DGS-NTA(Ni) lipid in a 7:3 ratio, followed by drying with nitrogen gas and 
resuspension in buffer. The nanotubes were coated with a regular array of capsid by incubating 
with purified MLV CA-His protein. The coated nanotubes were then incubated with lysate 
extracted from cells expressing Fv1 following transduction with a LxIG-Fv1 retroviral vector. 
Nanotubes together with bound Fv1 were separated from lysate and unbound Fv1 by pelleting 
through a 40% sucrose cushion using ultracentrifugation. The amount of bound Fv1 in the pellet 
was analysed by western blotting using an anti-Fv1 antibody.  
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Figure 4.3 Immobilisation of capsid-coated nanotubes to streptavidin-
coated microplates by biotin-functionalised lipids 
 
(A) Composition of biotinyl lipid nanotube. In addition to GalCer and DGS-NTA(Ni) lipids used in 
the original pull down assay, one of the biotin-functionalised lipids was also included. The three 
biotinyl lipids have linkers of different lengths between the biotin group and the nitrogen atom of 
PE. (B) Lipid nanotubes with 0, 1 or 5% (mole/mole) of biotinyl lipid was coated with N-MLV CA-
His. 5µg of capsid-coated nanotube was incubated in well in neutravidin-coated plate for 4h. 
Immobilised capsid was eluted by boiling in SDS-PAGE-loading buffer, and visualised after 
SDS-PAGE by coomassie blue staining. 
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Two alternative procedures for immobilising capsid-coated nanotubes 
were tested (Figure 4.4). In method A, lipid nanotubes were first coated with 
CA-His before addition to the microplate. However, this method led to stronger 
immobilisation of N-like capsids (N-MLV wt and B-MLV E110R) than B-like 
capsids (B-MLV wt and N-MLV R110E). This could pose a problem in the 
interpretation of binding data when comparing Fv1 binding to different capsids. 
In method B, naked lipid nanotubes were first attached to microplate, before 
coating with CA-His. Using method B, the amount of capsid detected was 
similar for both N-like and B-like capsid-coated nanotubes, and therefore allows 
the comparison of Fv1 binding to same amount of different capsid. Using this 
method, some of the CA-His could be non-specifically bound to the plastic or 
protein content of the microplate. However, such non-specific binding of capsid 
should have very minimal effect on the detected bound signal because of the 
lack of Fv1 binding to monomeric capsid (Dodding et al., 2005), and the fact 
that the amount of polymerised capsid was determined by the fixed quantity of 
lipid nanotubes in each well. During the development of the binding assay, 
microtitre plates were individually coated with neutravidin and then blocked with 
BSA. Due to high variability in the amount of capsid immobilised between 
experiments, this was subsequently changed to commercially available 
microplates pre-coated with streptavidin. 
 
4.1.2 Optimisation of Fv1 lysate production from transduced MTDF cells 
 
In the original capsid pull down assay, TE671 cells transduced with LxIG-Fv1 
vectors at high MOI was used as the source of cell lysate (Hilditch et al., 2011). 
Since all previous Fv1 restriction experiments were carried out in the Fv1o 
MDTF cell lines, it would be preferable to carry out binding studies using the 
same cell line. Figure 4.5A shows that the expression of Fv1 in transduced 
MDTF cells were comparable to that in transduced TE671 cells. Due to the use 
of lipid nanotubes, lysate was prepared in a hypotonic detergent-free lysis 
buffer. The inefficient procedure of preparing cell lysates by Dounce 
homogenisation also limited the number of lysates that could be assayed. The 
yield of lysate prepared by mechanical sheering through QIAShredder spin 
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Figure 4.4 Two alternative methods for capsid-coated nanotube 
immobilisation 
 
Lipid nanotubes could be coated with CA-His either before (Method A) or after (Method B) 
anchoring to neutravidin-coated microplates. Using method A, nanotubes pre-coated with N-like 
capsids (N-MLV wt and B-MLV E110R) were immobilised more efficiently than those pre-coated 
with B-like capsids (B-MLV wt and N-MLV R110E). In contrast, using method B, coating with 
CA-His after attaching of lipid nanotube to microplate led to even immobilisation of all MLV 
capsids. 
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columns was compared to Dounce homogenisation in Figure 4.5. Higher yields 
were obtained using the spin columns, and it allowed preparation of a large 
number of lysate samples in parallel. The protein level of Fv1n is higher than 
that of Fv1b in these lysates, consistent with previous finding that the 
overexpression level of Fv1n is higher than that of Fv1b. 
 
4.1.3 Demonstration of specific binding of Fv1n to B-MLV using a 
microplate pull down assay 
  
The optimisations described earlier led to the development of a microtitre capsid 
pull down assay, as illustrated in Figure 4.6. In this assay, lipid nanotubes 
containing 0.5% (v/v) of the BioPEG-PE lipid were first immobilised to 
streptavidin-coated plate, then coated with MLV CA-His, followed by incubation 
with Fv1 lysate. MDTF cells transduced with LxIG-Fv1 vector at a high MOI was 
used as a source of cell lysate to test if the binding phenotype described by 
Hilditch et al could be demonstrated using this microplate assay. As discussed 
in Chapter 3, the overexpression level of Fv1n was higher than that of Fv1b; 
therefore the Fv1n lysate was diluted by 4 to 8 fold with blank lysate from 
untransduced MDTF cells to the same level as Fv1b. However, from these early 
attempts, even Fv1n appeared to bind non-specifically to all capsids. It was 
hypothesised that the lack of specificity could be due to high level of non-
specific binding to microplate surface, requiring further optimisation on the 
stringency of the washing and binding buffers. In a typical ELISA assay, the 
wash and binding buffer is often supplemented with a detergent such as tween-
20 to allow efficient removal of unbound proteins. However, due to the use of 
lipid nanotube, detergent was omitted from the wash buffer which could lead to 
a lower stringency of the washing steps. It was noted that in purification of His-
tagged protein using Nickel-chelating columns, a buffer with high ionic strength 
(300mM NaCl) is often used in the binding and washing step to reduce non-
specific binding.  
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Figure 4.5 Generation of cell lysates from transduced MDTF cells 
 
(A) Western blot analysis of Fv1 in lysate prepared from transduced MDTF and TE671. Lysate 
from cells transduced with 500µl of LxIG-Fv1 vector was compared to lysate from untransduced 
cells (-CTR). Equal amounts of protein was loaded to each well. Western blot was carried out 
with anti-Fv1 (#6689) antibody and HRP-conjugated secondary antibody. (B) Western blot 
analysis of Fv1 in lysate prepared by Dounce homogenisation and centrifugation through 
QIAShredder spin columns. Cells were suspended in hypotonic buffer, and subjected to either 
Dounce homogenisation or a 2min centrifugation through a QIAShredder column. Equal amount 
of protein was loaded to each lane for SDS-PAGE. Western blot was carried out with anti-Fv1 
(#6689) antibody. 
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Figure 4.6 Procedure of the microplate capsid pull down assay 
 
10µg/ml lipid nanotubes containing 0.5% (v/v) BioPEG-PE lipid was incubated in Streptavidin-
coated microplate for 1h at room temperature. After 3 washes, 500µg/ml of CA-His was added 
and incubated at room temperature for 1h. After 3 washes, 500µg/ml lysate was added and 
incubated at room temperature for 1h. After 10 washes, bound Fv1 and capsid were eluted 
using a buffer containing 2% SDS and 500mM imidazole at 37
o
C for 20min. Eluted samples 
were analysed along with input Fv1 samples by western blot analysis.  
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The use of high salt buffer (300mM NaCl) allowed the detection of specific 
binding of Fv1n to B-MLV and N-MLV R110E mutant (Figure 4.7). The binding 
of Fv1b resembles that from the study by Hilditch et al, with similar amount of 
bound Fv1 to all capsids. In order to provide a source of Fv1 lysate with 
consistent Fv1 concentration, SCCs of MDTF cells with “superexpression” of 
Fv1n and Fv1b were selected for subsequent optimisation and validation 
experiments. The effect of the ionic strength of binding buffer was further 
studied by combining the binding assay with semi-quantitative western blot 
analysis (Figure 4.8). Using the LI-COR western blot system, Fv1 and CA were 
detected simultaneously at the 800nm and 700nm channels, respectively. It 
appeared that using a binding buffer with 150mM NaCl, a high level of non-
specific binding of Fv1 could be detected even in the absence of CA or 
nanotubes. This non-specific binding was almost completely eliminated by the 
use of a binding buffer with 300mM NaCl. Further increase in salt concentration 
to 500mM NaCl completely removed all the bound Fv1 signals (data not 
shown). Together, the data suggested that specific binding of Fv1n could be 
demonstrated using a microplate pull down assay with high stringency buffer, 
and the detected binding phenotype of Fv1b was the same in as the previous 
study. 
 
4.1.4 Detection of Fv1 binding signal required assembled CA lattice 
 
In order to validate that bound Fv1 signal detected using the microplate assay 
was due to the presence of assembled capsid lattice on nanotubes rather than 
non-specific binding, the binding of Fv1n and Fv1b to MLV capsids with P1G and 
D54A mutations were tested. A salt bridge between P1 and D54 stabilised the 
N-terminal β-hairpin structure in MLV CA (Mortuza et al., 2004), and such 
disruption had been shown to cause deformation of the regular CA lattice on 
capsid-coated nanotubes by electron microscopy (Hilditch et al., 2011). In 
agreement to the previous study, these mutations significantly reduced Fv1n 
binding (Figure 4.9), confirming that the majority of eluted Fv1n signal was 
bound to assembled capsid lattice. A similar effect was observed with Fv1b, 
although the effect of D54A mutation to the binding of Fv1b to N-MLV was 
consistently weaker. Using a separate approach to validate the CA dependency  
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Figure 4.7 Binding of Fv1n and Fv1b to MLV capsids 
 
(A) Lysate from MDTF cells transduced at high MOI was tested for binding using the procedure 
described in Figure 4.6 and a buffer with high ionic strength in the washing and binding steps. 
Fv1 was detected by western blot using an anti-Fv1 (#6689) antibody and HRP-conjugated 
secondary antibody. CA was visualised from SDS-PAGE gel by Coomassie blue staining. (B) 
Result of Fv1 binding from another independent experiment. 
  
196 
 
Figure 4.8 Semi-quantitative analysis of non-specific binding at different 
ionic strength 
 
Lysate from SCCs expressing of Fv1
n
 and Fv1
b
 were used for binding assay as described in 
Figure 4.5. In this experiment, while a wash buffer of 150mM NaCl was used, the binding buffer 
contained either 150mM or 300mM NaCl. (A) Eluted proteins were analysed by LI-COR western 
blot. Fv1 was detected at the 800nm channel (green) using an anti-Fv1 (#6689) primary 
antibody and an IRDye-800 conjugated secondary antibody. CA was detected at the 700nm 
channel (red) using a monoclonal anti-5His primary antibody and an IRDye-680 conjugated 
secondary antibody. (B) Bound Fv1 signals from the blot above were illustrated using a bar 
chart. 
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Figure 4.9 Detection of Fv1 binding signal requires assembled CA lattice 
 
Binding of Fv1 to wt CA or lattice-destabilising CA mutants was analysed using lysate from 
SCCs. A binding experiment with 500mM imidazole included in the wash buffer was carried out 
in parallel. (A) Fv1 (green) and CA (red) signals were detected using LI-COR western blot 
analysis as described in Figure 4.8. (B) Bound Fv1 signals from the blot above were illustrated 
using a bar chart. 
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of bound Fv1 signal, 500mM imidazole was included in the wash buffer in a 
parallel binding experiment. The imidazole wash should release all CA-His 
together with all CA-bound Fv1, leaving only non-specifically bound Fv1. In all 
cases, the presence of imidazole in wash buffer caused significant reduction in 
both CA and bound Fv1 signals, confirming that the detected Fv1 signals 
reflected binding to assembled CA.  
 
4.1.5 The use of frozen lysate did not significantly alter binding results 
 
Fresh lysate prepared immediately before binding experiment had been used in 
all previous Fv1 binding studies. The use of frozen aliquots of lysate for binding 
experiments could be beneficial in several ways. First, the separation of the 
lysate preparation step would allow the comparison of more lysate samples in 
the same experiment. Secondly, as the expression level of Fv1 in SCCs varied 
between passages, the use of frozen lysate allowed repeat of binding 
experiments at the exact same Fv1 concentration. Lastly, the use of frozen 
aliquots allowed the determination of Fv1 concentration in lysate prior to binding 
assay, therefore allowing the study of binding activity of different Fv1 mutants at 
the same concentration. In Figure 4.10, the bound Fv1 signals from a binding 
experiment using fresh lysate was compared to a repeated experiment a day 
later using frozen lysate. A single freeze-thaw cycle did not appear to 
significantly alter the binding results. However, it was also found that after 3 
months storage at -20oC, the majority of proteins in aliquots of frozen lysate 
were precipitated. Storage of lysate at -80oC after snap freezing in liquid 
nitrogen may be better for long term storage of Fv1 lysate. 
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Figure 4.10 Freezing cell lysate did not significantly affect binding results 
 
Lysates prepared from SCCs expressing Fv1
n
 and Fv1
b
 were used in binding assay, and the 
remaining lysate was frozen as aliquots of above 1mg/ml concentration at -20
o
C overnight. The 
binding assay was repeated on the next day with thawed lysate. (A) Western blot analysis of 
bound Fv1 (Green) and CA (red) signals. (B) A bar chart illustrating the bound Fv1 signal from 
the western blot analysis.   
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4.2 Study of Fv1 binding using a microplate pull down assay 
 
4.2.1 Specific binding of Fv1b could not be detected 
 
The first aim of using this novel microplate pull down assay was to compare the 
CA binding at multiple Fv1b concentrations, in an attempt to detect specific 
binding of Fv1b to N-MLV. Lysates containing different concentrations of Fv1 
can be generated in two ways. First, a lysate sample from MDTF cells 
transduced with the LxIG-Fv1 vector at a very high MOI can be serially diluted 
with a blank lysate from untransduced MDTF cells. However, there was a 
concern on whether this method would results in lysates with predominantly 
aggregated Fv1. Since T5 has been shown to form aggregation (Langelier et 
al., 2008), Fv1 may also aggregate at high concentrations. It is possible that the 
specific binding of Fv1b requires a less aggregated form of Fv1 which is 
maintained at a lower concentration. The formation of Fv1 aggregation at high 
concentration could potentially be irreversible, so diluting of such sample with 
blank lysate may only result in a lower concentration of aggregated Fv1 rather 
than increasing amount of dimeric Fv1. A second way is to generate lysate from 
MDTF cells transduced with LxIG-Fv1 vectors at different MOIs. Using this 
method, the lysate samples with lower total Fv1 concentration have not been 
exposed to the “super-expression” level of Fv1, therefore minimising the 
chances of Fv1 aggregation.  
 
 Figure 4.11 shows a comparison of CA nanotube binding by Fv1n and 
Fv1b using lysates with different Fv1 concentrations. At the lowest 
concentrations of Fv1n, only binding to B-MLV could be detected. At high 
concentrations of Fv1n, strong non-specific binding could be detected in binding 
reactions even without CA. In contrast, Fv1b appears to bind all MLV CA equally 
even at the lowest concentration where binding could be detected. The data 
suggested that within the sensitivity limits of this microplate pull down assay, no 
specific binding of Fv1b could be detected. 
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Figure 4.11 Binding studies at low concentrations of Fv1n and Fv1b 
 
(A) Quantities of Fv1 in cell lysates prepared from MDTF cells transduced with LxIG-Fv1 vectors 
at different MOI were analysed by quantitative western blot using purified Fv1NTD standards as 
described in Chapter 3. The quantity of Fv1 from the western blot was illustrated in the bar 
chart. (B) Western blot analysis of bound Fv1
n
 (green) and CA (red) signals using lysate shown 
in (A). 
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4.2.2 Study of correlation between binding and restriction by Fv1 
 
As discussed in Chapter 3, Fv1n, Fv1b, the mix-and-match mutants and the tail 
mutants all display different restriction phenotypes. The variety in restriction 
phenotypes made them ideal targets for studying the correlation between 
restriction and binding. The aim of this study was to compare the binding of all 
10 Fv1 variants to MLV capsids in the same experiment at very similar Fv1 
concentrations, using N-MLV P1G as a control for non-specific binding. Similar 
to the study in 4.2.1, MDTF cells were transduced with LxIG-Fv1 vectors 
expressing one of the 10 Fv1 variants at 7 different MOIs to generate a library 
of Fv1 lysates. After growing of transduced cells to large quantity, stock lysates 
was prepared and stored as aliquots at -80oC after snap freezing with liquid 
nitrogen. An aliquot of each sample in the lysate library was thawed for analysis 
of total protein and Fv1 concentrations. By mixing Fv1 lysate, blank lysate and 
buffer, diluted Fv1 lysates with specific total protein and Fv1 concentrations 
could be generated. Nevertheless, as illustrated in Figure 4.12A, despite the 
best attempts to standardise the Fv1 concentrations between Fv1 variants 
tested in the same experiment, there was still a two-fold difference between the 
samples with highest and lowest Fv1 concentration. 
 
The results for the binding study are illustrated in Figure 4.12B and C. 
The binding phenotype of Fv1n and Fv1b were similar to previous binding 
studies, supporting the idea that the use of frozen lysate did not affect binding 
results. In some binding reactions with NB-MLV CA, the normalised percentage 
of bound Fv1 was negative indicating that the binding to NB-MLV was lower 
than to the N-MLV P1G control. However, in most of these cases the values 
were close to zero. Table 4.1 compares the sequence, restriction, binding and 
overexpression protein levels of all 10 variants. Among all the sequence 
determinants, the influence of E358 on restriction, binding and expression was 
most obvious. The previous studies have reported that E358 from Fv1b strongly 
correlates with the restriction of N-MLV (Bishop et al., 2001; Bock et al., 2000), 
although Fv1nnb is able to inhibit N-MLV despite having K358. The presence of 
E358 is also associated with lower Fv1 protein level. Interestingly, the 6 Fv1  
 
203 
 
 
Figure 4.12 Binding data from Fv1n, Fv1b and mutants 
 
(A) Western blot analysis of input Fv1 in each lysate sample used in a binding study. The 
amount of Fv1 in each diluted lysate was analysed by quantitative western blot using purified 
Fv1NTD standards. (B) Western blot analysis of the amount of bound Fv1 of all 10 Fv1 variants. 
N1 indicates samples with N-MLV P1G control. (C) A bar chart showing binding data of all 10 
Fv1 variants. Quantity of bound Fv1 was expressed as a percentage of quantity of input Fv1, 
with non-specific binding to N-MLV P1G subtracted. The height of each bar represents the 
mean value from two binding experiments, while the error bars show values of mean deviation. 
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Table 4.1 Summary of sequence, restriction activity, binding activity 
and overexpression level of all 10 Fv1 variants 
 
The table was arranged in the order of decreasing restriction activities at the endogenous (TGx) 
and at the overexpression (LxIG) Fv1 levels. Positively charged amino acids were highlighted in 
red, while negatively charges amino acids were highlighted in blue. The red bars indicate mean 
restriction values from 3 experiments using the TGx-Fv1 vector in the presence of 1µg/ml 
doxycycline, these values are derived from Table 3.2. The green bars indicate mean restriction 
values from 3 experiments using the LxIG-Fv1 vector in MDTF-R18 cells, these values are 
derived Table 3.2. The blue bars show the mean Fv1 expression level (unit: 10
3
 molecules per 
cell) from 2 experiments in MDTF cells transduced with LxIG-Fv1 at MOI of 1, these values are 
derived from Figure 3.3). In comparison, the endogenous levels of Fv1
n
 and Fv1
b
 are 77 x 
10
3
/cell and 26 x 10
3
/cell, respectively. The yellow bars show mean percentage Fv1 binding 
from 2 experiments, as shown earlier in Figure 4.12. 
  
N-MLV Fv1 358 399 Tail TGx LxIG Fv1/cell Binding
bbn E R TKL 0.17 0.06 1071 42.7%
bbb E R GLTSVGSVGVLSLSPWKHQSNS 0.17 0.07 680 22.6%
bnn E V TKL 0.18 0.09 1886 20.5%
bnb E V GLTSVGSVGVLSLSPWKHQSNS 0.22 0.06 805 21.3%
bb_ E R 1.07 0.06 762 35.4%
nnb K V GLTSVGSVGVLSLSPWKHQSNS 1.07 0.58 1572 21.5%
nbb K R GLTSVGSVGVLSLSPWKHQSNS 1.05 0.93 2587 10.3%
nbn K R TKL 1.12 1.02 3434 11.7%
nn_ K V 1.09 1.10 851 11.7%
nnn K V TKL 1.16 1.07 2865 7.4%
B-MLV Fv1 358 399 Tail TGx LxIG Fv1/cell Binding
nbn K R TKL 0.23 0.08 3434 25.8%
nnn K V TKL 0.24 0.06 2865 27.5%
bbn E R TKL 0.29 0.07 1071 25.2%
nnb K V GLTSVGSVGVLSLSPWKHQSNS 0.52 0.09 1572 10.7%
nbb K R GLTSVGSVGVLSLSPWKHQSNS 0.66 0.07 2587 26.1%
bnn E V TKL 0.93 0.12 1886 28.2%
nn_ K V 1.07 0.09 851 44.1%
bb_ E R 1.09 0.22 762 23.8%
bbb E R GLTSVGSVGVLSLSPWKHQSNS 1.10 0.63 680 22.4%
bnb E V GLTSVGSVGVLSLSPWKHQSNS 1.08 1.11 805 22.6%
NB-MLV Fv1 358 399 Tail TGx LxIG Fv1/cell Binding
bbn E R TKL 0.19 0.08 1071 46.1%
nbn K R TKL 0.33 0.09 3434 19.9%
bbb E R GLTSVGSVGVLSLSPWKHQSNS 0.79 0.21 680 9.0%
bb_ E R 1.07 0.05 762 32.7%
bnn E V TKL 1.12 0.98 1886 -2.7%
nnb K V GLTSVGSVGVLSLSPWKHQSNS 1.07 1.07 1572 -7.9%
bnb E V GLTSVGSVGVLSLSPWKHQSNS 1.08 1.12 805 4.2%
nbb K R GLTSVGSVGVLSLSPWKHQSNS 1.12 1.10 2587 -3.4%
nn_ K V 1.12 1.11 851 -2.3%
nnn K V TKL 1.18 1.08 2865 -0.5%
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variants which show strong inhibition or restriction of N-MLV at the over-
expression level (bbn, bbb, bnn, bnb, bb_ and nnb) also show stronger binding 
to N-MLV CA nanotubes. Similarly, the 4 Fv1 variants which restrict NB-MLV at 
the over-expression level (bbn, nbn, bbb, bb_) all show stronger binding to NB-
MLV CA nanotubes. 9 out of 10 Fv1 variants restrict or inhibit B-MLV at the 
over-expression level, with Fv1bnb as the exception. However, the binding of 
Fv1bnb to B-MLV CA nanotubes is not significantly lower than other mutants. 
Since all Fv1 mutants were derived from Fv1n and Fv1b, both of which inhibits 
B-MLV, it is likely that they all possess at least a weak apparent binding affinity 
towards B-MLV CA.  
 
To test whether CA nanotube binding is correlated with MLV restriction 
by Fv1, binding and restriction data from all 10 variants were subjected to two-
tailed correlation analysis (Figure 4.13). Interestingly, strong correlations were 
identified for N-MLV and NB-MLV between binding and restriction at 
overexpression level (LxIG-Fv1). In the case of N-MLV, all 6 Fv1 variants that 
conferred full or partial restriction of N-MLV when overexpressed also showed 
strong binding to N-MLV capsid exceeding 20% of input Fv1. A two-tailed test 
confirmed the significant correlation between N-MLV binding and restriction at 
overexpression, with a Pearson correlation coefficient of 0.0053. In the case of 
NB-MLV, all 4 variants that showed restriction of NB-MLV at overexpression 
level also demonstrated strong binding of at least 9%. The two-tailed test 
confirmed the significance of the correlation between NB-MLV binding and 
restriction at overexpression, with a Pearson correlation coefficient of 0.0014. In 
contrast, no correlation could be found between B-MLV binding and restriction. 
When overexpressed, 8 out of 10 Fv1 variants conferred full restriction of B-
MLV. The two exceptions were Fv1b, which conferred partial restriction of B-
MLV, and Fv1bnb, which did not show any inhibition towards B-MLV. All Fv1 
variants except Fv1bnb display some inhibition against B-MLV, and therefore 
must have some interaction with B-MLV core. Since the binding of the non-
restrictive Fv1bnb appears to be similar to other restrictive variants, the data 
suggested that all 10 Fv1 variants were capable of binding to B-MLV CA.  
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Figure 4.13 Correlation analyses between Fv1 binding and restriction 
 
Binding data from 2 experiments and restriction data (either LxIG-Fv1 or TGx-Fv1 with 1µg/ml 
Dox) from 2 experiments were subjected to two-tailed correlation test. P value shows the 
Pearson correlation coefficient. Vertical dotted lines indicate restriction values of 0.3 and 0.7. 
Horizontal dotted lines show potential separation of capsid-binding and non-binding 
phenotypes.  
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In contrast to the strong correlation between N-MLV binding and 
restriction at overexpression level, no significant correlation was found between 
N-MLV binding and restriction at endogenous level (TGx-Fv1 +Dox). This was 
mainly due to the lack of restriction at endogenous level by two variants which 
strongly bind N-MLV, Fv1bb_ and Fv1nnb. Similarly, the lack of NB-MLV 
restriction by Fv1bb_ at endogenous level led to a weak correlation between 
NB-MLV binding and restriction at endogenous level. Together, these data 
suggested that the binding of Fv1 to CA nanotubes indicates an apparent 
binding affinity which is sufficient to cause MLV inhibition at an over-expression 
level, but may be insufficient to cause inhibition at the endogenous level. 
 
 
 
 
4.3 Discussion 
 
In this chapter, the development of a microplate pull down assay designed to 
allow the study of the relationship between MLV binding and Fv1 concentration, 
and between MLV binding and restriction by Fv1 is described. By studying the 
binding of Fv1n and Fv1b to MLV CA nanotubes at different Fv1 concentrations, 
it was observed that while Fv1n specifically binds B-MLV CA nanotubes, 
Fv1b binds N-MLV, B-MLV and NB-MLV CA nanotubes equally. In contrast, 
Fv1b is abrogated by N-MLV but not B-MLV (Boone et al., 1990), suggesting a 
measurable difference in the apparent binding affinity of Fv1b towards MLV of 
different tropisms. So what causes the difference in the apparent binding 
specificities of Fv1b to MLV cores and CA nanotubes?  
 
The apparent lack of binding specificity of Fv1b to CA nanotubes could 
be due to the high concentration of CA and/or Fv1 required for the detection of 
bound Fv1 in the assay. At the binding equilibrium, the concentration of bound 
Fv1:CA complex is dependent on concentrations of both Fv1 and CA. Data from 
the restriction studies in Chapter 3 suggested that the strong inhibitions of NB-
MLV and B-MLV is observed only at high Fv1b concentration, but not at the low 
endogenous Fv1b concentration. Although Fv1b appeared to bind MLVs of all 
tropisms equally even at the lowest Fv1b concentration which allowed detection 
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of bound Fv1b, it remains possible that this low Fv1 concentration is already 
sufficient to overcome the weaker apparent binding affinity of Fv1b to NB-MLV 
and B-MLV. However, the concentration of Fv1 used in the binding assay is 
actually relatively low compared with the concentration of CA. Among the 
proteins eluted from binding reactions, a band corresponding to MLV CA is 
clearly visible on SDS gel by Coomassie blue staining (Figure 4.7), while Fv1 
can only be detected by western blot. It is more likely that the high 
concentration of CA in the binding reaction overcomes the weak apparent 
binding affinity of Fv1b to NB-MLV and B-MLV, leading to the equal binding to 
MLV CA of all tropisms. At a low concentration, the Fv1n appears to bind CA 
nanotubes of B-MLV only, this suggested that the apparent affinity of Fv1n to 
CA of N-MLV and NB-MLV are much lower than to B-MLV, and cannot be 
overcome by the high CA concentration. It is possible that at a higher Fv1n 
concentration, Fv1n binds to CA of all MLV tropisms equally. However, the high 
background non-specific binding of Fv1n to the microplate well does not allow 
one to confidently distinguish the bound Fv1n signal from background signal. 
Instead of studying Fv1 binding with lysates containing different Fv1 
concentrations, it may be possible to detect stronger binding of Fv1b to N-MLV 
than to NB-MLV and B-MLV by using a fixed amount of Fv1 and different 
amount of CA nanotubes. The quantitation of both Fv1 and CA in such binding 
assay may allow one to distinguish small differences in apparent binding 
affinities of Fv1b against MLV CA of different tropisms. However, it is anticipated 
that the study of Fv1 binding at lower CA nanotube concentrations may be 
difficult for several reasons. First, the limited sensitivity of the Fv1 western blot 
may not be sufficient to detect the lower amount of bound Fv1 at lower CA 
concentrations. Secondly, even if Fv1b binds exclusively to N-MLV CA 
nanotubes at a low CA concentration, it would be difficult to distinguish such 
weak binding from background signals resulted from the non-specific binding of 
Fv1 to the microplate well.  
 
The differences between the CA lattice on lipid nanotubes and the CA 
lattice on mature MLV core could also mean that the binding apparent affinity of 
Fv1 to nanotubes and core may be different. First, the curved CA array on lipid 
nanotube may not mimic those found in mature core. The CA array is formed on 
the curved surface of lipid nanotubes imposed by the lipid GalCer, forming 
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tubes with a diameter of 50nm (Hilditch et al., 2011). In contrast, the mature 
core of MLV was described as polygonal and roughly spherical, with variable 
diameter within a particle of 120nm (Yeager et al., 1998). Secondly, the C-
terminus of CA is attached to DGS-NTA lipid via a His-tag (Hilditch et al., 2011), 
while in MLV mature core both N- and C-termini of CA are not tethered. 
Importantly, these differences may lead to the difference in the spacing 
between CA hexamers, which may influence the recognition of CA by Fv1. The 
inter-hexamer spacing is known to be different between immature and mature 
CA lattice. In HIV-1 core, the inter-hexamer spacing changes from 80Å in 
immature core to 96Å in mature core (Briggs et al., 2004). In MLV, the inter-
hexameric spacing immature-like lattice of MLV CA tethered in one or both ends 
are about 80Å (Barklis et al., 1997; Yeager et al., 1998; Zuber et al., 2000), but 
crystal structure of processed MLV CA showed an inter-hexameric spacing of 
99Å (Burns, 2009; Mortuza et al., 2008). The crystal structure of mature MLV 
CA showed that the CA-CTD forms CTD-CTD inter-hexameric interactions, and 
the conformational changes in CA-CTD may be contributing to this increase in 
inter-hexamer spacing (Burns, 2009). In MLV CA nanotubes, the inter-hexamer 
spacing was found to be about 70Ǻ (Hilditch et al., 2011), which resembles that 
of an immature CA lattice. Although the processed N-terminus allows the 
stabilisation of β-hairpin, the tethering of the C-terminus of CA may still prevent 
some structural changes in the CA-CTD required the formation of a mature-like 
lattice. How the presence of an immature-like lattice on the CA nanotube could 
affect binding is not known. N-MLV with the processing of gag at the CA/NC 
junction abolished by protease site mutation failed to abrogate Fv1b (Dodding et 
al., 2005), however an electron microscopy study also showed defect in core 
formation of this mutant (Oshima et al., 2004), therefore it is difficult to conclude 
whether a CA lattice with processing at the N-terminus but not the C-terminus 
can be recognised by Fv1. Since the inter-hexamer spacing of an immature-like 
CA lattice is lower than that of a mature CA lattice, the density of CA hexamers 
in an immature-like lattice would be higher than in a mature CA lattice. The 
higher density of binding sites for Fv1 may potentially enhance the apparent 
binding affinity of Fv1 to CA, which may overcome the weak apparent affinities 
of Fv1b against CA of NB-MLV and B-MLV. Testing whether the C-terminal 
processing of CA is required for Fv1 binding in vitro would require the 
comparison between the binding of Fv1 to an immature-like CA lattice such as 
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those on lipid nanotubes, and binding of Fv1 to a mature CA lattice on an in 
vitro assembly. Currently there is no in vitro assembly with a mature MLV CA 
lattice, since purified MLV CA does not polymerised into in vitro assemblies. 
Identification of an alternative method for polymerizing CA, insensitive to 
detergent washing, might provide a possible approach to this problem. 
 
The studies of binding and restriction of 10 different Fv1 variants 
revealed a strong correlation between the observed binding to CA nanotube 
and the restriction phenotype at over-expression level of Fv1 for both N-MLV 
and NB-MLV. All Fv1 variants except Fv1bnb show at least some inhibition 
towards B-MLV at over-expression level of Fv1. Since the binding of the non-
restrictive Fv1bnb to B-MLV CA nanotubes appears to be similar to other 
restrictive Fv1 variants, it is likely that all 10 Fv1 variants were capable of 
binding to B-MLV CA. The correlations between CA nanotube binding and 
restriction at an over-expression level are in agreement with the hypothesis that 
the apparent lack of binding specificity to CA nanotubes may be due to the high 
concentrations of CA and/or Fv1 present in the binding reaction. Therefore, 
strong binding of Fv1 to MLV CA nanotubes may indicate that the Fv1 possess 
an apparent affinity to cores that is sufficient for MLV inhibition when Fv1 is 
over-expressed, but such interaction may be too weak for any measurable 
inhibition as a lower concentration close to the endogenous level. As for the 
Fv1bnb mutant, it is likely Fv1bnb has some very weak apparent affinity against 
B-MLV CA, which is insufficient to cause inhibition of B-MLV even at a high 
concentration Fv1. 
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Chapter 5 
 
Attempts to study binding of T5 to MLV CA 
 
RhT5, but not HuT5, restricts HIV-1 (Stremlau et al., 2004). The interaction 
between rhesus T5 to in vitro capsid assemblies of purified HIV-1 CA-NC 
proteins (Gross et al., 1997) could be demonstrated using a pull down assay 
(Stremlau et al., 2006), which involved pelleting of tubular CA-NC complexes 
through a 70% sucrose cushion by ultracentrifugation. This assay had since 
been used in numerous studies mainly from the Sodroski lab to study the 
binding of T5 to HIV capsids (Kar et al., 2008; Kim et al., 2011; Langelier et al., 
2008; Li et al., 2006b; Li et al., 2006c; Liberatore and Bieniasz, 2011; Lienlaf et 
al., 2011; Yang et al., 2014).  
 
Similar to the endogenous restriction specificity of Fv1b, both HuT5 and 
RhT5 also restrict N-MLV but not B-MLV (Hatziioannou et al., 2004; Perron et 
al., 2004; Yap et al., 2004). Since N-MLV capsid is the target of both T5 and 
Fv1 restriction, there has been strong interest in our lab to develop an assay 
that would allow comparison of the binding of these two restriction factors to 
MLV capsid. Previously, the specific binding of T5 to N-MLV capsid using a CA-
pulled down assay had been described by the Luban lab (Sebastian and Luban, 
2005). This assay involved pull-down of CA by GST-tagged T5 from core 
particles prepared by stripping the membrane envelope of MLV virions with 
detergent, and was used in a subsequent study in their lab (Sebastian et al., 
2009). However, despite many attempts in our lab, the specific binding of T5 to 
MLV could not be demonstrated using this assay (Sadayuki Ohkura, 
unpublished data). In the previous study by Laura Hilditch, the original MLV CA-
coated nanotube pull down assay that had been used to demonstrate Fv1 
binding was applied to study T5 (Hilditch, 2010). However, pull down of HA-
tagged RhT5 (RhT5HA) or HA-tagged HuT5 (HuT5HA) by MLV CA-coated 
nanotubes could not be demonstrated. Data in this chapter describes further 
attempts to show specific binding of T5 to MLV capsid in vitro. 
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5.1 Binding of T5 to MLV capsid-coated nanotube 
 
Since the microplate pull down assay described in chapter 4 allowed detection 
of specific Fv1n to B-MLV reproducibly, it might be thought that this assay could 
be used to study T5 binding to MLV capsids. Compared to the original nanotube 
pull down assay (Figure 4.1), the microplate assay could eliminate the potential 
bias in binding results due to aggregation of restriction factor at high 
concentration. T5 had been known to localise to cytoplasmic bodies (Reymond 
et al., 2001) related to aggresomes (Diaz-Griffero et al., 2006). Since 
aggresomes contain aggregated cytoplasmic proteins (Johnston et al., 1998), 
this suggested T5 may have aggregation properties. Aggregated T5 in cell 
lysate might then be pelleted through sucrose cushion even in the absence of 
capsid, causing a high background of binding signal.  
 
5.1.1 Human T5HA showed stronger binding to B-MLV than N-MLV 
 
In the previous study, Laura Hilditch suggested that the failure to detect binding 
of HA-tagged T5 (T5HA) to MLV capsid using the original pull down assay could 
be largely due to the low concentration of T5HA in cell lysate (Hilditch, 2010).  
Therefore, SCCs of MDTF cells transduced with LxIY-T5HA vectors at very high 
MOI were picked and screened for high T5HA expression by LI-COR western 
blot (Figure 5.1). Since antibody with good sensitivity against both HuT5 and 
RhT5 was not available, constructs with C-terminal HA-tag was once again 
used in this study. It had been shown previously that the presence of a C-
terminal HA-tag did not have any significant effect on HIV-1 restriction by T5 
(Stremlau et al., 2004). Some of the clones that expressed high level of Hu 
T5HA had much slower cell division, and would not serve as a reliable source of 
cell lysate for binding assays. A clone was selected each for HuT5HA and 
RhT5HA, and both clones have similar T5HA expression to eliminate the need 
for diluting T5HA lysate with blank lysate. 
 
Parallel binding experiments using the microplate assay described in 
chapter 4 was carried out with lysates from SCCs expressing Fv1n, Fv1b, 
HuT5HA and RhT5HA (Figure 5.2).  As expected, binding of Fv1n to B-MLV 
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only and binding of Fv1b to both capsids were observed. Surprisingly, a much 
stronger binding of HuT5HA to B-MLV than to N-MLV was observed. This 
observed binding specificity is inconsistent with the specific restriction of N-MLV 
by HuT5HA. At the same concentration, binding of RhT5HA to neither N-MLV 
nor B-MLV capsids could be observed. Results from repeated experiments 
were consistent. Since the signal from HuT5HA bound to B-MLV was weak 
compared to the input, there was a possibility that the concentration of T5HA 
was too low for detectable specific binding, and the observed binding signal 
was difference in non-specific binding. It is also impossible to compare the 
amount of input Fv1 and T5 used in these binding experiments because the 
detection of Fv1 and T5 were carried out using different antibodies.  
 
In order to increase the specific binding of T5HA to polymerised CA, the 
assay was repeated with increasing amount of lipid nanotubes (Figure 5.3). 
Since binding of RhT5HA to MLV capsids could not be observed earlier, binding 
to nanotubes coated with HIV-1 CA-p2 was also tested. A regular array had 
been found on lipid nanotubes coated with HIV-1 CA-p2 by electron microscopy 
(Goldstone et al., 2014; Hilditch, 2010), and this construct had been used to 
form capsid array to study binding of Fv1Cyp (Goldstone et al., 2014). In 
agreement to previous restriction data, binding of RhT5HA but not HuT5HA to 
HIV-1 CA-p2 was detected at all nanotube concentrations. At all nanotube 
concentrations, the signal of B-MLV binding was significantly higher than that of 
N-MLV or no CA control. As the amount of nanotube increases, the detected 
signal of HuT5HA bound to B-MLV also increases. At 40ng/ml nanotube 
concentration, more than 50% of input HuT5HA is bound to B-MLV CA. The 
binding of HuT5HA to N-MLV was not significantly higher than to the CA-
negative control. The restriction phenotypes of HuT5HA and RhT5HA were 
confirmed by two colour restriction assay (Table 5.1). Both T5HA alleles restrict 
N-MLV but not B-MLV, although for HuT5 and HuT5HA a weak inhibition of B-
MLV could be observed. The fact that T5 restriction can be abrogated by N-
MLV but not B-MLV (Towers et al., 2002) strongly suggested that T5 specifically 
recognises N-MLV cores but not B-MLV cores. Therefore, the observed 
stronger binding of HuT5HA to B-MLV than N-MLV is unlikely to reflect the 
specific binding of HuT5HA to MLV cores. 
  
214 
 
 
Figure 5.1  Screening of MDTF SCCs expressing human and rhesus T5HA 
 
MDTF cells were transduced with LxIY vectors (EYFP-expressing version of LxIG) expressing 
either human or rhesus T5HA at high MOI (500µl per 12 well plate). SCCs were picked at 
limiting cell dilution. A lysate sample was prepared from each SCC and normalised by total 
protein concentration. The relative expression level of T5HA was analysed by LI-COR western 
blot using a monoclonal anti-HA primary antibody, and IRDye-800 conjugated secondary 
antibody. Signals at 800nm from T5HA bands were illustrated in the bar chart. SCCs with slow 
cell division are indicated by the green bars. The selected SCCs expressing HuT5HA and 
RhT5HA were indicated by the red bars.  
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Figure 5.2 Binding of Fv1 and T5HA to MLV capsids 
 
Cell lysate from SCCs expressing (A) Fv1 or (B) T5HA were used to binding assay against N-
MLV and B-MLV using the microplate assay described in chapter 4 with 10µg/ml nanotubes. As 
a negative control, binding reactions were also carried out in the absence of CA. Fv1 was 
detected using an anti-Fv1 (#6689) antibody, T5HA was detected using an anti-HA antibody, 
and CA was detected using an anti-His antibody. An IRDye800-conjugated secondary antibody 
was used in all blots. 
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Figure 5.3 Binding of T5HA to MLV and HIV-1 capsids 
 
(A) Lysate from SCCs expressing human or rhesus T5HA were tested for binding to nanotubes 
coated with N-MLV CA, B-MLV CA, HIV-1 CA-p2 or no capsids using the microplate assay. 
T5HA was detected by LI-COR western blot with anti-HA antibody. (B) The bound T5HA signals 
were illustrated in the bar chart. 
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Table 5.1 Restriction phenotypes of T5 and T5HA 
 
(A) Restriction data of HuT5 and RhT5 from a previous study (Yap et al., 2005). (B) Restriction 
data of HuT5, RhT5, HuT5HA and RhT5HA from this study. Restriction ratio of less than 0.3 is 
highlighted in black. 
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5.2 An attempt to generate hyperstable MLV cores for binding 
studies of T5 and Fv1 
 
Since the binding of RhT5HA and HuT5HA to MLV CA nanotubes do not 
appear to reflect their interaction with MLV cores, it may be possible that T5 
recognises some structures of N-MLV that is not present in capsid lattice 
formed on the lipid nanotubes in vitro, and the detection of specific binding of 
T5 to MLV may require purified cores. Unfortunately, successful purification of 
intact mature MLV cores has not been demonstrated. Although membrane 
envelope can be stripped from virions by incubation with mild detergents such 
as X-100, the use of such treatment followed by separation through equilibrium 
density gradient did not allow recovery of intact mature cores (Andersen, 2013; 
Fassati and Goff, 1999). Purification of HIV-1 cores had been achieved by 
ultracentrifugation of virion through a layer of detergent overlaid on a density 
gradient (Forshey and Aiken, 2003), but a previous attempt in our lab to use this 
method for extraction of intact MLV cores was unsuccessful (Dodding, 2006). 
The lack of previous success could be due to a low stability of MLV cores in the 
absence of the membrane envelope. One way to circumvent this difficulty could 
be by introducing mutations that enhance stability of MLV cores. 
 
 Based on the hexamer structure of HIV-1 CA, a previous study screened 
for pairs of cysteine mutations which could lead to crosslinking between purified 
CA monomers through introduction of disulphide bonds (Pornillos et al., 2010). 
Pairs of cysteine mutations were introduced at residues in close proximity with 
each other between helix 1 (H1), helix 2 (H2) and helix 3 (H3). Two particular 
mutants, A14C/E45C and A42C/T54C, showed strong stabilisation of capsid 
hexamer (Figure 5.4). The introduction of additional mutations W184A/M185A 
to destabilise CTD-CTD interaction allowed the purification of soluble hexamers, 
from which crystal structures had been determined (Pornillos et al., 2010). 
Enrichment of capsid hexamers could also be observed in HIV-1 vector virions 
harbouring A14C/E45C mutations (Meng et al., 2012). Therefore, we 
hypothesised that similar double cysteine mutations might stabilise the mature 
MLV core, allowing purification on equilibrium density gradients. The  
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work described in this section was carried out in collaboration with Ophélie 
Cosnefroy (Kate Bishop’s lab, Division of Virology, NIMR), and her contributions 
to this work are clearly stated in the figure legend.  
 
5.2.1 Design of N-MLV double cysteine mutants 
 
Figure 5.5 shows an alignment between capsid sequence of N-MLV and HIV-1. 
The first approach of selecting residues for cysteine mutations would be to 
identify the equivalent positions of the HIV-1 A14C/E45C and A42C/T54C 
mutations on the MLV CA structure. Unfortunately, the equivalent of A14 in N-
MLV CA would be P14, and the mutation of a proline is not desirable as it often 
leads to changes in protein structure (Ian Taylor, personal communication).  
The equivalent for the A42C/T54C mutations in N-MLV would be S43C/Q57C. 
Cysteine mutations were introduced to pairs of residues among H1, H2 and H3 
with less than 6Å distance between beta-carbons (Cβ) in the screening of HIV-1 
crosslinking mutants, and this Cβ-Cβ distance was suggested as the optimal 
spacing for the formation of disulphide bonds between cysteine residues 
(Pornillos et al., 2010). Table 5.2 summarises the mutants tested and the 
distance between mutated residues. Apart from S43/Q57, four other pairs of 
residues including S17/D19, S17/N22, Y21/N26 and T46/D53 were also within 
the 6Å distance and were included in the screen. It was anticipated that some 
double mutants could have defects in virus production or proteolytic processing, 
and therefore not suitable for generation of hyperstable cores for studying 
restriction factor binding. To maximize the chance of success, additional 
mutants were picked by selecting the next closest residues to Q57 and D53, 
leading to the selection of V44/Q57, T47/Q57 and T46/D53. Finally, two pairs of 
distant residues with Cβ-Cβ distance over 10Å, Y21/N27 and H48/Q57, were 
selected as negative controls. The locations of these 10 double mutations were 
shown in Figure 5.6 and Figure 5.7. While 4 mutants were selected for H1-H1 
crosslinking, 6 mutants were selected for H2-H3 crosslinking. 
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Figure 5.4 Double-cysteine mutations of HIV-1 CA 
 
The two pairs of double-cysteine mutations that had been previously described to stabilise the 
capsid hexamer of HIV-1 in vitro (Pornillos et al., 2010) were illustrated on the hexamer 
structure of HIV-1 capsid (PDB: 3H4E) (Pornillos et al., 2009). The positions of A14C/E45C 
mutations were labelled with blue spheres, while the positions of A42C/T54C mutations were 
labelled with red spheres.  
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Figure 5.5 Alignment of N-MLV and HIV-1 CA sequence 
 
Amino acid sequences of N-terminal domains of N-MLV and HIV-1 CA were aligned based on 
the secondary structure, modified from Mortuza et al, 2004. Positions of alpha helices, beta-
sheet and cyclophilin-binding loop (labelled as CypA) were indicated by underlined residues. 
Mutated residues in the HIV-1 A14C/E45C and A42C/T54C capsid mutants (Pornillos et al., 
2010) were coloured in green and purple, respectively. Residues mutated in this study for H1-
H1 crosslinking were coloured in blue. Residues mutated for H2-H3 crosslinking of N-MLV CA 
were labelled in red. 
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Table 5.2 Summary of N-MLV double cysteine mutations 
 
Site-directed mutagenesis of pCIG-N for production of N-MLV vectors with double cysteine 
mutations were carried out jointly with Ophélie Cosnefroy. All mutants which included the Q57C 
mutation were constructed by Ophélie Cosnefroy, while other mutants were constructed by me. 
Distances between Cβ were measured using the published crystal structure of N-MLV hexamer 
(PDB: 1U7K) (Mortuza et al., 2004).   
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Figure 5.6  Positions of double cysteine mutations on N-MLV CA hexamer 
 
Double cysteine mutations listed in table 5.2 were illustrated on the crystal structure of N-MLV 
CA hexamer (PDB: 1U7K) (Mortuza et al., 2004). Mutations for H1-H1 crosslinking were 
represented by blue spheres and dotted lines. Mutations for H2-H3 crosslinking were shown by 
red spheres and dotted lines. 
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Figure 5.7 Magnified view of N-MLV double cysteine mutations 
 
(A)  A magnified view of the structure in Figure 5.6 of showing pairs of residues mutated for 
crosslinking. (B) A magnified view of mutations selected for H1-H1 crosslinking. (C-D) Magnified 
views of mutations selected for H2-H3 crosslinking. 
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5.2.2 Screening of N-MLV double cysteine mutants for CA crosslinking in 
virions 
 
Before the screening of N-MLV double cysteine mutants, I first tested whether 
crosslinking of HIV-1 A14C/E45C mutant could be detected by non-reducing 
western blot analysis (Figure 5.8). A slow migration band with size expected 
from a CA hexamer (180kDa) was observed with the A14C/E45C mutant but 
not wt HIV-1 in non-reduced samples. Based on the fluorescent signals from CA 
bands, about 50% of CA was crosslinked as hexamers. Only CA monomers 
were detected in presence of reducing agent. Therefore, this method appeared 
to be effective in screening crosslinking within virions.  
 
Site-directed mutagenesis was first performed to generate single and 
double mutants with the S43C/Q57C mutations. Surprisingly, western blot 
analysis of CA in wt and mutant virions under reducing condition showed that a 
band with high molecular weight was found in all mutants with the S43C 
mutation (Figure 5.9). Since all disulphide bonds between crosslinked CA 
multimers would be reduced by the presence of β-mercaptoethanol, the band 
with high molecular weight would most likely be unprocessed p65-gag 
polyprotein. This suggested that the S43C mutation could have led to a defect 
in proteolytic processing of gag (Figure 5.9). We therefore excluded 
S43C/Q57C and S43C/D53C from later studies.  
 
I then analysed CA from MLV virions of other mutants by western blot 
under reducing or non-reducing conditions (Figure 5.10). From the analysis of 
non-reduced samples, S17C/D19C, S17C/N22C, T47C/Q57C, and to less 
extent V44C/Q57C mutants showed bands at high molecular weight exceeding 
180kDa. For S17C/D19C, T47C/Q57C and V44C/Q57C mutants, CA signals 
could be detected even above 300kDa. A 60kDa band was detected for four 
single mutants S17C, N22C, Y21C and N26C, most likely reflecting the 
formation of CA dimer. A band with molecular weight just below 70kDa could be 
observed in both reducing and non-reducing samples of S17C/D19C, Y21C and 
V44C/Q57C. Similar to the earlier observation with the S43C mutant, this band 
would most likely represent unprocessed p65gag polyprotein. Despite two  
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Figure 5.8 Western blot analysis of HIV-1 virion with A14C/E45C 
mutations 
 
HIV-1 virions of WT and A14C/E45C (CC) mutant were generated by transient transfection in 
293T cells. Virions were pelleted by ultracentrifugation, and analysed by SDS-PAGE with or 
without 2% β-mercaptoethanol in loading buffer. The western blot was carried out with a 
monoclonal anti-p24 primary antibody and an IRDye800-conjugated secondary antibody. 
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Figure 5.9 Reducing western blot analysis of N-MLV S43C/Q57C mutant 
 
Ophélie Cosnefroy carried out both mutagenesis and reducing western blot analysis shown in 
this figure. N-MLV virions produced by transient transfection of 293T cells were pelleted and 
analysed by western blot under reducing conditions. CA western blot was performed using a 
monoclonal anti-CA antibody.   
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Figure 5.10 Screening of N-MLV double cysteine mutations 
 
I carried out screening of CA crosslinking in virions using mutants constructed by me and 
Ophélie Cosnefroy. Virions were produced by transient transfection of 293T cells and pellet by 
centrifugation. Samples were analysed by SDS-PAGE with or without 2% β-mercaptoethanol in 
loading buffer. Western blots were carried out with a monoclonal anti-p30 primary antibody and 
an HRP-conjugated secondary antibody. 
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attempts, very low amount of CA could be detected from virion samples of 
T46C/D53C. From this screen, S17C/N22C and T47C/Q57C mutants 
(illustrated in Figure 5.11) appeared to allow formation of large crosslinked CA 
complex without noticeable defect in gag processing. These mutants were 
characterised in detail in later studies.   
 
5.2.3 MLV mutants with crosslinked cores were non-infectious and 
defective in reverse transcription 
 
The infectivity and reverse transcription of the two selected double cysteine 
mutants were studied in detail by Ophélie Cosnefroy. Figure 5.12 shows the 
infectivity data. The S17C/N22C double mutant was found to be non-infectious, 
and so were the single mutants S17C and N22C. The T47C/Q57C appeared to 
have very low infectivity, while single mutants T47C and Q57C had infectivity 
comparable to wt N-MLV. Figure 5.13 shows the quantification of early (strong 
stop) and late (second strand) RT products. Compared to wt N-MLV, both 
S17C/N22C and T47C/Q57C showed 3-log decreases in quantity of both strong 
stop and second strand DNA, suggesting strong impairment before reverse 
transcription of both mutants.  
 
5.2.4 Crosslinked MLV cores failed to abrogate T5 and Fv1 restriction 
 
Since the goal of this project was to compare binding of Fv1 and T5 to the same 
hyperstable MLV core, it was important that cores with the selected double 
cysteine mutations could be recognised by Fv1 and T5. The recognition of 
capsid core by a restriction factor could be tested using an abrogation assay 
(Duran-Troise et al., 1977). In a typical assay, cells are first treated with 
abrogating virus at a high MOI, followed by the infection of a second tester virus 
that is normally restricted by the restriction factor. If the abrogating virus is 
recognised by the restriction factor, it leads to saturation of restriction factor in 
the cell and therefore allows infection of the tested virus. If the abrogating virus 
is not recognised by the restriction factor, the tester virus will be restricted. I 
compared the ability of wt B-MLV, wt N-MLV, S17C/N22C N-MLV and 
T47C/Q57C N-MLV to abrogate restriction of endogenous HuT5 in TE671 cells 
  
230 
 
Figure 5.11 Locations of S17C/N22C and T47C/Q57C on N-MLV CA 
hexamer 
 
The two selected double cysteine mutants, S17C/N22C (blue) and T47C/Q57C (red), were 
labelled on the hexamer CA structure of N-MLV.  
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Figure 5.12 Infectivity of N-MLV mutants S17C/N22C and T47C/Q57C 
 
The infectivity assay was carried out by Ophélie Cosnefroy. D17 cells were infected with 
different volume of GFP-expressing tested virus with wt, or mutant N-MLV capsid sequence. 
The percentages of GFP
+
 cells were measured by FACS analysis. 
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Figure 5.13 Reverse transcription by N-MLV mutants S17C/N22C and 
T47C/Q57C 
 
The quantification of early and late reverse transcription products was carried out by Ophélie 
Cosnefroy. D17 cells were infected with different volume of GFP-expressing tested virus with 
wt, or mutant N-MLV capsid sequence. The strong stop and second strand viral DNA products 
were detected using quantitative PCR. 
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and of endogenous Fv1b in B-3T3 cells (Figure 5.14). Similar to B-MLV, neither 
of the double cysteine N-MLV mutants was capable of abrogating restriction by 
HuT5 or Fv1b. The abrogation of Fv1b appeared to be more difficult than of T5, 
restriction was relieved by just 3% even with the highest amount of N-MLV 
abrogating virus. These results suggested that the S17C/N22C N-MLV and 
T47C/Q57C crosslinking mutants were not recognised by Fv1 and T5, and 
would not be suitable for studying binding of these restriction factors to MLV 
cores. 
 
 
5.3 Discussion 
 
This chapter described attempts to study binding of T5 to MLV capsid through 
two different approached. Unfortunately, while the binding of T5 to MLV CA 
nanotubes does not appear to reflect the binding specificity of T5 to MLV core 
detected from abrogation assays, crosslinked MLV cores with double cysteine 
mutations were recognised by neither Fv1 nor T5. 
 
 Using the microplate binding assay, HuT5 appeared to bind more 
strongly to the non-restrictive B-MLV than to the restrictive N-MLV, and this 
result is reproducible. This result resembles the finding that Fv1bnb binds to B-
MLV nanotubes but does not restrict B-MLV even when over-expressed. 
Abrogation studies showed that HuT5 restriction is abrogated by N-MLV but not 
B-MLV (Towers et al., 2002), suggesting that at the endogenous level T5 
recognises N-MLV but not B-MLV. Therefore, the recognition of CA nanotubes 
by HuT5HA under the conditions of the binding assay may be different from the 
recognition of the capsid shell on the mature MLV cores at an endogenous 
HuT5 concentration. However, HuT5HA and HuT5 may possess some weak 
apparent affinity towards B-MLV CA, since both HuT5HA and HuT5 appear to 
weakly inhibit B-MLV when over-expressed using the LxIY vector, a variant of 
LxIG vector which expresses EYFP instead of EGFP (Table 5.1). The high 
concentration of B-MLV CA used in the binding assay may allow the detection 
of this weak binding. 
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Figure 5.14 Abrogation of Fv1 and Trim5α restriction by double cysteine 
mutants of N-MLV 
(A) Abrogation of human Trim5α restriction in TE671 cells. TE671 cells in 12 well plates were 
incubated with various amount of abrogating particles with LacZ-expressing genome and capsid 
sequence from B-MLV, N-MLV, N-MLV S17C/N22C mutant or N-MLV T47C/Q57C mutant. After 
3h incubation, cells were infected with N-MLV tester virus containing a GFP-expressing 
genome. The percentage of GFP
+
 cells in each sample was determined at 72hpi by FACS 
analysis. The amount of CA in each sample of abrogating particle was determined by 
quantitative western blot using a monoclonal anti-p30 primary antibody, an IRDye800-
conjugated secondary antibody, and purified CA standards of known concentrations. Data from 
triplicate samples from the same experiment is shown. (B) Abrogation of Fv1
b
 restriction in B-
3T3 cells. The abrogation assay was carried out in the same way as (A) except it was 
performed on 24 well plates. 
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It was also surprising that despite the fact HuT5 restriction is abrogated 
by N-MLV but not B-MLV (Dodding et al., 2005; Towers et al., 2002), the 
HuT5HA appeared to show stronger binding to B-MLV than N-MLV CA 
nanotubes.  First, it is possible that the high concentration of restrictive N-MLV 
capsid in the binding reaction could have triggered proteasomal degradation of 
HuT5HA in vitro. A previous study had demonstrated that infection of cells 
expressing HuT5 with N-MLV but not B-MLV at high MOI could induce 
proteasomal degradation of HuT5 (Rold and Aiken, 2008). However, since the 
proteasomal degradation of RhT5 by HIV-1 infection at high MOI had also been 
reported in the study, it is hard to comprehend how this effect could only affect 
binding of HuT5 to N-MLV but not RhT5 to HIV-1. Future binding experiments 
carried out in the presence of proteasome inhibitors could test whether N-MLV 
causes T5 degradation. Secondly, it is also possible that the presence of RhT5 
and HuT5 leads to disruption of the N-MLV CA lattice on lipid nanotubes, which 
in turns disrupt the binding of T5 to the CA lattice. The disruption to HIV-1 CA-
NC tubes by lysate containing RhT5 has been demonstrated in vitro (Black and 
Aiken, 2010; Zhao et al., 2011), and similar disruption to N-MLV CA nanotube 
could occur. However, it is important to point out that despite this reported CA 
disruption activity, binding of RhT5 to HIV-1 CA-NC tubes has been observed in 
many studies (Kar et al., 2008; Kim et al., 2011; Langelier et al., 2008; Li et al., 
2006b; Li et al., 2006c; Liberatore and Bieniasz, 2011; Lienlaf et al., 2011; 
Stremlau et al., 2006; Yang et al., 2014), suggesting that the disruption to the 
CA-lattice by RhT5 does not prevent the detection of RhT5 binding. Therefore, 
the potential disruptions to N-MLV CA nanotubes by RhT5HA is unlikely to 
prevent the detection of RhT5HA binding to N-MLV CA nanotubes. Lastly, it is 
possible that the binding of T5HA to N-MLV cores require a structure that is not 
present on the N-MLV CA lattice of lipid nanotubes. For example, the inter-
hexameric spacing of the CA lattice found on nanotubes is different from that of 
mature cores. As a result, the binding specificity of T5HA to CA nanotubes may 
not reflect the binding specificity of T5HA to MLV cores. 
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Two pairs of double cysteine mutations, S17C/N22C and T47C/Q57C, 
were able to form crosslinked CA complexes when introduced to virions of N-
MLV. The crosslink patterns of the two double mutants appeared to be different. 
The S17C/N22C mutant showed a ladder pattern of distinct bands up to 250kD, 
which resembles the phenotypes of many HIV-1 mutants with double cysteine 
mutations designed for the crosslinking between H1 of adjacent monomers 
(Meng et al., 2012; Pornillos et al., 2010). The T47C/Q57C mutant showed a 
“smeared” pattern at high molecular weight above 250kD rather than distinct 
bands. This suggested that the T47C/Q57C mutant could form large aggregates 
with crosslinking between multiple hexamers. 6 major bands could be observed 
for the S17C/N22C mutant, which could represent multimers of CA formed with 
1 to 6 monomers. Since H1 is present close to the central point of the CA 
hexamer, these mutations would not be expected to form inter-hexamer 
crosslinking. Formation of crosslinked dimer had been observed for many single 
cysteine mutations in H1, but not in H2 or H3. This is within expectations 
because in the hexameric CA structure, the same residues on H1 from adjacent 
monomers are in close proximity near the central pore to allow formation of 
disulphide bond. In contrast, same residues on H2 or H3 from adjacent 
monomers are well separated. Nevertheless, the formation of crosslinked dimer 
is sufficient to completely abolish the infectivity in single mutants. The formation 
of large irregular CA aggregates could explain why T47C/Q57C mutant was not 
recognised by Fv1 and T5. However, the crosslinked CA complexes observed 
for the S17C/N22C mutant appeared to be more regular, yet this mutant is 
unable to abrogate Fv1 and T5. It is possible that the introduction of disulphide 
bonds between monomers of CA-NTD leads to unpredictable structural 
changes, turning the core unrecognisable by restriction factors. Ongoing work 
carried out by Neil Ball (Ian Taylor’s lab, Division of Molecular Structure, NIMR) 
will attempt to express and purify recombinant N-MLV CA protein with 
S17C/N22C and T47C/Q57C mutations for in vitro crosslinking and further 
structural work.  
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The HIV-1 A14C/E45C mutant forms hexamers exclusively as in purified 
CA protein, and in virion this mutant shows ladder pattern but with enrichment 
of a band corresponding to CA hexamer (Meng et al., 2012; Pornillos et al., 
2010). Interestingly, in contrast to the N-MLV double cysteine mutants, this HIV-
1 A14C/E45C mutant can abrogate RhT5 in Vero cells (Ophélie Cosnefroy, 
unpublished data). The equivalent mutation in N-MLV would be P14C/H48C, 
although as mentioned earlier that mutating a Pro residue may alter the 
structure of CA, future experiments should test if such mutations would 
generate particles recognisable by Fv1 and T5.    
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Chapter 6 
 
Discussion 
 
 
6.1 Over-expression of Fv1b leads to restriction of NB-MLV 
and inhibition of B-MLV 
 
An early study of N, B, and NB tropism showed some apparent differences in 
the restriction specificity of Fv1b between cells endogenously expressing Fv1b 
and cells transiently expressing Fv1b delivered using a retrovirus vector (Bock 
et al., 2000). Restriction of N-MLV only was observed in cells expressing 
endogenous Fv1b, while restriction of NB-MLV and inhibition of B-MLV was also 
observed in cells with vector mediated Fv1b expression. A later study revealed 
that the vector-mediated expression level of Fv1 is higher than that in cells 
endogenously expressing Fv1 (Yap and Stoye, 2003). This led to the 
hypothesis that the gain of NB-MLV and B-MLV inhibition could be linked to a 
higher expression level of Fv1b. This was followed up by a study which showed 
that at the low expression level mediated by the endogenous Fv1 promoter, 
Fv1b appeared to restrict N-MLV only; while at the high vector-mediated 
expression level, Fv1b also appeared to restrict NB-MLV and inhibit B-MLV 
(Felton, 2012). It also showed that further increase in Fv1b expression from an 
over-expression level leads to reduced NB-MLV and B-MLV infectivity, 
supporting a role of Fv1b expression level in the inhibition of NB-MLV and B-
MLV (Felton, 2012).  
 
Chapter 3 in this thesis described the development of an assay to 
quantify the amount of Fv1 expressed in cells, and a novel inducible expression 
system which allow the study of Fv1 restriction from a very low level to an over-
expression level. By correlating Fv1 protein level with restriction phenotype, it 
provided solid evidence that over-expression of Fv1b leads to the restriction of 
NB-MLV and inhibition of B-MLV. It also confirmed an early observation that at 
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the endogenous level, the restriction of N-MLV is accompanied by a weak 
inhibition of NB-MLV (Bock et al., 2000). In contrast, no restriction of N-MLV 
and NB-MLV could be observed even at very high “super-expression” levels of 
Fv1n. This suggested that while Fv1b is capable of recognising the cores of all 
three MLV strains, though with different apparent binding affinities, Fv1n does 
not recognise cores of N-MLV and NB-MLV at all. 
 
6.2 Novel assays to compare the apparent binding affinities 
of restriction factors to retroviral cores 
 
The combination of a novel inducible expression system with minimal leakiness 
and a two colour FACS assay described in Chapter 3 allows the study of the 
relationship between restriction and Fv1 expression level. The data presented 
in Chapter 3 on Fv1b and on wild mice Fv1 illustrated how this assay can be 
used to compare the relative binding affinity of Fv1 to different retroviral cores. 
The ability of expressing Fv1 or T5 at a low, saturable concentration may also 
allow the development of a new abrogation assay to binding of recombinant 
restriction factors to retroviral cores. Previously, all abrogation assays were 
carried out in cells endogenously expressing a restriction factor. Although 
recombinant restriction factors can be transiently expressed using the LxIG or 
LxIY vectors, the restriction factor is over-expressed in transduced cells and 
would require very high concentration of abrogating virus in order to achieve 
detectable saturation. By transducing MDTF cells with one of the new inducible 
vectors such as TYIx, recombinant restriction factors can be expressed at a low, 
saturable level. Pre-treatment of these cells with abrogating particles before 
infection with GFP tester virus, followed by incubation with a high dose of 
doxycycline would allow the detection of the loss of restriction in cells 
expressing the recombinant restriction factor. The YFP- cells, which do not 
express the recombinant restriction factor, can also serve as an internal control 
showing what the infectivity of the GFP tester virus would be with a complete 
saturation of restriction factors. Such system would be particularly useful to 
study determinants of Fv1 and T5 which affect their binding to retroviral cores, 
by comparing the ability of viral cores to abrogate wt and mutant restriction 
factors.  
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6.3 Strong binding of CA may be necessary but not sufficient 
for Fv1 restriction 
 
Many early attempts failed to demonstrate direct binding of Fv1 to monomeric 
CA (Dodding et al., 2005). This led to the hypothesis that Fv1 interacts with a 
polymeric form of CA, such as the CA lattice found on the capsid shell of mature 
MLV core. This was supported by evidence that abrogation of Fv1 restriction 
requires processing at both N-terminus and C-terminus of CA (Dodding et al., 
2005). Subsequently, a binding assay was developed for studying the binding of 
Fv1 from cell lysate to regular array of MLV CA presented on the surface of 
functionalised lipid nanotubes (Hilditch et al., 2011). Fv1n binds to B-MLV CA 
nanotubes, but neither N-MLV nor NB-MLV CA nanotubes. The binding 
requires some structures present on the mature lattice such as a stable β-
hairpin, which only forms after the processing at the N-terminus of CA (Kyere et 
al., 2008; Mortuza et al., 2004). The binding specificities of Fv1n and Fv1nr to 
MLV CA nanotubes appeared to correlate with their restriction specificities, 
concluded from binding experiments using many CA mutants. However, Fv1b 
appears to bind strongly to CA of N-MLV, B-MLV and NB-MLV presented on 
lipid nanotubes. Since Fv1b appears to display higher specificity at lower 
expression level, as discussed in the previous section, it was hypothesised that 
specificity of Fv1b binding to CA nanotubes may be observable only at low 
concentrations of Fv1.  
 
Chapter 4 described the development of a medium-throughput binding 
assay which allows the comparison of the specificity of Fv1 binding to CA 
nanotubes using a range of Fv1 concentrations. However, in agreement to the 
previous study (Hilditch et al., 2011), Fv1b appears to bind to all MLV CA 
presented on lipid nanotubes even at the lowest concentration where bound 
Fv1b could be detected. Since endogenous Fv1b in B-3T3 cells could be 
abrogated by genome-deficient particles of N-MLV but not B-MLV (Boone et al., 
1990), it is unlikely that this non-differential binding to CA nanotubes reflect the 
binding specificity towards MLV cores. However, the lack of Fv1n binding to N-
MLV and NB-MLV CA nanotubes did correlate with the lack of N-MLV and NB-
MLV restrictions even at very high Fv1n expression level. It is possible that 
presence of high concentration of CA and/or Fv1 in the binding reaction could 
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overcome some weak interactions such as Fv1b against B-MLV, but not very 
weak interactions such as Fv1n against N-MLV. Further binding studies of 10 
Fv1 variants with various restriction phenotypes suggested a strong correlation 
between binding to CA nanotube and with the ability to restrict N-MLV and NB-
MLV when over-expressed. However, Fv1bnb appears to bind B-MLV CA 
nanotubes but does not restrict B-MLV. These data suggested that in vitro 
binding to CA nanotube may represent an interaction that is required but 
insufficient for the binding to MLV core.  
 
A model can be proposed to explain the findings in Chapter 3 and 4 
regarding the binding and restriction specificities of Fv1n and Fv1b, illustrated in 
Figure 6.1. Fv1n has a strong apparent affinity towards B-MLV CA, but very 
weak apparent affinities towards N-MLV and NB-MLV CA. At the endogenous 
concentration, Fv1n only binds and restricts B-MLV cores. Fv1b has a strong 
apparent affinity towards N-MLV CA, a moderate apparent affinity towards NB-
MLV CA, and a weak apparent affinity towards B-MLV CA. At the endogenous 
concentration, Fv1b binds N-MLV cores strongly and binds NB-MLV moderately, 
leading to the restriction of N-MLV and the inhibition of NB-MLV. Even at over-
expression level, Fv1n still only binds and restricts B-MLV cores. The high 
concentration of Fv1b overcomes the weaker apparent affinities of Fv1b to NB-
MLV and B-MLV, allowing the restriction of NB-MLV and the inhibition of B-
MLV. In the in vitro binding assay, the high concentrations of CA and/or Fv1 
overcome the weaker apparent affinities of Fv1b to NB-MLV and B-MLV, 
allowing the detection of similar binding of Fv1b to CA nanotubes of all tropisms. 
However, the apparent affinities of Fv1n to N-MLV and NB-MLV are much 
weaker than those of Fv1b to NB-MLV and B-MLV, and cannot be overcome by 
the high CA and/or Fv1 concentrations used in the binding reaction. 
 
6.4 The role of restriction factor multimerisation in CA 
binding 
 
The ability to multimerise has been clearly demonstrated for T5 and TCyp. Like 
Fv1, the coiled-coil within the RBCC domain mediates the formation of an 
antiparallel T5 dimer (Goldstone et al., 2014). T5 dimers also form higher order  
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Figure 6.1 A model for Fv1 concentration, binding and restriction 
 
(A) Binding and restriction by endogenously expressed Fv1. Fv1
n
 has a strong apparent affinity 
towards B-MLV CA, but very weak apparent affinity towards N-MLV and NB-MLV CA. At the 
endogenous concentration, Fv1
n
 only binds and restricts B-MLV cores. Fv1
b
 has a strong 
apparent affinity towards N-MLV CA, a moderate apparent affinity towards NB-MLV CA, and a 
weak apparent affinity towards B-MLV CA. At the endogenous concentration, Fv1
b
 binds N-MLV 
cores strongly and binds NB-MLV moderately, leading to the restriction of N-MLV and the 
inhibition of NB-MLV. (B) Binding and restriction by over-expressed Fv1. Even at over-
expression level, Fv1
n
 still only binds and restricts B-MLV cores. The high concentration of Fv1
b
 
overcomes the weaker apparent affinities of Fv1
b
 to NB-MLV and B-MLV, allowing the 
restriction of NB-MLV and the inhibition of B-MLV. (C) Binding of Fv1 to CA nanotubes. The 
high concentrations of CA and/or Fv1 overcome the weaker apparent affinities of Fv1
b
 to NB-
MLV and B-MLV, allowing the detection of similar binding of Fv1
b
 to CA nanotubes of all 
tropisms. However, the apparent affinities of Fv1
n
 to N-MLV and NB-MLV are much weaker 
than those of Fv1
b
 to NB-MLV and B-MLV, and cannot be overcome by the high CA and/or Fv1 
concentrations used in the binding reaction.   
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assemblies, and studies of chemically crosslinked T5 mutants suggested that 
this requires the RING domain, the B-Box2 domain, the L2 region but not the 
B30.2 domain (Diaz-Griffero et al., 2009; Li and Sodroski, 2008; Liberatore and 
Bieniasz, 2011). The formation of higher order assembly correlates with 
stronger binding to HIV-1 CA-NC assemblies in vitro (Diaz-Griffero et al., 2009; 
Li and Sodroski, 2008; Liberatore and Bieniasz, 2011). The recombinant T5-
21R protein with a Trim21 RING domain and a mutated B-Box2 domain which 
was found to self-assemble into a hexagonal super-lattice in vitro, has provided 
to the structural basis of T5 higher order self-association (Ganser-Pornillos et 
al., 2011). This T5 lattice has an inter-hexameric spacing of about 350Å, and 
would link across multiple CA hexamers on a CA lattice which has an inter-
hexameric distance of less than 100Å (Ganser-Pornillos et al., 2011). The 
crystal structures of a soluble fragment of RhT5 comprising B-Box2, coiled coil 
and L2 (BCCL2) has been solved recently (Goldstone et al., 2014). BCCL2 
forms an antiparallel dimer with the coiled-coil region forming a long rod, and 
one B-Box2 domain on each site of the rod. Since the B-Box and RING domain 
have been implicated in the higher order self-association of T5 (Diaz-Griffero et 
al., 2009; Li and Sodroski, 2008; Liberatore and Bieniasz, 2011), it is likely that 
each end of the rod interacts to link T5 dimers at the 3-fold symmetry axis of the 
T5 hexagonal lattice (Figure 6.2C) (Goldstone et al., 2014). Structural 
alignments between BCCL2 and the structure of RhT5 L2-B30.2 region 
suggested that the two B30.2 domains would be positioned at the centre of the 
T5 dimer (Goldstone et al., 2014; Yang et al., 2012). Therefore the B30.2 
domains in the T5 super lattice would interact with a small number of CA 
monomers, and this was in agreement with the finding that TCyp only requires 
25% of restriction-sensitive CA (Shi et al., 2013). The ability of T5 to form 
dimers and higher order assemblies suggest that the recognition of retroviral 
cores by T5 may involve avidity binding, where one T5 dimer binds across two 
CA hexamers, and the T5 hexagonal lattice binds to multiple sites on the CA 
lattice (Figure 6.2C). This avidity binding may involve positive cooperativity, for 
example binding of one B30.2 domain of a T5 dimer to CA lattice may make the 
binding of the second B30.2 domain to CA more favourable. The avidity binding 
of T5 is likely to enhance the observed apparent affinity of T5. The specific 
positioning of B30.2 domain on the T5 hexagonal lattice could also mean that  
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Figure 6.2 Interactions of Fv1Cyp and RhT5 to HIV-1 CA lattice  
 
(A) A layer of HIV-1 CA lattice taken from PDB: 3J34. Red spheres mark the CypA binding 
loops and the gray region highlights those that are spaced at 130–170 Å from the central Cyp 
loop (yellow) and accessible to bind the second CypA of Fv1Cyp. (B) The SAXS envelope of 
Fv1Cyp dimer is positioned with one CypA domain located on the Cyp loop of a central 
hexamer and the second spaced between 140–150 Å located on the Cyp loop of an adjacent 
CA hexamer. (C) A schematic representation of the HIV-CA lattice (green) with the Trim5-21R 
lattice (Ganser-Pornillos et al., 2011) is overlaid as dashed lines (black). The SAXS model for 
the RhT5 (88–296) EK/RD dimer shown in orange surface representation has dimensions 
equating to the length of a single edge of the hexamer in the Trim5-21R lattice and sufficient to 
span adjacent hexamers in the CA lattice. The B-boxes are shown as cyan circles at the 
interface between Trim5α dimers and the B30.2 domains are represented by the magenta ovals 
toward the Trim5-21R twofold axis. Reproduced from the Proceedings of the National Academy 
of Science (Goldstone et al., 2014), with permission.  
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the CA lattice needs to be positioned in a certain way for avidity binding of T5 
higher order assemblies, and the inter-hexameric distance between mature and 
immature lattice may affect this avidity binding.  
 
Multimerisation of Fv1 has also been demonstrated before. Purified Fv1-
NTD and the Fv1Cyp fusion protein are both found to be dimeric in solution 
(Bishop et al., 2006; Goldstone et al., 2014). The dimerisation of Fv1 is 
mediated by the coiled-coil region of the Fv1-NTD (Bishop et al., 2006). The 
fusion of CypA to Fv1-NTD, T5 RBCC, or other dimerisation domains such as 
the BAR domain, separated by a linker region, allows restriction of HIV-1 (Yap 
et al., 2007). This suggests that the dimerisation is essential for the recognition 
of retroviral core by Fv1 and T5. Fv1n but not Fv1n-CTD binds to B-MLV CA 
nanotubes, suggesting that the dimerisation is necessary for Fv1 binding 
(Hilditch et al., 2011). The binding of Fv1Cyp and CypA to lipid nanotubes 
coated with C-terminally His-tagged CA-SP1 have been compared by surface 
plasmon resonance (SPR) analysis, and the apparent affinity of Fv1Cyp to HIV-
1 CA lattice was found to be 18-fold higher than of CypA  (Goldstone et al., 
2014). This demonstrated how the avidity binding of Fv1 dimer to CA lattice can 
lead to a higher apparent affinity. Low resolution structures of Fv1-NTD and 
Fv1Cyp dimers have been recently determined by small-angle X-ray scattering 
(SAXS) (Goldstone et al., 2014). Fv1Cyp was found to contain two globular 
CypA domains 150Å apart, suggesting that the Fv1-NTD forms antiparallel 
dimer (Goldstone et al., 2014). Modelling of Fv1Cyp bound to the mature lattice 
of HIV-1 CA suggested that this interaction would involve binding of one 
Fv1Cyp to monomers of two CA hexamers (Figure 6.2 A-B) (Goldstone et al., 
2014). A similar avidity binding interface would be expected between Fv1 dimer 
and MLV CA assay on the lipid nanotubes. Therefore, it is likely that the MLV 
CA lattice on lipid nanotubes allow binding of both Fv1-CTD on the same Fv1 
dimer to CA, this may involve cooperative avidity binding in which binding of the 
first Fv1-CTD to CA lattice favours the binding of the second Fv1-CTD. In 
addition to dimerisation, crosslinking experiments in our lab have suggested a 
second multimerisation site within the Fv1-CTD which is sensitive to mutations 
at the MHR (Cécile Lemaître, unpublished data). The possession of two 
multimerisation sites could potentially allow the formation of higher order 
assemblies, similar to the hexagonal super-lattice observed for T5. Since in the 
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SAXS model Fv1Cyp, the capsid-targeting Fv1-CTD domain is placed on both 
ends of the dumb-bell shaped dimer (Goldstone et al., 2014), it may be possible 
for the Fv1-CTD of adjacent dimers to interact to form higher order assemblies. 
Therefore, like T5, the binding of Fv1 could involve avidity binding of dimers and 
higher order assemblies across multiple hexamers on the CA lattice. 
 
Although the coiled-coil mediated dimerisation of Fv1 and T5 has been 
well characterised, future work should study the mechanism of Fv1 and T5 
binding and should focus on the relationship between restriction factor 
multimerisation and the apparent binding affinity. In particular, it would be 
desirable to quantify and compare the contributions to the apparent binding 
affinity or restriction activity by the affinity between capsid-binding domain and 
CA monomer, the avidity due to dimerisation of restriction factor, and the avidity 
due to the formation of higher order assemblies. Using TCyp as a model 
system, one can compare the effects on restriction activity by mutations which 
modulate the binding affinity between CypA domain and CA such as D66N 
(Price et al., 2009), and by mutations which disrupt higher order assembly such 
as E120K/R121D in B-box2 (Diaz-Griffero et al., 2009) and deletion in the L2 
linker region (Liberatore and Bieniasz, 2011). The use of new inducible vectors 
may allow better quantitation of the inhibitory effects of these mutations, while 
use of an abrogation assay with wt and mutant TCyp may allow the confirmation 
of the effects of mutations on the apparent binding affinity of TCyp. Similarly, 
the study of CypA D66N mutant of Fv1Cyp would also allow us to find out how 
much the affinity between the capsid-binding domain and CA contributed 
towards the interaction between a dimeric T5 protein and the CA lattice on viral 
core. Since the Fv1-CTD is probably involved in both CA binding and 
multimerisation, future work should also attempt to identify specific determinants 
in Fv1-CTD which affects multimerisation but not the affinity to CA.  
 
6.5 Towards a common CA binding assay for Fv1 and T5 
 
Since Fv1b and HuT5 both restrict N-MLV and show overlapping viral 
determinants for restriction (Bock et al., 2000; Ohkura et al., 2011; Ohkura and 
Stoye, 2013; Stevens et al., 2004), there has been strong interest in developing 
a system to compare the binding requirement for these two restriction factors to 
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N-MLV CA. Like Fv1, HuT5 can be abrogated by N-MLV (Towers et al., 2002), 
and abrogation requires the processing on both ends of MLV CA (Dodding et 
al., 2005). Binding of T5 to MLV CA nanotubes could not be detected in a 
previous study using the co-pelleting assay (Hilditch, 2010). Chapter 5 
described another unsuccessful attempt to detect T5 to MLV CA nanotubes with 
the new microplate binding assay. It is possible that the avidity of T5 dimer to 
CA lattice on lipid nanotube is weak; the binding of T5 to core is more co-
operative than Fv1 and is highly dependent on the correct inter-hexamer 
spacing of mature CA lattice. Since the low stability of MLV mature core 
prohibited the purification for binding study, the stabilisation of MLV core by 
introducing disulphide crosslinking was attempted. Two double cysteine 
mutants were found to form crosslinked CA without defects in gag processing. 
However, abrogation studies in cells endogenously expressing Fv1b and HuT5 
suggested that the cores of these mutants do not form a structure that can be 
recognised by restriction factors. This is in contrast with the HIV-1 crosslink 
mutant A14C/E45C which abrogates RhT5 restriction (Ophélie Cosnefroy, 
unpublished data). The equivalent mutation in N-MLV would be P14C/H48C, 
although as mentioned earlier that mutating a Pro residue may alter the 
structure of CA, future experiments should test if such mutations would 
generate particles recognisable by Fv1 and T5. It is also possible that the 
crosslinking at the NTD-NTD interface within the MLV hexamer may disrupt 
some structure that is required for T5 and Fv1 recognition. Future experiments 
should also explore the crosslinking at the CTD-CTD inter-hexamer dimer 
interface. In addition to MLV, there are other retroviruses that can be 
recognised by both Fv1 and T5 alleles (Figure 6.3). The lentivirus EIAV is 
restricted by both HuT5 and RhT5 (Hatziioannou et al., 2004), and by two wild 
mice Fv1 alleles Fv1SPR1 and Fv1MAC (Yap et al., 2014). The binding of 
recombinant T5-21R to purified EIAV core has been reported (Langelier et al., 
2008), and may provide an alternative binding substrate for the comparison 
between Fv1 and T5 recognition in future. 
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6.6 The significance of partial restriction activities 
 
Using the novel inducible expression system described in chapter 3, it was 
found that many other wild mice Fv1 alleles also possess partial restriction 
activities against retroviruses at an expression level similar to endogenous 
Fv1b, which turns into full restriction when at over-expression Fv1 level (Yap et 
al., 2014). However, without analysis of the Fv1 protein expression level from 
cells of wild mice, it is not known what the endogenous concentrations actually 
are. The difference between Fv1n in N-3T3 cells and Fv1b in B-3T3 cells 
suggested that Fv1 expression level may vary between mice species. There 
may also be variation in Fv1 expression level among different cell types, a 
higher expression level in the target cell type may be sufficient to control 
infection. Furthermore, the combined inhibition exerted by the partial restriction 
of these Fv1 alleles and other restriction factors such as murine APOBEC3 may 
be sufficient to confer protection (Rulli et al., 2008). A number of hypotheses 
can be suggested on how these partial restriction activities emerged.  Some of 
these partial restriction activities could be once positively selected for due to the 
circulation of a retrovirus in the past, but as Fv1 evolves to recognise another 
new emerging virus, it accumulates mutations which lead to the decrease in 
restriction activity against the old virus. It is also possible that some of these 
Fv1 alleles are under selection from multiple retroviruses simultaneously, and 
Fv1 has been selected to inhibit all of these viruses, with the cost of weaker 
restriction against each of these viruses. It has been shown that forced passage 
of B-MLV in cells expressing Fv1n rapidly leads to the isolation of NB-MLV, 
while forced passage of N-MLV in Fv1b cells does not (Hopkins et al., 1977; Lilly 
and Pincus, 1973). The partial restriction activity against NB-MLV by Fv1b could 
have an important role in preventing the emergence of NB-tropic virus resulted 
from adaptation of B-MLV. It would also be interesting to see if similar 
concentration dependency of restriction can be found in T5 alleles, particular 
those which recognise multiple retroviruses (Figure 6.3). Future work should 
study the restriction by RhT5 against N-MLV, HIV-1 and EIAV at different 
expression levels of RhT5, similar to the analysis shown in Table 3.2. This 
would allow the comparison of the relative apparent affinities of RhT5 to 
different retroviral cores. 
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Figure 6.3 Restriction activities of selected Fv1 and T5 
 
Solid lines represent full restriction activities, while dash lines represent partial restriction 
activities. Data from (Bock et al., 2000; Hatziioannou et al., 2004; Ohkura et al., 2006; Yap et 
al., 2014). 
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6.7 Evolution of the Fv1 gene 
 
In additional to Fv1n, Fv1b and Fv1nr alleles isolated from inbred lab mice, 
previous studies have identified many Fv1 alleles in wild mice (Yan et al., 2009; 
Yap et al., 2014) (Figure 6.4). Among different murine species, Fv1 alleles could 
be amplified from Mus mus, Mus nannomys and Mus pyromys sub-genera, but 
not from the Mus coelomys sub-genus or the Rattus genus, suggesting that the 
Fv1 gene was inserted about 5 million years ago roughly about the time when 
the Mus sub-genera diverged (Ellis, 2000; Qi et al., 1998b; Yap et al., 2014), 
probably as part of an endogenous retrovirus MERV-L (Benit et al., 1997; Best 
et al., 1996). Since then, these Fv1 alleles diverged in their restriction 
specificities (Yap et al., 2014). Several Mus nannomys Fv1 alleles, including 
Fv1MIN1 and Fv1MIN2 from M. n. minutoides and Fv1SET from M. n. 
setulosus, have evolved the ability to restrict multiple strains of MLV (Yan et al., 
2009; Yap et al., 2014). Among the Mus mus Fv1 alleles, restriction activities 
against non-MLV retroviruses have also been identified (Yap et al., 2014). 
These include Fv1SPR1 from M. m. spretus and Fv1MAC from M. m. 
macedonicus, which not only restrict MLV but also the lentivirus EIAV; as well 
as Fv1CAR1 from M. m. caroli, which restricts FFV (Yap et al., 2014). Data from 
chapter 3 showed that the restriction of EIAV and FFV by these alleles can be 
observed at relatively low expression levels (Figure 3.25), suggesting that these 
non-MLV restriction activities are most likely present when expressed at the 
endogenous level in cells of wild mice. 
 
 6 codons in the Fv1 gene had been identified to show evidence of 
positive selections, including positions 261, 265, 270, 352, 399 and 401 (Yan et 
al., 2009). Interestingly, many residues that have been identified as key 
determinants for Fv1 restriction activities overlap with the sites of positive 
selection (Yap et al., 2014). Key determinants of Fv1 restriction include residues 
352, 358 and 399 of Fv1n, Fv1b and Fv1nr which are important for defining MLV 
restriction specificity (Bock et al., 2000; Stevens et al., 2004); residues 261, 268 
and 270 of Fv1SPR1 which are important for its MLV and EIAV restriction 
activities (Yap et al., 2014); and residues 349 and 352 which are important for  
the FFV restriction activity of Fv1CAR1 (Yap et al., 2014).  
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Figure 6.4. Restriction activities of Fv1 alleles from lab and wild mice 
 
A phylogenetic tree showing the approximate times of Fv1 acquisition, retroviral 
restriction activities (using LxIY-Fv1 vector), and hypothetical virus infections 
leading to selection of new activities. +, restriction; (+) partial restriction. Sub-
genera: M.m., Mus mus; M.n., Mus nannomys; M.p., Mus pyromys; M.c., Mus 
coelomys. Modified from (Yap et al., 2014), with permission under PLOS open-
access license and the Creative Commons Attribution (CC BY) license.  
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 In the case of the emergence of Fv1n and Fv1b  alleles, genetic and 
function studies of Fv1 alleles from lab and wild mice have provided insights on 
the events involved in the evolution of these genes (Ellis, 2000). In comparison 
to Fv1b, Fv1n contains different sequence at positions 358 and 399, as well as a 
19aa shorter C-terminal tail resulted from a 1.3kb deletion in the genomic DNA 
(Best et al., 1996). Among the Mus mus sub-genus, all Fv1 alleles have the 
Fv1n sequence of K358 and V399, except for Fv1b which has the sequence 
E358 and R399, and for Fv1MOL from M. m. molossinus, which has the 
sequence K358 and R399 (Ellis, 2000). This suggested that the progenitor of 
Mus mus Fv1 alleles is likely to have the K358 and V399, with the V399R 
mutation acquired by the common progenitor of Fv1MOL and Fv1b, followed by 
the K358E mutation acquired by Fv1b after its divergence from Fv1MOL. At the 
C-terminus, most Fv1 alleles possess an Fv1b-like long tail. In contrast, Fv1n, 
Fv1nr, as well as Fv1 from M. m. domesticus and M. m. musculus all have 
identical 3aa short C-terminal tail. 3 other Fv1 alleles including Fv1FAM from M. 
m. famulus, Fv1MIN1/2 from M. n. minutoides, and Fv1PLA from M. p. platythrix 
also possess shorter C-terminal tails (Ellis, 2000; Yap et al., 2014). However, 
the short C-terminal tails in these diverged Fv1 alleles were caused by 
independent insertion events, all resulting in slightly different insertion of B1 
repeat element, and are unrelated to the short tail in Fv1n. The fact that most 
Fv1 alleles possess the long Fv1b-like tail suggested that the progenitor of Fv1 
would have a long C-terminal tail, and that the short C-terminal tail of Fv1n has 
evolved after the divergence of Fv1n and Fv1b from Fv1MOL and Fv1b. 
Together, these observations suggested that the common progenitor of Fv1n 
and Fv1b possess a sequence similar to the mutant Fv1nnb, with K358, V399, 
and a Fv1b-like long C-terminal tail. 
 
6.8 Selection pressure driving Fv1 evolution 
 
The question remains on what drives the divergence of restriction specificities of 
different Fv1 alleles after the insertion of the Fv1 gene. The observed Fv1 
activities against EIAV and FFV could be the results of one of the two scenarios 
(Yap et al., 2014). First, Fv1SPR1, Fv1MAC and Fv1CAR1 could be selected to 
recognise EIAV and FFV in additional to MLV, due to prior exposure to similar 
lentivirus and spumavirus. Alternatively, these Fv1 alleles could be selected to 
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recognise MLV only, but the adaptations for MLV recognition also enables 
these Fv1 alleles to interact with EIAV and FFV capsids. There are increasing 
lines of evidence against the second scenario. First, Fv1SPR1 and Fv1MAC 
appeared to have evolved different mechanisms to restrict EIAV, while the 
restriction of both N-MLV and EIAV by Fv1SPR1 require C268, Fv1MAC has 
the sequence R268 but still restrict N-MLV and EIAV (Yap et al., 2014). The 
convergent evolution of EIAV restriction activities using different mechanisms 
suggested that these Fv1 alleles were likely to be under selection pressure from 
EIAV-like viruses. Secondly, although the C268R mutation can abolish both 
MLV and EIAV restriction activities of Fv1SPR1, there are mutations which can 
abolish EIAV but not MLV activities of Fv1MAC (Melvyn Yap, unpublished data). 
This suggested that the EIAV activity is unlikely to be simply the consequence 
of the selection against MLV, but most likely due to the exposure to an EIAV-
like virus 
 
 Different Fv1 alleles appear to display different restriction specificities 
towards MLV of different tropisms, suggesting that they may be under different 
selection pressure through exposure to different MLVs. Some Fv1 alleles have 
broad range activities against N-MLV, B-MLV and NB-MLV. For example, 
Fv1MIN2 restricts all 3 MLVs when overexpressed, although at low 
concentration it has slightly weaker activity against NB-MLV (Figure 3.25). 
Similarly, Fv1b can restrict N-MLV and NB-MLV when overexpressed, but has 
slightly weaker activity against NB-MLV (Figure 3.25). On the other hand, some 
other Fv1 alleles show high restriction specificities. For example, Fv1n only 
restrict B-MLV even when overexpressed, while Fv1MAC only restrict N-MLV 
even when overexpressed. So what are the viruses which drove the selection of 
MLV restriction activities of Fv1, and the subsequent divergence of restriction 
specificity towards MLV of different tropisms? The identification of many 
endogenous MLVs present in mice genome has provided insight on what these 
viruses might be. Non-ecotropic (such as xenotropic and polytropic) 
endogenous MLVs have been found in the germline of M. m. domesticus, M. m. 
musculus, M. m. molossinus, M. m. castaneous and M. m. spretus (Ellis, 2000), 
and sequence analysis suggested that most of these viruses carry determinants 
for B-tropism (Stevens et al., 2004). Ecotropic endogenous MLVs have also 
been found in the genomes of many lab mice strains as well as in M. m. 
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molossinus (Inaguma et al., 1991; Kozak, 2014), most of which are N-tropic 
(Kozak, 2014). Although most of these endogenous MLVs contain fatal 
mutations which prevented the expression of infectious particles (Kozak, 2014), 
they are evidence that after the insertion of Fv1, mice in the Mus mus sub-
genus had once been exposed to infectious N-tropic and B-tropic MLVs, which 
could create strong selection pressure against these viruses. Once these MLVs 
entered the germ line, there is additional selection pressure for Fv1 to evolve 
restriction activities against N-tropic and B-tropic viruses in order to control the 
endogenous MLVs. Since the mostly B-tropic non-ecotropic endogenous MLVs 
appeared to have entered the germ line earlier than the mostly N-tropic 
ecotropic endogenous MLVs in the Mus mus lineage (Ellis, 2000), it is likely that 
the progenitor of Fv1n and Fv1b alleles were first selected for restriction of B-
MLV, and later also selected for restriction of N-MLV in some mice which gave 
rise to the Fv1b allele.  
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